KR20160029124A - Pd-1 항원 또는 pd-1 리간드 항원을 포함하는 바이러스 유사 입자 - Google Patents
Pd-1 항원 또는 pd-1 리간드 항원을 포함하는 바이러스 유사 입자 Download PDFInfo
- Publication number
- KR20160029124A KR20160029124A KR1020167003373A KR20167003373A KR20160029124A KR 20160029124 A KR20160029124 A KR 20160029124A KR 1020167003373 A KR1020167003373 A KR 1020167003373A KR 20167003373 A KR20167003373 A KR 20167003373A KR 20160029124 A KR20160029124 A KR 20160029124A
- Authority
- KR
- South Korea
- Prior art keywords
- thr
- ala
- val
- gly
- pro
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 209
- 102000036639 antigens Human genes 0.000 title claims abstract description 209
- 108091007433 antigens Proteins 0.000 title claims abstract description 209
- 239000002245 particle Substances 0.000 title claims abstract description 198
- 239000003446 ligand Substances 0.000 title claims abstract description 56
- 241000700605 Viruses Species 0.000 title claims description 53
- 108010087302 Viral Structural Proteins Proteins 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 67
- 239000013598 vector Substances 0.000 claims description 58
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 210000000234 capsid Anatomy 0.000 claims description 32
- 101710132601 Capsid protein Proteins 0.000 claims description 26
- 101710094648 Coat protein Proteins 0.000 claims description 26
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 26
- 101710125418 Major capsid protein Proteins 0.000 claims description 26
- 101710141454 Nucleoprotein Proteins 0.000 claims description 26
- 101710083689 Probable capsid protein Proteins 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 16
- 101710091045 Envelope protein Proteins 0.000 claims description 15
- 101710188315 Protein X Proteins 0.000 claims description 15
- 102100021696 Syncytin-1 Human genes 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 13
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 12
- 241000283073 Equus caballus Species 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 8
- 108090000565 Capsid Proteins Proteins 0.000 claims description 7
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 229920002101 Chitin Polymers 0.000 claims description 4
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 230000012121 regulation of immune response Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 11
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 96
- 241001502567 Chikungunya virus Species 0.000 description 51
- 239000012634 fragment Substances 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 24
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 108010054155 lysyllysine Proteins 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 108010047495 alanylglycine Proteins 0.000 description 18
- 108010050848 glycylleucine Proteins 0.000 description 17
- 241000880493 Leptailurus serval Species 0.000 description 16
- 108010087924 alanylproline Proteins 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 13
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 13
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 13
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 13
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 13
- 108010085325 histidylproline Proteins 0.000 description 13
- 108010018006 histidylserine Proteins 0.000 description 13
- 108010073969 valyllysine Proteins 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 108010060035 arginylproline Proteins 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 12
- 108010051110 tyrosyl-lysine Proteins 0.000 description 12
- 206010057190 Respiratory tract infections Diseases 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 241000710929 Alphavirus Species 0.000 description 10
- 108010064997 VPY tripeptide Proteins 0.000 description 10
- 108010016616 cysteinylglycine Proteins 0.000 description 10
- 108010036413 histidylglycine Proteins 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 108010070643 prolylglutamic acid Proteins 0.000 description 10
- WRDANSJTFOHBPI-FXQIFTODSA-N Ala-Arg-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N WRDANSJTFOHBPI-FXQIFTODSA-N 0.000 description 9
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 9
- 108010077245 asparaginyl-proline Proteins 0.000 description 9
- 108010092854 aspartyllysine Proteins 0.000 description 9
- 108010060199 cysteinylproline Proteins 0.000 description 9
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 9
- 108010015792 glycyllysine Proteins 0.000 description 9
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 9
- OWSMKCJUBAPHED-JYJNAYRXSA-N Arg-Pro-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OWSMKCJUBAPHED-JYJNAYRXSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 241000710831 Flavivirus Species 0.000 description 8
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 8
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 8
- 108010065920 Insulin Lispro Proteins 0.000 description 8
- BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 8
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 8
- 108010041407 alanylaspartic acid Proteins 0.000 description 8
- 108010005233 alanylglutamic acid Proteins 0.000 description 8
- 102000048362 human PDCD1 Human genes 0.000 description 8
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 8
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 7
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 7
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 7
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 7
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 7
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 7
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 7
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 7
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 7
- OHDXOXIZXSFCDN-RCWTZXSCSA-N Thr-Met-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OHDXOXIZXSFCDN-RCWTZXSCSA-N 0.000 description 7
- BMOFUVHDBROBSE-DCAQKATOSA-N Val-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N BMOFUVHDBROBSE-DCAQKATOSA-N 0.000 description 7
- QWCZXKIFPWPQHR-JYJNAYRXSA-N Val-Pro-Tyr Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QWCZXKIFPWPQHR-JYJNAYRXSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 108010004073 cysteinylcysteine Proteins 0.000 description 7
- 108010089804 glycyl-threonine Proteins 0.000 description 7
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108010029020 prolylglycine Proteins 0.000 description 7
- 108010026333 seryl-proline Proteins 0.000 description 7
- QUMKPKWYDVMGNT-NUMRIWBASA-N Asn-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QUMKPKWYDVMGNT-NUMRIWBASA-N 0.000 description 6
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 6
- LNDVNHOSZQPJGI-AVGNSLFASA-N His-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNDVNHOSZQPJGI-AVGNSLFASA-N 0.000 description 6
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 6
- AXVIGSRGTMNSJU-YESZJQIVSA-N Leu-Tyr-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N AXVIGSRGTMNSJU-YESZJQIVSA-N 0.000 description 6
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 6
- PYFNONMJYNJENN-AVGNSLFASA-N Lys-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N PYFNONMJYNJENN-AVGNSLFASA-N 0.000 description 6
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 6
- XJROSHJRQTXWAE-XGEHTFHBSA-N Pro-Cys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJROSHJRQTXWAE-XGEHTFHBSA-N 0.000 description 6
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 6
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 6
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 6
- 101710172711 Structural protein Proteins 0.000 description 6
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 6
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 6
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 6
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 6
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 6
- 108010070944 alanylhistidine Proteins 0.000 description 6
- 108010062796 arginyllysine Proteins 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 6
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 6
- 108010012058 leucyltyrosine Proteins 0.000 description 6
- 108010005942 methionylglycine Proteins 0.000 description 6
- 108091005573 modified proteins Proteins 0.000 description 6
- 102000035118 modified proteins Human genes 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 108010073101 phenylalanylleucine Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108010077112 prolyl-proline Proteins 0.000 description 6
- 108010079317 prolyl-tyrosine Proteins 0.000 description 6
- 108010015796 prolylisoleucine Proteins 0.000 description 6
- 108010090894 prolylleucine Proteins 0.000 description 6
- 108010061238 threonyl-glycine Proteins 0.000 description 6
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 5
- WUHJHHGYVVJMQE-BJDJZHNGSA-N Ala-Leu-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WUHJHHGYVVJMQE-BJDJZHNGSA-N 0.000 description 5
- DHBKYZYFEXXUAK-ONGXEEELSA-N Ala-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 DHBKYZYFEXXUAK-ONGXEEELSA-N 0.000 description 5
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 5
- AQPVUEJJARLJHB-BQBZGAKWSA-N Arg-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N AQPVUEJJARLJHB-BQBZGAKWSA-N 0.000 description 5
- IGFJVXOATGZTHD-UHFFFAOYSA-N Arg-Phe-His Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc2c[nH]cn2)C(=O)O IGFJVXOATGZTHD-UHFFFAOYSA-N 0.000 description 5
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 5
- UULLJGQFCDXVTQ-CYDGBPFRSA-N Arg-Pro-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UULLJGQFCDXVTQ-CYDGBPFRSA-N 0.000 description 5
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 5
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 5
- RRIJEABIXPKSGP-FXQIFTODSA-N Cys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CS RRIJEABIXPKSGP-FXQIFTODSA-N 0.000 description 5
- 108010090461 DFG peptide Proteins 0.000 description 5
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 5
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 5
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 5
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 5
- JCOSMKPAOYDKRO-AVGNSLFASA-N His-Glu-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N JCOSMKPAOYDKRO-AVGNSLFASA-N 0.000 description 5
- PGXZHYYGOPKYKM-IHRRRGAJSA-N His-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CCCCN)C(=O)O PGXZHYYGOPKYKM-IHRRRGAJSA-N 0.000 description 5
- WKEABZIITNXXQZ-CIUDSAMLSA-N His-Ser-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N WKEABZIITNXXQZ-CIUDSAMLSA-N 0.000 description 5
- GIRSNERMXCMDBO-GARJFASQSA-N His-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O GIRSNERMXCMDBO-GARJFASQSA-N 0.000 description 5
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 5
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 5
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 5
- KTNGVMMGIQWIDV-OSUNSFLBSA-N Ile-Pro-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O KTNGVMMGIQWIDV-OSUNSFLBSA-N 0.000 description 5
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 5
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- RSFGIMMPWAXNML-MNXVOIDGSA-N Leu-Gln-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSFGIMMPWAXNML-MNXVOIDGSA-N 0.000 description 5
- JKSIBWITFMQTOA-XUXIUFHCSA-N Leu-Ile-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O JKSIBWITFMQTOA-XUXIUFHCSA-N 0.000 description 5
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 5
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 5
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 5
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 5
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 5
- XFBBBRDEQIPGNR-KATARQTJSA-N Lys-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O XFBBBRDEQIPGNR-KATARQTJSA-N 0.000 description 5
- OVAOHZIOUBEQCJ-IHRRRGAJSA-N Lys-Leu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OVAOHZIOUBEQCJ-IHRRRGAJSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 5
- NMELOOXSGDRBRU-YUMQZZPRSA-N Pro-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 NMELOOXSGDRBRU-YUMQZZPRSA-N 0.000 description 5
- UIUWGMRJTWHIJZ-ULQDDVLXSA-N Pro-Tyr-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O UIUWGMRJTWHIJZ-ULQDDVLXSA-N 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- JEHPKECJCALLRW-CUJWVEQBSA-N Ser-His-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEHPKECJCALLRW-CUJWVEQBSA-N 0.000 description 5
- IXZHZUGGKLRHJD-DCAQKATOSA-N Ser-Leu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IXZHZUGGKLRHJD-DCAQKATOSA-N 0.000 description 5
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 5
- FHVCMIMUGUFIOJ-IHPCNDPISA-N Trp-His-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC4=CN=CN4)C(=O)O)N FHVCMIMUGUFIOJ-IHPCNDPISA-N 0.000 description 5
- UIDJDMVRDUANDL-BVSLBCMMSA-N Trp-Tyr-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UIDJDMVRDUANDL-BVSLBCMMSA-N 0.000 description 5
- LMLBOGIOLHZXOT-JYJNAYRXSA-N Tyr-Glu-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O LMLBOGIOLHZXOT-JYJNAYRXSA-N 0.000 description 5
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 5
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 5
- 108010013835 arginine glutamate Proteins 0.000 description 5
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 5
- 108010087823 glycyltyrosine Proteins 0.000 description 5
- 108010040030 histidinoalanine Proteins 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 108010078274 isoleucylvaline Proteins 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 108010003700 lysyl aspartic acid Proteins 0.000 description 5
- 108010064235 lysylglycine Proteins 0.000 description 5
- 108010053725 prolylvaline Proteins 0.000 description 5
- 108010009962 valyltyrosine Proteins 0.000 description 5
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 4
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 4
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 4
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 4
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 4
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 4
- ANGAOPNEPIDLPO-XVYDVKMFSA-N Ala-His-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N ANGAOPNEPIDLPO-XVYDVKMFSA-N 0.000 description 4
- HJGZVLLLBJLXFC-LSJOCFKGSA-N Ala-His-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O HJGZVLLLBJLXFC-LSJOCFKGSA-N 0.000 description 4
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 4
- XHNLCGXYBXNRIS-BJDJZHNGSA-N Ala-Lys-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XHNLCGXYBXNRIS-BJDJZHNGSA-N 0.000 description 4
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 4
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 4
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 4
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 4
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 4
- NVUIWHJLPSZZQC-CYDGBPFRSA-N Arg-Ile-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NVUIWHJLPSZZQC-CYDGBPFRSA-N 0.000 description 4
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 4
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 4
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 description 4
- FOWOZYAWODIRFZ-JYJNAYRXSA-N Arg-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)N FOWOZYAWODIRFZ-JYJNAYRXSA-N 0.000 description 4
- RRVBEKYEFMCDIF-WHFBIAKZSA-N Asn-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)C(=O)N RRVBEKYEFMCDIF-WHFBIAKZSA-N 0.000 description 4
- ULRPXVNMIIYDDJ-ACZMJKKPSA-N Asn-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N ULRPXVNMIIYDDJ-ACZMJKKPSA-N 0.000 description 4
- JZDZLBJVYWIIQU-AVGNSLFASA-N Asn-Glu-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JZDZLBJVYWIIQU-AVGNSLFASA-N 0.000 description 4
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 4
- SGAUXNZEFIEAAI-GARJFASQSA-N Asn-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)C(=O)O SGAUXNZEFIEAAI-GARJFASQSA-N 0.000 description 4
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 4
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 description 4
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 4
- VTYQAQFKMQTKQD-ACZMJKKPSA-N Asp-Ala-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O VTYQAQFKMQTKQD-ACZMJKKPSA-N 0.000 description 4
- NYLBGYLHBDFRHL-VEVYYDQMSA-N Asp-Arg-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NYLBGYLHBDFRHL-VEVYYDQMSA-N 0.000 description 4
- HOQGTAIGQSDCHR-SRVKXCTJSA-N Asp-Asn-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HOQGTAIGQSDCHR-SRVKXCTJSA-N 0.000 description 4
- ZSVJVIOVABDTTL-YUMQZZPRSA-N Asp-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N ZSVJVIOVABDTTL-YUMQZZPRSA-N 0.000 description 4
- PGUYEUCYVNZGGV-QWRGUYRKSA-N Asp-Gly-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PGUYEUCYVNZGGV-QWRGUYRKSA-N 0.000 description 4
- QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 4
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 4
- BJDHEININLSZOT-KKUMJFAQSA-N Asp-Tyr-Lys Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(O)=O BJDHEININLSZOT-KKUMJFAQSA-N 0.000 description 4
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 4
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 4
- SFRQEQGPRTVDPO-NRPADANISA-N Cys-Gln-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O SFRQEQGPRTVDPO-NRPADANISA-N 0.000 description 4
- WZZGXXNRSZIQFC-VGDYDELISA-N Cys-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CS)N WZZGXXNRSZIQFC-VGDYDELISA-N 0.000 description 4
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 4
- UKHNKRGNFKSHCG-CUJWVEQBSA-N Cys-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CS)N)O UKHNKRGNFKSHCG-CUJWVEQBSA-N 0.000 description 4
- IRKLTAKLAFUTLA-KATARQTJSA-N Cys-Thr-Lys Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCCCN)C(O)=O IRKLTAKLAFUTLA-KATARQTJSA-N 0.000 description 4
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 4
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 4
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 4
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 4
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 4
- OXEMJGCAJFFREE-FXQIFTODSA-N Glu-Gln-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O OXEMJGCAJFFREE-FXQIFTODSA-N 0.000 description 4
- MIQCYAJSDGNCNK-BPUTZDHNSA-N Glu-Gln-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MIQCYAJSDGNCNK-BPUTZDHNSA-N 0.000 description 4
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 4
- BCYGDJXHAGZNPQ-DCAQKATOSA-N Glu-Lys-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O BCYGDJXHAGZNPQ-DCAQKATOSA-N 0.000 description 4
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 4
- JHSRJMUJOGLIHK-GUBZILKMSA-N Glu-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N JHSRJMUJOGLIHK-GUBZILKMSA-N 0.000 description 4
- ZIYGTCDTJJCDDP-JYJNAYRXSA-N Glu-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZIYGTCDTJJCDDP-JYJNAYRXSA-N 0.000 description 4
- QJVZSVUYZFYLFQ-CIUDSAMLSA-N Glu-Pro-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O QJVZSVUYZFYLFQ-CIUDSAMLSA-N 0.000 description 4
- DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 4
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 4
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 4
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 4
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 4
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 4
- CIMULJZTTOBOPN-WHFBIAKZSA-N Gly-Asn-Asn Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CIMULJZTTOBOPN-WHFBIAKZSA-N 0.000 description 4
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 4
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 4
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 4
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 4
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 4
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 4
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 4
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 4
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 4
- OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 4
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 4
- BDFCIKANUNMFGB-PMVVWTBXSA-N His-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 BDFCIKANUNMFGB-PMVVWTBXSA-N 0.000 description 4
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 4
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 4
- FBOMZVOKCZMDIG-XQQFMLRXSA-N His-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBOMZVOKCZMDIG-XQQFMLRXSA-N 0.000 description 4
- DXUJSRIVSWEOAG-NAKRPEOUSA-N Ile-Arg-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N DXUJSRIVSWEOAG-NAKRPEOUSA-N 0.000 description 4
- BALLIXFZYSECCF-QEWYBTABSA-N Ile-Gln-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N BALLIXFZYSECCF-QEWYBTABSA-N 0.000 description 4
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 4
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 4
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 4
- JJQQGCMKLOEGAV-OSUNSFLBSA-N Ile-Thr-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)O)N JJQQGCMKLOEGAV-OSUNSFLBSA-N 0.000 description 4
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 4
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 4
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 4
- WRLPVDVHNWSSCL-MELADBBJSA-N Leu-His-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N WRLPVDVHNWSSCL-MELADBBJSA-N 0.000 description 4
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 4
- JVTYXRRFZCEPPK-RHYQMDGZSA-N Leu-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)N)O JVTYXRRFZCEPPK-RHYQMDGZSA-N 0.000 description 4
- HGUUMQWGYCVPKG-DCAQKATOSA-N Leu-Pro-Cys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N HGUUMQWGYCVPKG-DCAQKATOSA-N 0.000 description 4
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 4
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 4
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 4
- NCZIQZYZPUPMKY-PPCPHDFISA-N Lys-Ile-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NCZIQZYZPUPMKY-PPCPHDFISA-N 0.000 description 4
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 4
- XKJUFUPCHARJKX-UWVGGRQHSA-N Met-Gly-His Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 XKJUFUPCHARJKX-UWVGGRQHSA-N 0.000 description 4
- TZHFJXDKXGZHEN-IHRRRGAJSA-N Met-His-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O TZHFJXDKXGZHEN-IHRRRGAJSA-N 0.000 description 4
- XIGAHPDZLAYQOS-SRVKXCTJSA-N Met-Pro-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 XIGAHPDZLAYQOS-SRVKXCTJSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- WMGVYPPIMZPWPN-SRVKXCTJSA-N Phe-Asp-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N WMGVYPPIMZPWPN-SRVKXCTJSA-N 0.000 description 4
- MMYUOSCXBJFUNV-QWRGUYRKSA-N Phe-Gly-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N MMYUOSCXBJFUNV-QWRGUYRKSA-N 0.000 description 4
- NAOVYENZCWFBDG-BZSNNMDCSA-N Phe-His-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 NAOVYENZCWFBDG-BZSNNMDCSA-N 0.000 description 4
- MYQCCQSMKNCNKY-KKUMJFAQSA-N Phe-His-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O)N MYQCCQSMKNCNKY-KKUMJFAQSA-N 0.000 description 4
- DVOCGBNHAUHKHJ-DKIMLUQUSA-N Phe-Ile-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O DVOCGBNHAUHKHJ-DKIMLUQUSA-N 0.000 description 4
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 4
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 4
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 4
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 4
- NGNNPLJHUFCOMZ-FXQIFTODSA-N Pro-Asp-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 NGNNPLJHUFCOMZ-FXQIFTODSA-N 0.000 description 4
- CMOIIANLNNYUTP-SRVKXCTJSA-N Pro-Gln-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O CMOIIANLNNYUTP-SRVKXCTJSA-N 0.000 description 4
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 4
- VWXGFAIZUQBBBG-UWVGGRQHSA-N Pro-His-Gly Chemical compound C([C@@H](C(=O)NCC(=O)[O-])NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 VWXGFAIZUQBBBG-UWVGGRQHSA-N 0.000 description 4
- XFFIGWGYMUFCCQ-ULQDDVLXSA-N Pro-His-Tyr Chemical compound C1=CC(O)=CC=C1C[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H]1[NH2+]CCC1)CC1=CN=CN1 XFFIGWGYMUFCCQ-ULQDDVLXSA-N 0.000 description 4
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 4
- WLJYLAQSUSIQNH-GUBZILKMSA-N Pro-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@@H]1CCCN1 WLJYLAQSUSIQNH-GUBZILKMSA-N 0.000 description 4
- WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 4
- BCKYYTVFBXHPOG-ACZMJKKPSA-N Ser-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N BCKYYTVFBXHPOG-ACZMJKKPSA-N 0.000 description 4
- COLJZWUVZIXSSS-CIUDSAMLSA-N Ser-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N COLJZWUVZIXSSS-CIUDSAMLSA-N 0.000 description 4
- MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 4
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 4
- XERQKTRGJIKTRB-CIUDSAMLSA-N Ser-His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CN=CN1 XERQKTRGJIKTRB-CIUDSAMLSA-N 0.000 description 4
- IUXGJEIKJBYKOO-SRVKXCTJSA-N Ser-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N IUXGJEIKJBYKOO-SRVKXCTJSA-N 0.000 description 4
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 4
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 4
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 4
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 4
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 4
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 4
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 4
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 4
- FHXGMDRKJHKLKW-QWRGUYRKSA-N Ser-Tyr-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 FHXGMDRKJHKLKW-QWRGUYRKSA-N 0.000 description 4
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 4
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 4
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 4
- LXWZOMSOUAMOIA-JIOCBJNQSA-N Thr-Asn-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O LXWZOMSOUAMOIA-JIOCBJNQSA-N 0.000 description 4
- YOSLMIPKOUAHKI-OLHMAJIHSA-N Thr-Asp-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YOSLMIPKOUAHKI-OLHMAJIHSA-N 0.000 description 4
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 4
- OHAJHDJOCKKJLV-LKXGYXEUSA-N Thr-Asp-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O OHAJHDJOCKKJLV-LKXGYXEUSA-N 0.000 description 4
- WPSDXXQRIVKBAY-NKIYYHGXSA-N Thr-His-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O WPSDXXQRIVKBAY-NKIYYHGXSA-N 0.000 description 4
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 4
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 4
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 4
- XGFYGMKZKFRGAI-RCWTZXSCSA-N Thr-Val-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N XGFYGMKZKFRGAI-RCWTZXSCSA-N 0.000 description 4
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 4
- WLQRIHCMPFHGKP-PMVMPFDFSA-N Trp-Leu-Phe Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CC(C)C)C(O)=O)C1=CC=CC=C1 WLQRIHCMPFHGKP-PMVMPFDFSA-N 0.000 description 4
- SDNVRAKIJVKAGS-LKTVYLICSA-N Tyr-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N SDNVRAKIJVKAGS-LKTVYLICSA-N 0.000 description 4
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 4
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 4
- YRBHLWWGSSQICE-IHRRRGAJSA-N Tyr-Asp-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O YRBHLWWGSSQICE-IHRRRGAJSA-N 0.000 description 4
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 4
- PQPWEALFTLKSEB-DZKIICNBSA-N Tyr-Val-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PQPWEALFTLKSEB-DZKIICNBSA-N 0.000 description 4
- UUYCNAXCCDNULB-QXEWZRGKSA-N Val-Arg-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O UUYCNAXCCDNULB-QXEWZRGKSA-N 0.000 description 4
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 4
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 4
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 4
- PWRITNSESKQTPW-NRPADANISA-N Val-Gln-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N PWRITNSESKQTPW-NRPADANISA-N 0.000 description 4
- MDYSKHBSPXUOPV-JSGCOSHPSA-N Val-Gly-Phe Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N MDYSKHBSPXUOPV-JSGCOSHPSA-N 0.000 description 4
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 4
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 4
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 4
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 4
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 4
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 4
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 4
- MIAZWUMFUURQNP-YDHLFZDLSA-N Val-Tyr-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N MIAZWUMFUURQNP-YDHLFZDLSA-N 0.000 description 4
- LMVWCLDJNSBOEA-FKBYEOEOSA-N Val-Tyr-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N LMVWCLDJNSBOEA-FKBYEOEOSA-N 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010044940 alanylglutamine Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 4
- 108010068265 aspartyltyrosine Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 108010054813 diprotin B Proteins 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 4
- 108010079547 glutamylmethionine Proteins 0.000 description 4
- 108010084264 glycyl-glycyl-cysteine Proteins 0.000 description 4
- 108010010147 glycylglutamine Proteins 0.000 description 4
- 108010081551 glycylphenylalanine Proteins 0.000 description 4
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108010020532 tyrosyl-proline Proteins 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108010027345 wheylin-1 peptide Proteins 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 3
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 3
- CVGNCMIULZNYES-WHFBIAKZSA-N Ala-Asn-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CVGNCMIULZNYES-WHFBIAKZSA-N 0.000 description 3
- GORKKVHIBWAQHM-GCJQMDKQSA-N Ala-Asn-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GORKKVHIBWAQHM-GCJQMDKQSA-N 0.000 description 3
- ZIBWKCRKNFYTPT-ZKWXMUAHSA-N Ala-Asn-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZIBWKCRKNFYTPT-ZKWXMUAHSA-N 0.000 description 3
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 3
- BLGHHPHXVJWCNK-GUBZILKMSA-N Ala-Gln-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BLGHHPHXVJWCNK-GUBZILKMSA-N 0.000 description 3
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 3
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 3
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 3
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 3
- MTDDMSUUXNQMKK-BPNCWPANSA-N Ala-Tyr-Arg Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N MTDDMSUUXNQMKK-BPNCWPANSA-N 0.000 description 3
- YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 3
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 3
- ZCUFMRIQCPNOHZ-NRPADANISA-N Ala-Val-Gln Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZCUFMRIQCPNOHZ-NRPADANISA-N 0.000 description 3
- NLYYHIKRBRMAJV-AEJSXWLSSA-N Ala-Val-Pro Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N NLYYHIKRBRMAJV-AEJSXWLSSA-N 0.000 description 3
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 3
- KJGNDQCYBNBXDA-GUBZILKMSA-N Arg-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N KJGNDQCYBNBXDA-GUBZILKMSA-N 0.000 description 3
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 3
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 3
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 3
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 3
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 3
- QHVRVUNEAIFTEK-SZMVWBNQSA-N Arg-Pro-Trp Chemical compound N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O QHVRVUNEAIFTEK-SZMVWBNQSA-N 0.000 description 3
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 3
- CTAPSNCVKPOOSM-KKUMJFAQSA-N Arg-Tyr-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O CTAPSNCVKPOOSM-KKUMJFAQSA-N 0.000 description 3
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 3
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 3
- GNKVBRYFXYWXAB-WDSKDSINSA-N Asn-Glu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O GNKVBRYFXYWXAB-WDSKDSINSA-N 0.000 description 3
- BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 description 3
- QUAWOKPCAKCHQL-SRVKXCTJSA-N Asn-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QUAWOKPCAKCHQL-SRVKXCTJSA-N 0.000 description 3
- ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 3
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 3
- TZQWZQSMHDVLQL-QEJZJMRPSA-N Asn-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N TZQWZQSMHDVLQL-QEJZJMRPSA-N 0.000 description 3
- XPGVTUBABLRGHY-BIIVOSGPSA-N Asp-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N XPGVTUBABLRGHY-BIIVOSGPSA-N 0.000 description 3
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 3
- SMZCLQGDQMGESY-ACZMJKKPSA-N Asp-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N SMZCLQGDQMGESY-ACZMJKKPSA-N 0.000 description 3
- TVIZQBFURPLQDV-DJFWLOJKSA-N Asp-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N TVIZQBFURPLQDV-DJFWLOJKSA-N 0.000 description 3
- UBPMOJLRVMGTOQ-GARJFASQSA-N Asp-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)C(=O)O UBPMOJLRVMGTOQ-GARJFASQSA-N 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 3
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 3
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 3
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 3
- ZXRQJQCXPSMNMR-XIRDDKMYSA-N Asp-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N ZXRQJQCXPSMNMR-XIRDDKMYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 201000009182 Chikungunya Diseases 0.000 description 3
- XMTDCXXLDZKAGI-ACZMJKKPSA-N Cys-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XMTDCXXLDZKAGI-ACZMJKKPSA-N 0.000 description 3
- AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 description 3
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 3
- CUXIOFHFFXNUGG-HTFCKZLJSA-N Cys-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CS)N CUXIOFHFFXNUGG-HTFCKZLJSA-N 0.000 description 3
- KKUVRYLJEXJSGX-MXAVVETBSA-N Cys-Ile-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CS)N KKUVRYLJEXJSGX-MXAVVETBSA-N 0.000 description 3
- XZKJEOMFLDVXJG-KATARQTJSA-N Cys-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)N)O XZKJEOMFLDVXJG-KATARQTJSA-N 0.000 description 3
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 3
- ORYFTECKJZTNQP-DCAQKATOSA-N Cys-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N ORYFTECKJZTNQP-DCAQKATOSA-N 0.000 description 3
- MQQLYEHXSBJTRK-FXQIFTODSA-N Cys-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N MQQLYEHXSBJTRK-FXQIFTODSA-N 0.000 description 3
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 3
- HDUDGCZEOZEFOA-KBIXCLLPSA-N Gln-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HDUDGCZEOZEFOA-KBIXCLLPSA-N 0.000 description 3
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 3
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 3
- SDSMVVSHLAAOJL-UKJIMTQDSA-N Gln-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N SDSMVVSHLAAOJL-UKJIMTQDSA-N 0.000 description 3
- KEBACWCLVOXFNC-DCAQKATOSA-N Glu-Arg-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O KEBACWCLVOXFNC-DCAQKATOSA-N 0.000 description 3
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 3
- LRPXYSGPOBVBEH-IUCAKERBSA-N Glu-Gly-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O LRPXYSGPOBVBEH-IUCAKERBSA-N 0.000 description 3
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 3
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 3
- CBOVGULVQSVMPT-CIUDSAMLSA-N Glu-Pro-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O CBOVGULVQSVMPT-CIUDSAMLSA-N 0.000 description 3
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 3
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 3
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 3
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 3
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 3
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 3
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 3
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 3
- KTSZUNRRYXPZTK-BQBZGAKWSA-N Gly-Gln-Glu Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KTSZUNRRYXPZTK-BQBZGAKWSA-N 0.000 description 3
- LXXANCRPFBSSKS-IUCAKERBSA-N Gly-Gln-Leu Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LXXANCRPFBSSKS-IUCAKERBSA-N 0.000 description 3
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 3
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 3
- OCPPBNKYGYSLOE-IUCAKERBSA-N Gly-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN OCPPBNKYGYSLOE-IUCAKERBSA-N 0.000 description 3
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 3
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 3
- BIAKMWKJMQLZOJ-ZKWXMUAHSA-N His-Ala-Ala Chemical compound C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(O)=O BIAKMWKJMQLZOJ-ZKWXMUAHSA-N 0.000 description 3
- MWWOPNQSBXEUHO-ULQDDVLXSA-N His-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 MWWOPNQSBXEUHO-ULQDDVLXSA-N 0.000 description 3
- AKEDPWJFQULLPE-IUCAKERBSA-N His-Glu-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O AKEDPWJFQULLPE-IUCAKERBSA-N 0.000 description 3
- VTMLJMNQHKBPON-QWRGUYRKSA-N His-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 VTMLJMNQHKBPON-QWRGUYRKSA-N 0.000 description 3
- YYOCMTFVGKDNQP-IHRRRGAJSA-N His-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N YYOCMTFVGKDNQP-IHRRRGAJSA-N 0.000 description 3
- PYNPBMCLAKTHJL-SRVKXCTJSA-N His-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O PYNPBMCLAKTHJL-SRVKXCTJSA-N 0.000 description 3
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 3
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 3
- KOPIAUWNLKKELG-SIGLWIIPSA-N Ile-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N KOPIAUWNLKKELG-SIGLWIIPSA-N 0.000 description 3
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 3
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 3
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 3
- YKZAMJXNJUWFIK-JBDRJPRFSA-N Ile-Ser-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)O)N YKZAMJXNJUWFIK-JBDRJPRFSA-N 0.000 description 3
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 3
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 3
- YHFPHRUWZMEOIX-CYDGBPFRSA-N Ile-Val-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N YHFPHRUWZMEOIX-CYDGBPFRSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 3
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 3
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 3
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 3
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 3
- DLCXCECTCPKKCD-GUBZILKMSA-N Leu-Gln-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DLCXCECTCPKKCD-GUBZILKMSA-N 0.000 description 3
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 3
- MUCIDQMDOYQYBR-IHRRRGAJSA-N Leu-Pro-His Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N MUCIDQMDOYQYBR-IHRRRGAJSA-N 0.000 description 3
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 3
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 3
- VHTIZYYHIUHMCA-JYJNAYRXSA-N Leu-Tyr-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VHTIZYYHIUHMCA-JYJNAYRXSA-N 0.000 description 3
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 3
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 3
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 3
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 3
- CFVQPNSCQMKDPB-CIUDSAMLSA-N Lys-Cys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N CFVQPNSCQMKDPB-CIUDSAMLSA-N 0.000 description 3
- GRADYHMSAUIKPS-DCAQKATOSA-N Lys-Glu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRADYHMSAUIKPS-DCAQKATOSA-N 0.000 description 3
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 3
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 3
- IUWMQCZOTYRXPL-ZPFDUUQYSA-N Lys-Ile-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O IUWMQCZOTYRXPL-ZPFDUUQYSA-N 0.000 description 3
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 3
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 3
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 3
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 3
- UDXSLGLHFUBRRM-OEAJRASXSA-N Lys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N)O UDXSLGLHFUBRRM-OEAJRASXSA-N 0.000 description 3
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 3
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 3
- RNAGAJXCSPDPRK-KKUMJFAQSA-N Met-Glu-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 RNAGAJXCSPDPRK-KKUMJFAQSA-N 0.000 description 3
- SODXFJOPSCXOHE-IHRRRGAJSA-N Met-Leu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O SODXFJOPSCXOHE-IHRRRGAJSA-N 0.000 description 3
- IRVONVRHHJXWTK-RWMBFGLXSA-N Met-Lys-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N IRVONVRHHJXWTK-RWMBFGLXSA-N 0.000 description 3
- PHURAEXVWLDIGT-LPEHRKFASA-N Met-Ser-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N PHURAEXVWLDIGT-LPEHRKFASA-N 0.000 description 3
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 3
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 3
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 3
- DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 3
- RYAUPBMDRMJVRM-BVSLBCMMSA-N Phe-Met-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)N RYAUPBMDRMJVRM-BVSLBCMMSA-N 0.000 description 3
- YVXPUUOTMVBKDO-IHRRRGAJSA-N Phe-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CS)C(=O)O YVXPUUOTMVBKDO-IHRRRGAJSA-N 0.000 description 3
- HBXAOEBRGLCLIW-AVGNSLFASA-N Phe-Ser-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HBXAOEBRGLCLIW-AVGNSLFASA-N 0.000 description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 3
- SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 3
- WFLWKEUBTSOFMP-FXQIFTODSA-N Pro-Cys-Cys Chemical compound OC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 WFLWKEUBTSOFMP-FXQIFTODSA-N 0.000 description 3
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 3
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 3
- JUJCUYWRJMFJJF-AVGNSLFASA-N Pro-Lys-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 JUJCUYWRJMFJJF-AVGNSLFASA-N 0.000 description 3
- ZVEQWRWMRFIVSD-HRCADAONSA-N Pro-Phe-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@@H]3C(=O)O ZVEQWRWMRFIVSD-HRCADAONSA-N 0.000 description 3
- FHZJRBVMLGOHBX-GUBZILKMSA-N Pro-Pro-Asp Chemical compound OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O FHZJRBVMLGOHBX-GUBZILKMSA-N 0.000 description 3
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 3
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 3
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 3
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 3
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 3
- CXGLFEOYCJFKPR-RCWTZXSCSA-N Pro-Thr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O CXGLFEOYCJFKPR-RCWTZXSCSA-N 0.000 description 3
- FZXSYIPVAFVYBH-KKUMJFAQSA-N Pro-Tyr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O FZXSYIPVAFVYBH-KKUMJFAQSA-N 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 3
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 3
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 3
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 3
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 3
- FGBLCMLXHRPVOF-IHRRRGAJSA-N Ser-Tyr-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FGBLCMLXHRPVOF-IHRRRGAJSA-N 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 3
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 3
- LHUBVKCLOVALIA-HJGDQZAQSA-N Thr-Arg-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LHUBVKCLOVALIA-HJGDQZAQSA-N 0.000 description 3
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 3
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 3
- OQCXTUQTKQFDCX-HTUGSXCWSA-N Thr-Glu-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O OQCXTUQTKQFDCX-HTUGSXCWSA-N 0.000 description 3
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 3
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 3
- YJCVECXVYHZOBK-KNZXXDILSA-N Thr-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H]([C@@H](C)O)N YJCVECXVYHZOBK-KNZXXDILSA-N 0.000 description 3
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 3
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 3
- KPNSNVTUVKSBFL-ZJDVBMNYSA-N Thr-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KPNSNVTUVKSBFL-ZJDVBMNYSA-N 0.000 description 3
- NYQIZWROIMIQSL-VEVYYDQMSA-N Thr-Pro-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O NYQIZWROIMIQSL-VEVYYDQMSA-N 0.000 description 3
- BJJRNAVDQGREGC-HOUAVDHOSA-N Thr-Trp-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O BJJRNAVDQGREGC-HOUAVDHOSA-N 0.000 description 3
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 3
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 3
- FNOQJVHFVLVMOS-AAEUAGOBSA-N Trp-Gly-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N FNOQJVHFVLVMOS-AAEUAGOBSA-N 0.000 description 3
- ZZDFLJFVSNQINX-HWHUXHBOSA-N Trp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)O ZZDFLJFVSNQINX-HWHUXHBOSA-N 0.000 description 3
- JBBYKPZAPOLCPK-JYJNAYRXSA-N Tyr-Arg-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O JBBYKPZAPOLCPK-JYJNAYRXSA-N 0.000 description 3
- CKKFTIQYURNSEI-IHRRRGAJSA-N Tyr-Asn-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CKKFTIQYURNSEI-IHRRRGAJSA-N 0.000 description 3
- BVDHHLMIZFCAAU-BZSNNMDCSA-N Tyr-Cys-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BVDHHLMIZFCAAU-BZSNNMDCSA-N 0.000 description 3
- NZFCWALTLNFHHC-JYJNAYRXSA-N Tyr-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NZFCWALTLNFHHC-JYJNAYRXSA-N 0.000 description 3
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 3
- VTCKHZJKWQENKX-KBPBESRZSA-N Tyr-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O VTCKHZJKWQENKX-KBPBESRZSA-N 0.000 description 3
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 3
- LYPKCSYAKLTBHJ-ILWGZMRPSA-N Tyr-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)N)C(=O)O LYPKCSYAKLTBHJ-ILWGZMRPSA-N 0.000 description 3
- GZWPQZDVTBZVEP-BZSNNMDCSA-N Tyr-Tyr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O GZWPQZDVTBZVEP-BZSNNMDCSA-N 0.000 description 3
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 3
- 206010046392 Ureteric cancer Diseases 0.000 description 3
- ZEVNVXYRZRIRCH-GVXVVHGQSA-N Val-Gln-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N ZEVNVXYRZRIRCH-GVXVVHGQSA-N 0.000 description 3
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 3
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 3
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 3
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 3
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 3
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 3
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 3
- TVGWMCTYUFBXAP-QTKMDUPCSA-N Val-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N)O TVGWMCTYUFBXAP-QTKMDUPCSA-N 0.000 description 3
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 3
- UEXPMFIAZZHEAD-HSHDSVGOSA-N Val-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](C(C)C)N)O UEXPMFIAZZHEAD-HSHDSVGOSA-N 0.000 description 3
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 3
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010040856 glutamyl-cysteinyl-alanine Proteins 0.000 description 3
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 108010092114 histidylphenylalanine Proteins 0.000 description 3
- 102000048776 human CD274 Human genes 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 108010027338 isoleucylcysteine Proteins 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 3
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 3
- 108010084572 phenylalanyl-valine Proteins 0.000 description 3
- 108010012581 phenylalanylglutamate Proteins 0.000 description 3
- 108010048818 seryl-histidine Proteins 0.000 description 3
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 3
- 108010071207 serylmethionine Proteins 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- 108010044292 tryptophyltyrosine Proteins 0.000 description 3
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- RRBGTUQJDFBWNN-MUGJNUQGSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2,6-diaminohexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O RRBGTUQJDFBWNN-MUGJNUQGSA-N 0.000 description 2
- 241000235389 Absidia Species 0.000 description 2
- 241000224424 Acanthamoeba sp. Species 0.000 description 2
- SBGXWWCLHIOABR-UHFFFAOYSA-N Ala Ala Gly Ala Chemical compound CC(N)C(=O)NC(C)C(=O)NCC(=O)NC(C)C(O)=O SBGXWWCLHIOABR-UHFFFAOYSA-N 0.000 description 2
- UGLPMYSCWHTZQU-AUTRQRHGSA-N Ala-Ala-Tyr Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UGLPMYSCWHTZQU-AUTRQRHGSA-N 0.000 description 2
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 2
- LZRNYBIJOSKKRJ-XVYDVKMFSA-N Ala-Asp-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LZRNYBIJOSKKRJ-XVYDVKMFSA-N 0.000 description 2
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 2
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 2
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 2
- IXTPACPAXIOCRG-ACZMJKKPSA-N Ala-Glu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N IXTPACPAXIOCRG-ACZMJKKPSA-N 0.000 description 2
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 2
- OKEWAFFWMHBGPT-XPUUQOCRSA-N Ala-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 OKEWAFFWMHBGPT-XPUUQOCRSA-N 0.000 description 2
- NJWJSLCQEDMGNC-MBLNEYKQSA-N Ala-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N)O NJWJSLCQEDMGNC-MBLNEYKQSA-N 0.000 description 2
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 2
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 2
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 2
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 2
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 2
- NHWYNIZWLJYZAG-XVYDVKMFSA-N Ala-Ser-His Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N NHWYNIZWLJYZAG-XVYDVKMFSA-N 0.000 description 2
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 2
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 2
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 2
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 2
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 description 2
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 2
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- YFWTXMRJJDNTLM-LSJOCFKGSA-N Arg-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFWTXMRJJDNTLM-LSJOCFKGSA-N 0.000 description 2
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 2
- WESHVRNMNFMVBE-FXQIFTODSA-N Arg-Asn-Asp Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)CN=C(N)N WESHVRNMNFMVBE-FXQIFTODSA-N 0.000 description 2
- DPNHSNLIULPOBH-GUBZILKMSA-N Arg-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N DPNHSNLIULPOBH-GUBZILKMSA-N 0.000 description 2
- GHNDBBVSWOWYII-LPEHRKFASA-N Arg-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GHNDBBVSWOWYII-LPEHRKFASA-N 0.000 description 2
- YWENWUYXQUWRHQ-LPEHRKFASA-N Arg-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O YWENWUYXQUWRHQ-LPEHRKFASA-N 0.000 description 2
- OBFTYSPXDRROQO-SRVKXCTJSA-N Arg-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N OBFTYSPXDRROQO-SRVKXCTJSA-N 0.000 description 2
- RYQSYXFGFOTJDJ-RHYQMDGZSA-N Arg-Thr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RYQSYXFGFOTJDJ-RHYQMDGZSA-N 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- ZPWMEWYQBWSGAO-ZJDVBMNYSA-N Arg-Thr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZPWMEWYQBWSGAO-ZJDVBMNYSA-N 0.000 description 2
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 2
- NMTANZXPDAHUKU-ULQDDVLXSA-N Arg-Tyr-Lys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 NMTANZXPDAHUKU-ULQDDVLXSA-N 0.000 description 2
- CPTXATAOUQJQRO-GUBZILKMSA-N Arg-Val-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O CPTXATAOUQJQRO-GUBZILKMSA-N 0.000 description 2
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 2
- VDCIPFYVCICPEC-FXQIFTODSA-N Asn-Arg-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O VDCIPFYVCICPEC-FXQIFTODSA-N 0.000 description 2
- YNSCBOUZTAGIGO-ZLUOBGJFSA-N Asn-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)N YNSCBOUZTAGIGO-ZLUOBGJFSA-N 0.000 description 2
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 2
- VJTWLBMESLDOMK-WDSKDSINSA-N Asn-Gln-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O VJTWLBMESLDOMK-WDSKDSINSA-N 0.000 description 2
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 2
- ICDDSTLEMLGSTB-GUBZILKMSA-N Asn-Met-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ICDDSTLEMLGSTB-GUBZILKMSA-N 0.000 description 2
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 2
- VWADICJNCPFKJS-ZLUOBGJFSA-N Asn-Ser-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O VWADICJNCPFKJS-ZLUOBGJFSA-N 0.000 description 2
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 2
- SKQTXVZTCGSRJS-SRVKXCTJSA-N Asn-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O SKQTXVZTCGSRJS-SRVKXCTJSA-N 0.000 description 2
- DXHINQUXBZNUCF-MELADBBJSA-N Asn-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O DXHINQUXBZNUCF-MELADBBJSA-N 0.000 description 2
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 2
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 2
- SDHFVYLZFBDSQT-DCAQKATOSA-N Asp-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N SDHFVYLZFBDSQT-DCAQKATOSA-N 0.000 description 2
- JDHOJQJMWBKHDB-CIUDSAMLSA-N Asp-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N JDHOJQJMWBKHDB-CIUDSAMLSA-N 0.000 description 2
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 2
- QQXOYLWJQUPXJU-WHFBIAKZSA-N Asp-Cys-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O QQXOYLWJQUPXJU-WHFBIAKZSA-N 0.000 description 2
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 2
- SPKCGKRUYKMDHP-GUDRVLHUSA-N Asp-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N SPKCGKRUYKMDHP-GUDRVLHUSA-N 0.000 description 2
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 2
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 2
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 2
- ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 description 2
- LEYKQPDPZJIRTA-AQZXSJQPSA-N Asp-Trp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LEYKQPDPZJIRTA-AQZXSJQPSA-N 0.000 description 2
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241001235572 Balantioides coli Species 0.000 description 2
- 241000710946 Barmah Forest virus Species 0.000 description 2
- 241000228405 Blastomyces dermatitidis Species 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000295636 Cryptosporidium sp. Species 0.000 description 2
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 2
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 2
- JIVJXVJMOBVCJF-ZLUOBGJFSA-N Cys-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)C(=O)N JIVJXVJMOBVCJF-ZLUOBGJFSA-N 0.000 description 2
- HNNGTYHNYDOSKV-FXQIFTODSA-N Cys-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N HNNGTYHNYDOSKV-FXQIFTODSA-N 0.000 description 2
- BCSYBBMFGLHCOA-ACZMJKKPSA-N Cys-Glu-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O BCSYBBMFGLHCOA-ACZMJKKPSA-N 0.000 description 2
- OXOQBEVULIBOSH-ZDLURKLDSA-N Cys-Gly-Thr Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O OXOQBEVULIBOSH-ZDLURKLDSA-N 0.000 description 2
- WTNLLMQAFPOCTJ-GARJFASQSA-N Cys-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)N)C(=O)O WTNLLMQAFPOCTJ-GARJFASQSA-N 0.000 description 2
- WAJDEKCJRKGRPG-CIUDSAMLSA-N Cys-His-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N WAJDEKCJRKGRPG-CIUDSAMLSA-N 0.000 description 2
- MRVSLWQRNWEROS-SVSWQMSJSA-N Cys-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CS)N MRVSLWQRNWEROS-SVSWQMSJSA-N 0.000 description 2
- ZHCCYSDALWJITB-SRVKXCTJSA-N Cys-Phe-Cys Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O ZHCCYSDALWJITB-SRVKXCTJSA-N 0.000 description 2
- SAEVTQWAYDPXMU-KATARQTJSA-N Cys-Thr-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O SAEVTQWAYDPXMU-KATARQTJSA-N 0.000 description 2
- IQXSTXKVEMRMMB-XAVMHZPKSA-N Cys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N)O IQXSTXKVEMRMMB-XAVMHZPKSA-N 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000224432 Entamoeba histolytica Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000224466 Giardia Species 0.000 description 2
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 2
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 2
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 2
- KJRXLVZYJJLUCV-DCAQKATOSA-N Gln-Arg-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O KJRXLVZYJJLUCV-DCAQKATOSA-N 0.000 description 2
- ZRXBYKAOFHLTDN-GUBZILKMSA-N Gln-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N ZRXBYKAOFHLTDN-GUBZILKMSA-N 0.000 description 2
- VNCLJDOTEPPBBD-GUBZILKMSA-N Gln-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N VNCLJDOTEPPBBD-GUBZILKMSA-N 0.000 description 2
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 2
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 2
- SMLDOQHTOAAFJQ-WDSKDSINSA-N Gln-Gly-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SMLDOQHTOAAFJQ-WDSKDSINSA-N 0.000 description 2
- NROSLUJMIQGFKS-IUCAKERBSA-N Gln-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N NROSLUJMIQGFKS-IUCAKERBSA-N 0.000 description 2
- YRWWJCDWLVXTHN-LAEOZQHASA-N Gln-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N YRWWJCDWLVXTHN-LAEOZQHASA-N 0.000 description 2
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 2
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 2
- KSKFIECUYMYWNS-AVGNSLFASA-N Gln-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N KSKFIECUYMYWNS-AVGNSLFASA-N 0.000 description 2
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 2
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 2
- KHHDJQRWIFHXHS-NRPADANISA-N Gln-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N KHHDJQRWIFHXHS-NRPADANISA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 2
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 2
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 2
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 2
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 2
- CAVMESABQIKFKT-IUCAKERBSA-N Glu-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N CAVMESABQIKFKT-IUCAKERBSA-N 0.000 description 2
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 2
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 description 2
- DXMOIVCNJIJQSC-QEJZJMRPSA-N Glu-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N DXMOIVCNJIJQSC-QEJZJMRPSA-N 0.000 description 2
- HAGKYCXGTRUUFI-RYUDHWBXSA-N Glu-Tyr-Gly Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)O)N)O HAGKYCXGTRUUFI-RYUDHWBXSA-N 0.000 description 2
- HBMRTXJZQDVRFT-DZKIICNBSA-N Glu-Tyr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HBMRTXJZQDVRFT-DZKIICNBSA-N 0.000 description 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 2
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 2
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 2
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 2
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 2
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 2
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 2
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 2
- NPSWCZIRBAYNSB-JHEQGTHGSA-N Gly-Gln-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPSWCZIRBAYNSB-JHEQGTHGSA-N 0.000 description 2
- JUBDONGMHASUCN-IUCAKERBSA-N Gly-Glu-His Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O JUBDONGMHASUCN-IUCAKERBSA-N 0.000 description 2
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 2
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 2
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 2
- HPAIKDPJURGQLN-KBPBESRZSA-N Gly-His-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 HPAIKDPJURGQLN-KBPBESRZSA-N 0.000 description 2
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 2
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 2
- VLIJYPMATZSOLL-YUMQZZPRSA-N Gly-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN VLIJYPMATZSOLL-YUMQZZPRSA-N 0.000 description 2
- QLQDIJBYJZKQPR-BQBZGAKWSA-N Gly-Met-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN QLQDIJBYJZKQPR-BQBZGAKWSA-N 0.000 description 2
- YLEIWGJJBFBFHC-KBPBESRZSA-N Gly-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 YLEIWGJJBFBFHC-KBPBESRZSA-N 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 2
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 2
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 2
- BXDLTKLPPKBVEL-FJXKBIBVSA-N Gly-Thr-Met Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O BXDLTKLPPKBVEL-FJXKBIBVSA-N 0.000 description 2
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 2
- NIOPEYHPOBWLQO-KBPBESRZSA-N Gly-Trp-Glu Chemical compound NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOPEYHPOBWLQO-KBPBESRZSA-N 0.000 description 2
- YDIDLLVFCYSXNY-RCOVLWMOSA-N Gly-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN YDIDLLVFCYSXNY-RCOVLWMOSA-N 0.000 description 2
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 2
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 2
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- QIVPRLJQQVXCIY-HGNGGELXSA-N His-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CCC(N)=O)C(O)=O QIVPRLJQQVXCIY-HGNGGELXSA-N 0.000 description 2
- HXKZJLWGSWQKEA-LSJOCFKGSA-N His-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 HXKZJLWGSWQKEA-LSJOCFKGSA-N 0.000 description 2
- HDXNWVLQSQFJOX-SRVKXCTJSA-N His-Arg-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HDXNWVLQSQFJOX-SRVKXCTJSA-N 0.000 description 2
- WYWBYSPRCFADBM-GARJFASQSA-N His-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O WYWBYSPRCFADBM-GARJFASQSA-N 0.000 description 2
- TXLQHACKRLWYCM-DCAQKATOSA-N His-Glu-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O TXLQHACKRLWYCM-DCAQKATOSA-N 0.000 description 2
- DYKZGTLPSNOFHU-DEQVHRJGSA-N His-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N DYKZGTLPSNOFHU-DEQVHRJGSA-N 0.000 description 2
- IWXMHXYOACDSIA-PYJNHQTQSA-N His-Ile-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O IWXMHXYOACDSIA-PYJNHQTQSA-N 0.000 description 2
- FHGVHXCQMJWQPK-SRVKXCTJSA-N His-Lys-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O FHGVHXCQMJWQPK-SRVKXCTJSA-N 0.000 description 2
- UMBKDWGQESDCTO-KKUMJFAQSA-N His-Lys-Lys Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O UMBKDWGQESDCTO-KKUMJFAQSA-N 0.000 description 2
- PBVQWNDMFFCPIZ-ULQDDVLXSA-N His-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 PBVQWNDMFFCPIZ-ULQDDVLXSA-N 0.000 description 2
- OWYIDJCNRWRSJY-QTKMDUPCSA-N His-Pro-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O OWYIDJCNRWRSJY-QTKMDUPCSA-N 0.000 description 2
- HIJIJPFILYPTFR-ACRUOGEOSA-N His-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HIJIJPFILYPTFR-ACRUOGEOSA-N 0.000 description 2
- SYPULFZAGBBIOM-GVXVVHGQSA-N His-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N SYPULFZAGBBIOM-GVXVVHGQSA-N 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- TZCGZYWNIDZZMR-UHFFFAOYSA-N Ile-Arg-Ala Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(C)C(O)=O)CCCN=C(N)N TZCGZYWNIDZZMR-UHFFFAOYSA-N 0.000 description 2
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 2
- FJWYJQRCVNGEAQ-ZPFDUUQYSA-N Ile-Asn-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N FJWYJQRCVNGEAQ-ZPFDUUQYSA-N 0.000 description 2
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 2
- LOXMWQOKYBGCHF-JBDRJPRFSA-N Ile-Cys-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O LOXMWQOKYBGCHF-JBDRJPRFSA-N 0.000 description 2
- YBJWJQQBWRARLT-KBIXCLLPSA-N Ile-Gln-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O YBJWJQQBWRARLT-KBIXCLLPSA-N 0.000 description 2
- PHIXPNQDGGILMP-YVNDNENWSA-N Ile-Glu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PHIXPNQDGGILMP-YVNDNENWSA-N 0.000 description 2
- NHJKZMDIMMTVCK-QXEWZRGKSA-N Ile-Gly-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N NHJKZMDIMMTVCK-QXEWZRGKSA-N 0.000 description 2
- BBQABUDWDUKJMB-LZXPERKUSA-N Ile-Ile-Ile Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O BBQABUDWDUKJMB-LZXPERKUSA-N 0.000 description 2
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 2
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 2
- YSGBJIQXTIVBHZ-AJNGGQMLSA-N Ile-Lys-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O YSGBJIQXTIVBHZ-AJNGGQMLSA-N 0.000 description 2
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 2
- OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 2
- CIJLNXXMDUOFPH-HJWJTTGWSA-N Ile-Pro-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CIJLNXXMDUOFPH-HJWJTTGWSA-N 0.000 description 2
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 241000701460 JC polyomavirus Species 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- 241001245510 Lambia <signal fly> Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000222727 Leishmania donovani Species 0.000 description 2
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 2
- ZURHXHNAEJJRNU-CIUDSAMLSA-N Leu-Asp-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZURHXHNAEJJRNU-CIUDSAMLSA-N 0.000 description 2
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 description 2
- GZAUZBUKDXYPEH-CIUDSAMLSA-N Leu-Cys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N GZAUZBUKDXYPEH-CIUDSAMLSA-N 0.000 description 2
- BOFAFKVZQUMTID-AVGNSLFASA-N Leu-Gln-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N BOFAFKVZQUMTID-AVGNSLFASA-N 0.000 description 2
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 2
- RVVBWTWPNFDYBE-SRVKXCTJSA-N Leu-Glu-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVVBWTWPNFDYBE-SRVKXCTJSA-N 0.000 description 2
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 2
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 2
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 2
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 2
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 2
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 2
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 2
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 2
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 2
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 2
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 2
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 2
- FZIJIFCXUCZHOL-CIUDSAMLSA-N Lys-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN FZIJIFCXUCZHOL-CIUDSAMLSA-N 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 2
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 2
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 2
- ZAWOJFFMBANLGE-CIUDSAMLSA-N Lys-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N ZAWOJFFMBANLGE-CIUDSAMLSA-N 0.000 description 2
- DFXQCCBKGUNYGG-GUBZILKMSA-N Lys-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN DFXQCCBKGUNYGG-GUBZILKMSA-N 0.000 description 2
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 2
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 2
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 2
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 2
- KYNNSEJZFVCDIV-ZPFDUUQYSA-N Lys-Ile-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O KYNNSEJZFVCDIV-ZPFDUUQYSA-N 0.000 description 2
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 2
- QKXZCUCBFPEXNK-KKUMJFAQSA-N Lys-Leu-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 QKXZCUCBFPEXNK-KKUMJFAQSA-N 0.000 description 2
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 2
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 2
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 2
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 2
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 2
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 2
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 2
- PPNCMJARTHYNEC-MEYUZBJRSA-N Lys-Tyr-Thr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 PPNCMJARTHYNEC-MEYUZBJRSA-N 0.000 description 2
- USPJSTBDIGJPFK-PMVMPFDFSA-N Lys-Tyr-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O USPJSTBDIGJPFK-PMVMPFDFSA-N 0.000 description 2
- VWJFOUBDZIUXGA-AVGNSLFASA-N Lys-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N VWJFOUBDZIUXGA-AVGNSLFASA-N 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- LMKSBGIUPVRHEH-FXQIFTODSA-N Met-Ala-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(N)=O LMKSBGIUPVRHEH-FXQIFTODSA-N 0.000 description 2
- TZLYIHDABYBOCJ-FXQIFTODSA-N Met-Asp-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O TZLYIHDABYBOCJ-FXQIFTODSA-N 0.000 description 2
- PNDCUTDWYVKBHX-IHRRRGAJSA-N Met-Asp-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PNDCUTDWYVKBHX-IHRRRGAJSA-N 0.000 description 2
- CRGKLOXHKICQOL-GARJFASQSA-N Met-Gln-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N CRGKLOXHKICQOL-GARJFASQSA-N 0.000 description 2
- PHWSCIFNNLLUFJ-NHCYSSNCSA-N Met-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N PHWSCIFNNLLUFJ-NHCYSSNCSA-N 0.000 description 2
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 2
- HWROAFGWPQUPTE-OSUNSFLBSA-N Met-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCSC)N HWROAFGWPQUPTE-OSUNSFLBSA-N 0.000 description 2
- QZPXMHVKPHJNTR-DCAQKATOSA-N Met-Leu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O QZPXMHVKPHJNTR-DCAQKATOSA-N 0.000 description 2
- HGAJNEWOUHDUMZ-SRVKXCTJSA-N Met-Leu-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O HGAJNEWOUHDUMZ-SRVKXCTJSA-N 0.000 description 2
- CGUYGMFQZCYJSG-DCAQKATOSA-N Met-Lys-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O CGUYGMFQZCYJSG-DCAQKATOSA-N 0.000 description 2
- CRVSHEPROQHVQT-AVGNSLFASA-N Met-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N CRVSHEPROQHVQT-AVGNSLFASA-N 0.000 description 2
- XGIQKEAKUSPCBU-SRVKXCTJSA-N Met-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCSC)N XGIQKEAKUSPCBU-SRVKXCTJSA-N 0.000 description 2
- NTYQUVLERIHPMU-HRCADAONSA-N Met-Phe-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N NTYQUVLERIHPMU-HRCADAONSA-N 0.000 description 2
- NHXXGBXJTLRGJI-GUBZILKMSA-N Met-Pro-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NHXXGBXJTLRGJI-GUBZILKMSA-N 0.000 description 2
- SBFPAAPFKZPDCZ-JYJNAYRXSA-N Met-Pro-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O SBFPAAPFKZPDCZ-JYJNAYRXSA-N 0.000 description 2
- WRXOPYNEKGZWAZ-FXQIFTODSA-N Met-Ser-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O WRXOPYNEKGZWAZ-FXQIFTODSA-N 0.000 description 2
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 2
- WYNIRYZIFZGWQD-BPUTZDHNSA-N Met-Trp-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N WYNIRYZIFZGWQD-BPUTZDHNSA-N 0.000 description 2
- KLGIQJRMFHIGCQ-ZFWWWQNUSA-N Met-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCSC)C(=O)NCC(O)=O)=CNC2=C1 KLGIQJRMFHIGCQ-ZFWWWQNUSA-N 0.000 description 2
- VYXIKLFLGRTANT-HRCADAONSA-N Met-Tyr-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N VYXIKLFLGRTANT-HRCADAONSA-N 0.000 description 2
- CQRGINSEMFBACV-WPRPVWTQSA-N Met-Val-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O CQRGINSEMFBACV-WPRPVWTQSA-N 0.000 description 2
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 241000235388 Mucorales Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 108010047562 NGR peptide Proteins 0.000 description 2
- 241000224438 Naegleria fowleri Species 0.000 description 2
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 2
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- BRDYYVQTEJVRQT-HRCADAONSA-N Phe-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BRDYYVQTEJVRQT-HRCADAONSA-N 0.000 description 2
- LJUUGSWZPQOJKD-JYJNAYRXSA-N Phe-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O LJUUGSWZPQOJKD-JYJNAYRXSA-N 0.000 description 2
- XMPUYNHKEPFERE-IHRRRGAJSA-N Phe-Asp-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMPUYNHKEPFERE-IHRRRGAJSA-N 0.000 description 2
- IDUCUXTUHHIQIP-SOUVJXGZSA-N Phe-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O IDUCUXTUHHIQIP-SOUVJXGZSA-N 0.000 description 2
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 2
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 2
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 2
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 2
- BSHMIVKDJQGLNT-ACRUOGEOSA-N Phe-Lys-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 BSHMIVKDJQGLNT-ACRUOGEOSA-N 0.000 description 2
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 2
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 2
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 2
- LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 2
- BPIFSOUEUYDJRM-DCPHZVHLSA-N Phe-Trp-Ala Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(O)=O)C1=CC=CC=C1 BPIFSOUEUYDJRM-DCPHZVHLSA-N 0.000 description 2
- APZNYJFGVAGFCF-JYJNAYRXSA-N Phe-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(O)=O APZNYJFGVAGFCF-JYJNAYRXSA-N 0.000 description 2
- 201000005746 Pituitary adenoma Diseases 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FZHBZMDRDASUHN-NAKRPEOUSA-N Pro-Ala-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(O)=O FZHBZMDRDASUHN-NAKRPEOUSA-N 0.000 description 2
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 2
- OCSACVPBMIYNJE-GUBZILKMSA-N Pro-Arg-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O OCSACVPBMIYNJE-GUBZILKMSA-N 0.000 description 2
- SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 2
- MLQVJYMFASXBGZ-IHRRRGAJSA-N Pro-Asn-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O MLQVJYMFASXBGZ-IHRRRGAJSA-N 0.000 description 2
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 2
- HQVPQXMCQKXARZ-FXQIFTODSA-N Pro-Cys-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O HQVPQXMCQKXARZ-FXQIFTODSA-N 0.000 description 2
- ODPIUQVTULPQEP-CIUDSAMLSA-N Pro-Gln-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ODPIUQVTULPQEP-CIUDSAMLSA-N 0.000 description 2
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 2
- KTFZQPLSPLWLKN-KKUMJFAQSA-N Pro-Gln-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KTFZQPLSPLWLKN-KKUMJFAQSA-N 0.000 description 2
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 2
- AJCRQOHDLCBHFA-SRVKXCTJSA-N Pro-His-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AJCRQOHDLCBHFA-SRVKXCTJSA-N 0.000 description 2
- CFVRJNZJQHDQPP-CYDGBPFRSA-N Pro-Ile-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 CFVRJNZJQHDQPP-CYDGBPFRSA-N 0.000 description 2
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 2
- MCWHYUWXVNRXFV-RWMBFGLXSA-N Pro-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 MCWHYUWXVNRXFV-RWMBFGLXSA-N 0.000 description 2
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 2
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 2
- INDVYIOKMXFQFM-SRVKXCTJSA-N Pro-Lys-Gln Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O INDVYIOKMXFQFM-SRVKXCTJSA-N 0.000 description 2
- ZJXXCGZFYQQETF-CYDGBPFRSA-N Pro-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1 ZJXXCGZFYQQETF-CYDGBPFRSA-N 0.000 description 2
- FYKUEXMZYFIZKA-DCAQKATOSA-N Pro-Pro-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FYKUEXMZYFIZKA-DCAQKATOSA-N 0.000 description 2
- NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 2
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 2
- POQFNPILEQEODH-FXQIFTODSA-N Pro-Ser-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O POQFNPILEQEODH-FXQIFTODSA-N 0.000 description 2
- UGDMQJSXSSZUKL-IHRRRGAJSA-N Pro-Ser-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O UGDMQJSXSSZUKL-IHRRRGAJSA-N 0.000 description 2
- GXWRTSIVLSQACD-RCWTZXSCSA-N Pro-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1)O GXWRTSIVLSQACD-RCWTZXSCSA-N 0.000 description 2
- ZYJMLBCDFPIGNL-JYJNAYRXSA-N Pro-Tyr-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O ZYJMLBCDFPIGNL-JYJNAYRXSA-N 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 2
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 2
- IDCKUIWEIZYVSO-WFBYXXMGSA-N Ser-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C)C(O)=O)=CNC2=C1 IDCKUIWEIZYVSO-WFBYXXMGSA-N 0.000 description 2
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 2
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 2
- OJPHFSOMBZKQKQ-GUBZILKMSA-N Ser-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO OJPHFSOMBZKQKQ-GUBZILKMSA-N 0.000 description 2
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 2
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 2
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 2
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 2
- CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 2
- RXSWQCATLWVDLI-XGEHTFHBSA-N Ser-Met-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RXSWQCATLWVDLI-XGEHTFHBSA-N 0.000 description 2
- ASGYVPAVFNDZMA-GUBZILKMSA-N Ser-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)N ASGYVPAVFNDZMA-GUBZILKMSA-N 0.000 description 2
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001149962 Sporothrix Species 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 2
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 2
- SHOMROOOQBDGRL-JHEQGTHGSA-N Thr-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SHOMROOOQBDGRL-JHEQGTHGSA-N 0.000 description 2
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 2
- FKIGTIXHSRNKJU-IXOXFDKPSA-N Thr-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CN=CN1 FKIGTIXHSRNKJU-IXOXFDKPSA-N 0.000 description 2
- YDWLCDQXLCILCZ-BWAGICSOSA-N Thr-His-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YDWLCDQXLCILCZ-BWAGICSOSA-N 0.000 description 2
- WPAKPLPGQNUXGN-OSUNSFLBSA-N Thr-Ile-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WPAKPLPGQNUXGN-OSUNSFLBSA-N 0.000 description 2
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 2
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 2
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 2
- CJXURNZYNHCYFD-WDCWCFNPSA-N Thr-Lys-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O CJXURNZYNHCYFD-WDCWCFNPSA-N 0.000 description 2
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 2
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 2
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 2
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 2
- NDXSOKGYKCGYKT-VEVYYDQMSA-N Thr-Pro-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O NDXSOKGYKCGYKT-VEVYYDQMSA-N 0.000 description 2
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 2
- OLFOOYQTTQSSRK-UNQGMJICSA-N Thr-Pro-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLFOOYQTTQSSRK-UNQGMJICSA-N 0.000 description 2
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 2
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 2
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 2
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- WFZYXGSAPWKTHR-XEGUGMAKSA-N Trp-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WFZYXGSAPWKTHR-XEGUGMAKSA-N 0.000 description 2
- OKAMOYTUQMIFJO-JBACZVJFSA-N Trp-Glu-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 OKAMOYTUQMIFJO-JBACZVJFSA-N 0.000 description 2
- BIBZRFIKOLGWFQ-XIRDDKMYSA-N Trp-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O BIBZRFIKOLGWFQ-XIRDDKMYSA-N 0.000 description 2
- RWTFCAMQLFNPTK-UMPQAUOISA-N Trp-Val-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 RWTFCAMQLFNPTK-UMPQAUOISA-N 0.000 description 2
- WGBFZZYIWFSYER-BVSLBCMMSA-N Trp-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N WGBFZZYIWFSYER-BVSLBCMMSA-N 0.000 description 2
- 241000223105 Trypanosoma brucei Species 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 2
- BURPTJBFWIOHEY-UWJYBYFXSA-N Tyr-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BURPTJBFWIOHEY-UWJYBYFXSA-N 0.000 description 2
- DLZKEQQWXODGGZ-KWQFWETISA-N Tyr-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KWQFWETISA-N 0.000 description 2
- HSVPZJLMPLMPOX-BPNCWPANSA-N Tyr-Arg-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O HSVPZJLMPLMPOX-BPNCWPANSA-N 0.000 description 2
- RCLOWEZASFJFEX-KKUMJFAQSA-N Tyr-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RCLOWEZASFJFEX-KKUMJFAQSA-N 0.000 description 2
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 2
- LOOCQRRBKZTPKO-AVGNSLFASA-N Tyr-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LOOCQRRBKZTPKO-AVGNSLFASA-N 0.000 description 2
- JKUZFODWJGEQAP-KBPBESRZSA-N Tyr-Gly-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O JKUZFODWJGEQAP-KBPBESRZSA-N 0.000 description 2
- GFJXBLSZOFWHAW-JYJNAYRXSA-N Tyr-His-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GFJXBLSZOFWHAW-JYJNAYRXSA-N 0.000 description 2
- BXPOOVDVGWEXDU-WZLNRYEVSA-N Tyr-Ile-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXPOOVDVGWEXDU-WZLNRYEVSA-N 0.000 description 2
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 2
- AVIQBBOOTZENLH-KKUMJFAQSA-N Tyr-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N AVIQBBOOTZENLH-KKUMJFAQSA-N 0.000 description 2
- QHLIUFUEUDFAOT-MGHWNKPDSA-N Tyr-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHLIUFUEUDFAOT-MGHWNKPDSA-N 0.000 description 2
- JAGGEZACYAAMIL-CQDKDKBSSA-N Tyr-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JAGGEZACYAAMIL-CQDKDKBSSA-N 0.000 description 2
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 2
- YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 2
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 2
- IEWKKXZRJLTIOV-AVGNSLFASA-N Tyr-Ser-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O IEWKKXZRJLTIOV-AVGNSLFASA-N 0.000 description 2
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 2
- BXJQKVDPRMLGKN-PMVMPFDFSA-N Tyr-Trp-Leu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 BXJQKVDPRMLGKN-PMVMPFDFSA-N 0.000 description 2
- JQOMHZMWQHXALX-FHWLQOOXSA-N Tyr-Tyr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JQOMHZMWQHXALX-FHWLQOOXSA-N 0.000 description 2
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 2
- KLOZTPOXVVRVAQ-DZKIICNBSA-N Tyr-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 KLOZTPOXVVRVAQ-DZKIICNBSA-N 0.000 description 2
- DJIJBQYBDKGDIS-JYJNAYRXSA-N Tyr-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O DJIJBQYBDKGDIS-JYJNAYRXSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- WOCYUGQDXPTQPY-FXQIFTODSA-N Val-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N WOCYUGQDXPTQPY-FXQIFTODSA-N 0.000 description 2
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- CWSIBTLMMQLPPZ-FXQIFTODSA-N Val-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N CWSIBTLMMQLPPZ-FXQIFTODSA-N 0.000 description 2
- AHHJARQXFFGOKF-NRPADANISA-N Val-Glu-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N AHHJARQXFFGOKF-NRPADANISA-N 0.000 description 2
- FXVDGDZRYLFQKY-WPRPVWTQSA-N Val-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C FXVDGDZRYLFQKY-WPRPVWTQSA-N 0.000 description 2
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 2
- MANXHLOVEUHVFD-DCAQKATOSA-N Val-His-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N MANXHLOVEUHVFD-DCAQKATOSA-N 0.000 description 2
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 2
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 2
- SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 2
- QRVPEKJBBRYISE-XUXIUFHCSA-N Val-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N QRVPEKJBBRYISE-XUXIUFHCSA-N 0.000 description 2
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 2
- GQMNEJMFMCJJTD-NHCYSSNCSA-N Val-Pro-Gln Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O GQMNEJMFMCJJTD-NHCYSSNCSA-N 0.000 description 2
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 2
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 2
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 2
- RLVTVHSDKHBFQP-ULQDDVLXSA-N Val-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 RLVTVHSDKHBFQP-ULQDDVLXSA-N 0.000 description 2
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 208000007456 balantidiasis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 108010054812 diprotin A Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940007078 entamoeba histolytica Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 108010037389 glutamyl-cysteinyl-lysine Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 2
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 108010050343 histidyl-alanyl-glutamine Proteins 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 2
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 108010038320 lysylphenylalanine Proteins 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000037959 spinal tumor Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 108010036387 trimethionine Proteins 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 2
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- UWQJHXKARZWDIJ-ZLUOBGJFSA-N Ala-Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O UWQJHXKARZWDIJ-ZLUOBGJFSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- STACJSVFHSEZJV-GHCJXIJMSA-N Ala-Asn-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STACJSVFHSEZJV-GHCJXIJMSA-N 0.000 description 1
- FRFDXQWNDZMREB-ACZMJKKPSA-N Ala-Cys-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRFDXQWNDZMREB-ACZMJKKPSA-N 0.000 description 1
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- NJPMYXWVWQWCSR-ACZMJKKPSA-N Ala-Glu-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NJPMYXWVWQWCSR-ACZMJKKPSA-N 0.000 description 1
- FBHOPGDGELNWRH-DRZSPHRISA-N Ala-Glu-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FBHOPGDGELNWRH-DRZSPHRISA-N 0.000 description 1
- CWEAKSWWKHGTRJ-BQBZGAKWSA-N Ala-Gly-Met Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O CWEAKSWWKHGTRJ-BQBZGAKWSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 1
- BFMIRJBURUXDRG-DLOVCJGASA-N Ala-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 BFMIRJBURUXDRG-DLOVCJGASA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- CYBJZLQSUJEMAS-LFSVMHDDSA-N Ala-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C)N)O CYBJZLQSUJEMAS-LFSVMHDDSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 1
- SFPRJVVDZNLUTG-OWLDWWDNSA-N Ala-Trp-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFPRJVVDZNLUTG-OWLDWWDNSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 1
- DCGLNNVKIZXQOJ-FXQIFTODSA-N Arg-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N DCGLNNVKIZXQOJ-FXQIFTODSA-N 0.000 description 1
- XTGGTAWGUFXJSV-NAKRPEOUSA-N Arg-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N XTGGTAWGUFXJSV-NAKRPEOUSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- FIQKRDXFTANIEJ-ULQDDVLXSA-N Arg-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FIQKRDXFTANIEJ-ULQDDVLXSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- XFXZKCRBBOVJKS-BVSLBCMMSA-N Arg-Phe-Trp Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 XFXZKCRBBOVJKS-BVSLBCMMSA-N 0.000 description 1
- FVBZXNSRIDVYJS-AVGNSLFASA-N Arg-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N FVBZXNSRIDVYJS-AVGNSLFASA-N 0.000 description 1
- LRPZJPMQGKGHSG-XGEHTFHBSA-N Arg-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N)O LRPZJPMQGKGHSG-XGEHTFHBSA-N 0.000 description 1
- WCZXPVPHUMYLMS-VEVYYDQMSA-N Arg-Thr-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O WCZXPVPHUMYLMS-VEVYYDQMSA-N 0.000 description 1
- AOJYORNRFWWEIV-IHRRRGAJSA-N Arg-Tyr-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 AOJYORNRFWWEIV-IHRRRGAJSA-N 0.000 description 1
- QCTOLCVIGRLMQS-HRCADAONSA-N Arg-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O QCTOLCVIGRLMQS-HRCADAONSA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 1
- CGXQUULXFWRJOI-SRVKXCTJSA-N Arg-Val-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O CGXQUULXFWRJOI-SRVKXCTJSA-N 0.000 description 1
- PFOYSEIHFVKHNF-FXQIFTODSA-N Asn-Ala-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PFOYSEIHFVKHNF-FXQIFTODSA-N 0.000 description 1
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 1
- YQNBILXAUIAUCF-CIUDSAMLSA-N Asn-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N YQNBILXAUIAUCF-CIUDSAMLSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 1
- QYXNFROWLZPWPC-FXQIFTODSA-N Asn-Glu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QYXNFROWLZPWPC-FXQIFTODSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- SXNJBDYEBOUYOJ-DCAQKATOSA-N Asn-His-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N SXNJBDYEBOUYOJ-DCAQKATOSA-N 0.000 description 1
- LTZIRYMWOJHRCH-GUDRVLHUSA-N Asn-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N LTZIRYMWOJHRCH-GUDRVLHUSA-N 0.000 description 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 1
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 1
- AYOAHKWVQLNPDM-HJGDQZAQSA-N Asn-Lys-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AYOAHKWVQLNPDM-HJGDQZAQSA-N 0.000 description 1
- MDDXKBHIMYYJLW-FXQIFTODSA-N Asn-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N MDDXKBHIMYYJLW-FXQIFTODSA-N 0.000 description 1
- MYVBTYXSWILFCG-BQBZGAKWSA-N Asn-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N MYVBTYXSWILFCG-BQBZGAKWSA-N 0.000 description 1
- WCRQQIPFSXFIRN-LPEHRKFASA-N Asn-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N WCRQQIPFSXFIRN-LPEHRKFASA-N 0.000 description 1
- VITDJIPIJZAVGC-VEVYYDQMSA-N Asn-Met-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VITDJIPIJZAVGC-VEVYYDQMSA-N 0.000 description 1
- BKFXFUPYETWGGA-XVSYOHENSA-N Asn-Phe-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BKFXFUPYETWGGA-XVSYOHENSA-N 0.000 description 1
- GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 1
- SZNGQSBRHFMZLT-IHRRRGAJSA-N Asn-Pro-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SZNGQSBRHFMZLT-IHRRRGAJSA-N 0.000 description 1
- JWQWPRCDYWNVNM-ACZMJKKPSA-N Asn-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N JWQWPRCDYWNVNM-ACZMJKKPSA-N 0.000 description 1
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 1
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 1
- KTDWFWNZLLFEFU-KKUMJFAQSA-N Asn-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O KTDWFWNZLLFEFU-KKUMJFAQSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 1
- AKPLMZMNJGNUKT-ZLUOBGJFSA-N Asp-Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AKPLMZMNJGNUKT-ZLUOBGJFSA-N 0.000 description 1
- IAMNNSSEBXDJMN-CIUDSAMLSA-N Asp-Cys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N IAMNNSSEBXDJMN-CIUDSAMLSA-N 0.000 description 1
- FTNVLGCFIJEMQT-CIUDSAMLSA-N Asp-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N FTNVLGCFIJEMQT-CIUDSAMLSA-N 0.000 description 1
- ZEDBMCPXPIYJLW-XHNCKOQMSA-N Asp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O ZEDBMCPXPIYJLW-XHNCKOQMSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- LDGUZSIPGSPBJP-XVYDVKMFSA-N Asp-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LDGUZSIPGSPBJP-XVYDVKMFSA-N 0.000 description 1
- WSXDIZFNQYTUJB-SRVKXCTJSA-N Asp-His-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O WSXDIZFNQYTUJB-SRVKXCTJSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- IOXWDLNHXZOXQP-FXQIFTODSA-N Asp-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N IOXWDLNHXZOXQP-FXQIFTODSA-N 0.000 description 1
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 1
- UXIPUCUHQBIQOS-SRVKXCTJSA-N Asp-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UXIPUCUHQBIQOS-SRVKXCTJSA-N 0.000 description 1
- OTKUAVXGMREHRX-CFMVVWHZSA-N Asp-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 OTKUAVXGMREHRX-CFMVVWHZSA-N 0.000 description 1
- XMKXONRMGJXCJV-LAEOZQHASA-N Asp-Val-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XMKXONRMGJXCJV-LAEOZQHASA-N 0.000 description 1
- JGLWFWXGOINXEA-YDHLFZDLSA-N Asp-Val-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JGLWFWXGOINXEA-YDHLFZDLSA-N 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000231314 Babanki virus Species 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000868138 Cabassou virus Species 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- ASHTVGGFIMESRD-LKXGYXEUSA-N Cys-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N)O ASHTVGGFIMESRD-LKXGYXEUSA-N 0.000 description 1
- HYKFOHGZGLOCAY-ZLUOBGJFSA-N Cys-Cys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O HYKFOHGZGLOCAY-ZLUOBGJFSA-N 0.000 description 1
- SMYXEYRYCLIPIL-ZLUOBGJFSA-N Cys-Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O SMYXEYRYCLIPIL-ZLUOBGJFSA-N 0.000 description 1
- CFQVGYWKSLKWFX-KBIXCLLPSA-N Cys-Glu-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CFQVGYWKSLKWFX-KBIXCLLPSA-N 0.000 description 1
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 1
- DZLQXIFVQFTFJY-BYPYZUCNSA-N Cys-Gly-Gly Chemical compound SC[C@H](N)C(=O)NCC(=O)NCC(O)=O DZLQXIFVQFTFJY-BYPYZUCNSA-N 0.000 description 1
- XVLMKWWVBNESPX-XVYDVKMFSA-N Cys-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CS)N XVLMKWWVBNESPX-XVYDVKMFSA-N 0.000 description 1
- DIUBVGXMXONJCF-KKUMJFAQSA-N Cys-His-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DIUBVGXMXONJCF-KKUMJFAQSA-N 0.000 description 1
- UVZFZTWNHOQWNK-NAKRPEOUSA-N Cys-Ile-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UVZFZTWNHOQWNK-NAKRPEOUSA-N 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- CIVXDCMSSFGWAL-YUMQZZPRSA-N Cys-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N CIVXDCMSSFGWAL-YUMQZZPRSA-N 0.000 description 1
- YXPNKXFOBHRUBL-BJDJZHNGSA-N Cys-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N YXPNKXFOBHRUBL-BJDJZHNGSA-N 0.000 description 1
- MXZYQNJCBVJHSR-KATARQTJSA-N Cys-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)O MXZYQNJCBVJHSR-KATARQTJSA-N 0.000 description 1
- WTEJFWOJHCJDML-FXQIFTODSA-N Cys-Met-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(O)=O WTEJFWOJHCJDML-FXQIFTODSA-N 0.000 description 1
- PEZINYWZBQNTIX-NAKRPEOUSA-N Cys-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N PEZINYWZBQNTIX-NAKRPEOUSA-N 0.000 description 1
- NITLUESFANGEIW-BQBZGAKWSA-N Cys-Pro-Gly Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O NITLUESFANGEIW-BQBZGAKWSA-N 0.000 description 1
- ABLQPNMKLMFDQU-BIIVOSGPSA-N Cys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)N)C(=O)O ABLQPNMKLMFDQU-BIIVOSGPSA-N 0.000 description 1
- WTXCNOPZMQRTNN-BWBBJGPYSA-N Cys-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)O WTXCNOPZMQRTNN-BWBBJGPYSA-N 0.000 description 1
- MHYHLWUGWUBUHF-GUBZILKMSA-N Cys-Val-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N MHYHLWUGWUBUHF-GUBZILKMSA-N 0.000 description 1
- LPBUBIHAVKXUOT-FXQIFTODSA-N Cys-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N LPBUBIHAVKXUOT-FXQIFTODSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000465885 Everglades virus Species 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- POPZASPRNPGIPZ-UHFFFAOYSA-N Gln Gln Ala Pro Chemical compound NC(=O)CCC(N)C(=O)NC(CCC(N)=O)C(=O)NC(C)C(=O)N1CCCC1C(O)=O POPZASPRNPGIPZ-UHFFFAOYSA-N 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- OETQLUYCMBARHJ-CIUDSAMLSA-N Gln-Asn-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OETQLUYCMBARHJ-CIUDSAMLSA-N 0.000 description 1
- SOBBAYVQSNXYPQ-ACZMJKKPSA-N Gln-Asn-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SOBBAYVQSNXYPQ-ACZMJKKPSA-N 0.000 description 1
- RRYLMJWPWBJFPZ-ACZMJKKPSA-N Gln-Asn-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RRYLMJWPWBJFPZ-ACZMJKKPSA-N 0.000 description 1
- PCKOTDPDHIBGRW-CIUDSAMLSA-N Gln-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N PCKOTDPDHIBGRW-CIUDSAMLSA-N 0.000 description 1
- IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 1
- DRDSQGHKTLSNEA-GLLZPBPUSA-N Gln-Glu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRDSQGHKTLSNEA-GLLZPBPUSA-N 0.000 description 1
- MTCXQQINVAFZKW-MNXVOIDGSA-N Gln-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MTCXQQINVAFZKW-MNXVOIDGSA-N 0.000 description 1
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 1
- DFRYZTUPVZNRLG-KKUMJFAQSA-N Gln-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N DFRYZTUPVZNRLG-KKUMJFAQSA-N 0.000 description 1
- QBEWLBKBGXVVPD-RYUDHWBXSA-N Gln-Phe-Gly Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N QBEWLBKBGXVVPD-RYUDHWBXSA-N 0.000 description 1
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 1
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- NKSGKPWXSWBRRX-ACZMJKKPSA-N Glu-Asn-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N NKSGKPWXSWBRRX-ACZMJKKPSA-N 0.000 description 1
- ISXJHXGYMJKXOI-GUBZILKMSA-N Glu-Cys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O ISXJHXGYMJKXOI-GUBZILKMSA-N 0.000 description 1
- FKGNJUCQKXQNRA-NRPADANISA-N Glu-Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O FKGNJUCQKXQNRA-NRPADANISA-N 0.000 description 1
- XMVLTPMCUJTJQP-FXQIFTODSA-N Glu-Gln-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N XMVLTPMCUJTJQP-FXQIFTODSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- QYPKJXSMLMREKF-BPUTZDHNSA-N Glu-Glu-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)N QYPKJXSMLMREKF-BPUTZDHNSA-N 0.000 description 1
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 1
- GXMXPCXXKVWOSM-KQXIARHKSA-N Glu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N GXMXPCXXKVWOSM-KQXIARHKSA-N 0.000 description 1
- ATVYZJGOZLVXDK-IUCAKERBSA-N Glu-Leu-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O ATVYZJGOZLVXDK-IUCAKERBSA-N 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- RBXSZQRSEGYDFG-GUBZILKMSA-N Glu-Lys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O RBXSZQRSEGYDFG-GUBZILKMSA-N 0.000 description 1
- BHXSLRDWXIFKTP-SRVKXCTJSA-N Glu-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N BHXSLRDWXIFKTP-SRVKXCTJSA-N 0.000 description 1
- KJBGAZSLZAQDPV-KKUMJFAQSA-N Glu-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N KJBGAZSLZAQDPV-KKUMJFAQSA-N 0.000 description 1
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 1
- ZKONLKQGTNVAPR-DCAQKATOSA-N Glu-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)N ZKONLKQGTNVAPR-DCAQKATOSA-N 0.000 description 1
- SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 1
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- RGJKYNUINKGPJN-RWRJDSDZSA-N Glu-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)O)N RGJKYNUINKGPJN-RWRJDSDZSA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- XRTDOIOIBMAXCT-NKWVEPMBSA-N Gly-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)CN)C(=O)O XRTDOIOIBMAXCT-NKWVEPMBSA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- SUDUYJOBLHQAMI-WHFBIAKZSA-N Gly-Asp-Cys Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O SUDUYJOBLHQAMI-WHFBIAKZSA-N 0.000 description 1
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- ADZGCWWDPFDHCY-ZETCQYMHSA-N Gly-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 ADZGCWWDPFDHCY-ZETCQYMHSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- BXICSAQLIHFDDL-YUMQZZPRSA-N Gly-Lys-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BXICSAQLIHFDDL-YUMQZZPRSA-N 0.000 description 1
- DBJYVKDPGIFXFO-BQBZGAKWSA-N Gly-Met-Ala Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O DBJYVKDPGIFXFO-BQBZGAKWSA-N 0.000 description 1
- FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 1
- LBDXVCBAJJNJNN-WHFBIAKZSA-N Gly-Ser-Cys Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O LBDXVCBAJJNJNN-WHFBIAKZSA-N 0.000 description 1
- CSMYMGFCEJWALV-WDSKDSINSA-N Gly-Ser-Gln Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O CSMYMGFCEJWALV-WDSKDSINSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- VOEGKUNRHYKYSU-XVYDVKMFSA-N His-Asp-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O VOEGKUNRHYKYSU-XVYDVKMFSA-N 0.000 description 1
- LSQHWKPPOFDHHZ-YUMQZZPRSA-N His-Asp-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LSQHWKPPOFDHHZ-YUMQZZPRSA-N 0.000 description 1
- QNILDNVBIARMRK-XVYDVKMFSA-N His-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CN=CN1)N QNILDNVBIARMRK-XVYDVKMFSA-N 0.000 description 1
- HQKADFMLECZIQJ-HVTMNAMFSA-N His-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CN=CN1)N HQKADFMLECZIQJ-HVTMNAMFSA-N 0.000 description 1
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 1
- STWGDDDFLUFCCA-GVXVVHGQSA-N His-Glu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O STWGDDDFLUFCCA-GVXVVHGQSA-N 0.000 description 1
- KAFZDWMZKGQDEE-SRVKXCTJSA-N His-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KAFZDWMZKGQDEE-SRVKXCTJSA-N 0.000 description 1
- CTGZVVQVIBSOBB-AVGNSLFASA-N His-His-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O CTGZVVQVIBSOBB-AVGNSLFASA-N 0.000 description 1
- HYWZHNUGAYVEEW-KKUMJFAQSA-N His-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HYWZHNUGAYVEEW-KKUMJFAQSA-N 0.000 description 1
- XIGFLVCAVQQGNS-IHRRRGAJSA-N His-Pro-His Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XIGFLVCAVQQGNS-IHRRRGAJSA-N 0.000 description 1
- NBWATNYAUVSAEQ-ZEILLAHLSA-N His-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O NBWATNYAUVSAEQ-ZEILLAHLSA-N 0.000 description 1
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 1
- XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 1
- CYHYBSGMHMHKOA-CIQUZCHMSA-N Ile-Ala-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CYHYBSGMHMHKOA-CIQUZCHMSA-N 0.000 description 1
- TZCGZYWNIDZZMR-NAKRPEOUSA-N Ile-Arg-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)O)N TZCGZYWNIDZZMR-NAKRPEOUSA-N 0.000 description 1
- QTUSJASXLGLJSR-OSUNSFLBSA-N Ile-Arg-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N QTUSJASXLGLJSR-OSUNSFLBSA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- KBHYLOIVRVBBEB-JBDRJPRFSA-N Ile-Cys-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N KBHYLOIVRVBBEB-JBDRJPRFSA-N 0.000 description 1
- VQUCKIAECLVLAD-SVSWQMSJSA-N Ile-Cys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VQUCKIAECLVLAD-SVSWQMSJSA-N 0.000 description 1
- QRTVJGKXFSYJGW-KBIXCLLPSA-N Ile-Glu-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N QRTVJGKXFSYJGW-KBIXCLLPSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- LNJLOZYNZFGJMM-DEQVHRJGSA-N Ile-His-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N LNJLOZYNZFGJMM-DEQVHRJGSA-N 0.000 description 1
- APDIECQNNDGFPD-PYJNHQTQSA-N Ile-His-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N APDIECQNNDGFPD-PYJNHQTQSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- WSSGUVAKYCQSCT-XUXIUFHCSA-N Ile-Met-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)O)N WSSGUVAKYCQSCT-XUXIUFHCSA-N 0.000 description 1
- XHBYEMIUENPZLY-GMOBBJLQSA-N Ile-Pro-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O XHBYEMIUENPZLY-GMOBBJLQSA-N 0.000 description 1
- CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- PZWBBXHHUSIGKH-OSUNSFLBSA-N Ile-Thr-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PZWBBXHHUSIGKH-OSUNSFLBSA-N 0.000 description 1
- GMUYXHHJAGQHGB-TUBUOCAGSA-N Ile-Thr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GMUYXHHJAGQHGB-TUBUOCAGSA-N 0.000 description 1
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 1
- GVEODXUBBFDBPW-MGHWNKPDSA-N Ile-Tyr-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 GVEODXUBBFDBPW-MGHWNKPDSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- BCISUQVFDGYZBO-QSFUFRPTSA-N Ile-Val-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O BCISUQVFDGYZBO-QSFUFRPTSA-N 0.000 description 1
- AUIYHFRUOOKTGX-UKJIMTQDSA-N Ile-Val-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N AUIYHFRUOOKTGX-UKJIMTQDSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 1
- WSGXUIQTEZDVHJ-GARJFASQSA-N Leu-Ala-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O WSGXUIQTEZDVHJ-GARJFASQSA-N 0.000 description 1
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- PRZVBIAOPFGAQF-SRVKXCTJSA-N Leu-Glu-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O PRZVBIAOPFGAQF-SRVKXCTJSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 1
- AZLASBBHHSLQDB-GUBZILKMSA-N Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C AZLASBBHHSLQDB-GUBZILKMSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- MAXILRZVORNXBE-PMVMPFDFSA-N Leu-Phe-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 MAXILRZVORNXBE-PMVMPFDFSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- SQUFDMCWMFOEBA-KKUMJFAQSA-N Leu-Ser-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SQUFDMCWMFOEBA-KKUMJFAQSA-N 0.000 description 1
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 1
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- YIRIDPUGZKHMHT-ACRUOGEOSA-N Leu-Tyr-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YIRIDPUGZKHMHT-ACRUOGEOSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- JCFYLFOCALSNLQ-GUBZILKMSA-N Lys-Ala-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JCFYLFOCALSNLQ-GUBZILKMSA-N 0.000 description 1
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
- WALVCOOOKULCQM-ULQDDVLXSA-N Lys-Arg-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WALVCOOOKULCQM-ULQDDVLXSA-N 0.000 description 1
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 1
- QQUJSUFWEDZQQY-AVGNSLFASA-N Lys-Gln-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN QQUJSUFWEDZQQY-AVGNSLFASA-N 0.000 description 1
- PGBPWPTUOSCNLE-JYJNAYRXSA-N Lys-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N PGBPWPTUOSCNLE-JYJNAYRXSA-N 0.000 description 1
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 1
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 1
- ZASPELYMPSACER-HOCLYGCPSA-N Lys-Gly-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O ZASPELYMPSACER-HOCLYGCPSA-N 0.000 description 1
- WAIHHELKYSFIQN-XUXIUFHCSA-N Lys-Ile-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O WAIHHELKYSFIQN-XUXIUFHCSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
- BPDXWKVZNCKUGG-BZSNNMDCSA-N Lys-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCCN)N BPDXWKVZNCKUGG-BZSNNMDCSA-N 0.000 description 1
- AEIIJFBQVGYVEV-YESZJQIVSA-N Lys-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)N)C(=O)O AEIIJFBQVGYVEV-YESZJQIVSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- SQRLLZAQNOQCEG-KKUMJFAQSA-N Lys-Tyr-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 SQRLLZAQNOQCEG-KKUMJFAQSA-N 0.000 description 1
- RPWQJSBMXJSCPD-XUXIUFHCSA-N Lys-Val-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(O)=O RPWQJSBMXJSCPD-XUXIUFHCSA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000763097 Me Tri virus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- YKWHHKDMBZBMLG-GUBZILKMSA-N Met-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCSC)N YKWHHKDMBZBMLG-GUBZILKMSA-N 0.000 description 1
- UKUMISIRZAVYOG-CIUDSAMLSA-N Met-Glu-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O UKUMISIRZAVYOG-CIUDSAMLSA-N 0.000 description 1
- GVIVXNFKJQFTCE-YUMQZZPRSA-N Met-Gly-Gln Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O GVIVXNFKJQFTCE-YUMQZZPRSA-N 0.000 description 1
- YCUSPBPZVJDMII-YUMQZZPRSA-N Met-Gly-Glu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O YCUSPBPZVJDMII-YUMQZZPRSA-N 0.000 description 1
- WXJXYMFUTRXRGO-UWVGGRQHSA-N Met-His-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CNC=N1 WXJXYMFUTRXRGO-UWVGGRQHSA-N 0.000 description 1
- DYTWOWJWJCBFLE-IHRRRGAJSA-N Met-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)CC1=CNC=N1 DYTWOWJWJCBFLE-IHRRRGAJSA-N 0.000 description 1
- DBXMFHGGHMXYHY-DCAQKATOSA-N Met-Leu-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O DBXMFHGGHMXYHY-DCAQKATOSA-N 0.000 description 1
- ZDJICAUBMUKVEJ-CIUDSAMLSA-N Met-Ser-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O ZDJICAUBMUKVEJ-CIUDSAMLSA-N 0.000 description 1
- RIIFMEBFDDXGCV-VEVYYDQMSA-N Met-Thr-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O RIIFMEBFDDXGCV-VEVYYDQMSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- MUDYEFAKNSTFAI-JYJNAYRXSA-N Met-Tyr-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O MUDYEFAKNSTFAI-JYJNAYRXSA-N 0.000 description 1
- 241000710949 Middelburg virus Species 0.000 description 1
- 241000283127 Mirounga leonina Species 0.000 description 1
- 241000465889 Mosso das Pedras virus Species 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 108010034522 NNQQ peptide Proteins 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010065395 Neuropep-1 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- AGYXCMYVTBYGCT-ULQDDVLXSA-N Phe-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O AGYXCMYVTBYGCT-ULQDDVLXSA-N 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- KIAWKQJTSGRCSA-AVGNSLFASA-N Phe-Asn-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KIAWKQJTSGRCSA-AVGNSLFASA-N 0.000 description 1
- WGXOKDLDIWSOCV-MELADBBJSA-N Phe-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O WGXOKDLDIWSOCV-MELADBBJSA-N 0.000 description 1
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 1
- PDUVELWDJZOUEI-IHRRRGAJSA-N Phe-Cys-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PDUVELWDJZOUEI-IHRRRGAJSA-N 0.000 description 1
- RORUIHAWOLADSH-HJWJTTGWSA-N Phe-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 RORUIHAWOLADSH-HJWJTTGWSA-N 0.000 description 1
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- AOKZOUGUMLBPSS-PMVMPFDFSA-N Phe-Trp-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O AOKZOUGUMLBPSS-PMVMPFDFSA-N 0.000 description 1
- XBCOOBCTVMMQSC-BVSLBCMMSA-N Phe-Val-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 XBCOOBCTVMMQSC-BVSLBCMMSA-N 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 1
- UVKNEILZSJMKSR-FXQIFTODSA-N Pro-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 UVKNEILZSJMKSR-FXQIFTODSA-N 0.000 description 1
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 1
- KIGGUSRFHJCIEJ-DCAQKATOSA-N Pro-Asp-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O KIGGUSRFHJCIEJ-DCAQKATOSA-N 0.000 description 1
- OGRYXQOUFHAMPI-DCAQKATOSA-N Pro-Cys-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O OGRYXQOUFHAMPI-DCAQKATOSA-N 0.000 description 1
- DRIJZWBRGMJCDD-DCAQKATOSA-N Pro-Gln-Met Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O DRIJZWBRGMJCDD-DCAQKATOSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- VPFGPKIWSDVTOY-SRVKXCTJSA-N Pro-Glu-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O VPFGPKIWSDVTOY-SRVKXCTJSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- LXVLKXPFIDDHJG-CIUDSAMLSA-N Pro-Glu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O LXVLKXPFIDDHJG-CIUDSAMLSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- IBGCFJDLCYTKPW-NAKRPEOUSA-N Pro-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 IBGCFJDLCYTKPW-NAKRPEOUSA-N 0.000 description 1
- SOACYAXADBWDDT-CYDGBPFRSA-N Pro-Ile-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SOACYAXADBWDDT-CYDGBPFRSA-N 0.000 description 1
- TYMBHHITTMGGPI-NAKRPEOUSA-N Pro-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 TYMBHHITTMGGPI-NAKRPEOUSA-N 0.000 description 1
- SXMSEHDMNIUTSP-DCAQKATOSA-N Pro-Lys-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SXMSEHDMNIUTSP-DCAQKATOSA-N 0.000 description 1
- AUYKOPJPKUCYHE-SRVKXCTJSA-N Pro-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1 AUYKOPJPKUCYHE-SRVKXCTJSA-N 0.000 description 1
- DYMPSOABVJIFBS-IHRRRGAJSA-N Pro-Phe-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CS)C(=O)O DYMPSOABVJIFBS-IHRRRGAJSA-N 0.000 description 1
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- VVAWNPIOYXAMAL-KJEVXHAQSA-N Pro-Thr-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VVAWNPIOYXAMAL-KJEVXHAQSA-N 0.000 description 1
- LEBTWGWVUVJNTA-FKBYEOEOSA-N Pro-Trp-Phe Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)O LEBTWGWVUVJNTA-FKBYEOEOSA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- FIDNSJUXESUDOV-JYJNAYRXSA-N Pro-Tyr-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O FIDNSJUXESUDOV-JYJNAYRXSA-N 0.000 description 1
- XDKKMRPRRCOELJ-GUBZILKMSA-N Pro-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 XDKKMRPRRCOELJ-GUBZILKMSA-N 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102220468946 Protein unc-13 homolog A_K64A_mutation Human genes 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 241000328499 Rio Negro virus Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 1
- MPPHJZYXDVDGOF-BWBBJGPYSA-N Ser-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CO MPPHJZYXDVDGOF-BWBBJGPYSA-N 0.000 description 1
- CRZRTKAVUUGKEQ-ACZMJKKPSA-N Ser-Gln-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CRZRTKAVUUGKEQ-ACZMJKKPSA-N 0.000 description 1
- MAWSJXHRLWVJEZ-ACZMJKKPSA-N Ser-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N MAWSJXHRLWVJEZ-ACZMJKKPSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- VDVYTKZBMFADQH-AVGNSLFASA-N Ser-Gln-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VDVYTKZBMFADQH-AVGNSLFASA-N 0.000 description 1
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
- IFPBAGJBHSNYPR-ZKWXMUAHSA-N Ser-Ile-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O IFPBAGJBHSNYPR-ZKWXMUAHSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 1
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 1
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 1
- ANOQEBQWIAYIMV-AEJSXWLSSA-N Ser-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N ANOQEBQWIAYIMV-AEJSXWLSSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 1
- DFTCYYILCSQGIZ-GCJQMDKQSA-N Thr-Ala-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFTCYYILCSQGIZ-GCJQMDKQSA-N 0.000 description 1
- STGXWWBXWXZOER-MBLNEYKQSA-N Thr-Ala-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 STGXWWBXWXZOER-MBLNEYKQSA-N 0.000 description 1
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 1
- JHBHMCMKSPXRHV-NUMRIWBASA-N Thr-Asn-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JHBHMCMKSPXRHV-NUMRIWBASA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 1
- UCCNDUPVIFOOQX-CUJWVEQBSA-N Thr-Cys-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 UCCNDUPVIFOOQX-CUJWVEQBSA-N 0.000 description 1
- YAAPRMFURSENOZ-KATARQTJSA-N Thr-Cys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O YAAPRMFURSENOZ-KATARQTJSA-N 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
- DKDHTRVDOUZZTP-IFFSRLJSSA-N Thr-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DKDHTRVDOUZZTP-IFFSRLJSSA-N 0.000 description 1
- YUOCMLNTUZAGNF-KLHWPWHYSA-N Thr-His-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N)O YUOCMLNTUZAGNF-KLHWPWHYSA-N 0.000 description 1
- JRAUIKJSEAKTGD-TUBUOCAGSA-N Thr-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N JRAUIKJSEAKTGD-TUBUOCAGSA-N 0.000 description 1
- AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 description 1
- XYFISNXATOERFZ-OSUNSFLBSA-N Thr-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XYFISNXATOERFZ-OSUNSFLBSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 1
- MCDVZTRGHNXTGK-HJGDQZAQSA-N Thr-Met-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O MCDVZTRGHNXTGK-HJGDQZAQSA-N 0.000 description 1
- XNTVWRJTUIOGQO-RHYQMDGZSA-N Thr-Met-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNTVWRJTUIOGQO-RHYQMDGZSA-N 0.000 description 1
- HSQXHRIRJSFDOH-URLPEUOOSA-N Thr-Phe-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HSQXHRIRJSFDOH-URLPEUOOSA-N 0.000 description 1
- MUAFDCVOHYAFNG-RCWTZXSCSA-N Thr-Pro-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MUAFDCVOHYAFNG-RCWTZXSCSA-N 0.000 description 1
- GVMXJJAJLIEASL-ZJDVBMNYSA-N Thr-Pro-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVMXJJAJLIEASL-ZJDVBMNYSA-N 0.000 description 1
- PRTHQBSMXILLPC-XGEHTFHBSA-N Thr-Ser-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PRTHQBSMXILLPC-XGEHTFHBSA-N 0.000 description 1
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- PJCYRZVSACOYSN-ZJDVBMNYSA-N Thr-Thr-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O PJCYRZVSACOYSN-ZJDVBMNYSA-N 0.000 description 1
- CSZFFQBUTMGHAH-UAXMHLISSA-N Thr-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O CSZFFQBUTMGHAH-UAXMHLISSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- XEVHXNLPUBVQEX-DVJZZOLTSA-N Thr-Trp-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N)O XEVHXNLPUBVQEX-DVJZZOLTSA-N 0.000 description 1
- NLWDSYKZUPRMBJ-IEGACIPQSA-N Thr-Trp-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O NLWDSYKZUPRMBJ-IEGACIPQSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 1
- CURFABYITJVKEW-QTKMDUPCSA-N Thr-Val-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O CURFABYITJVKEW-QTKMDUPCSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000951300 Trocara virus Species 0.000 description 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 description 1
- ZJKZLNAECPIUTL-JBACZVJFSA-N Trp-Gln-Tyr Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 ZJKZLNAECPIUTL-JBACZVJFSA-N 0.000 description 1
- OCCYDHCUKXRPSJ-SXNHZJKMSA-N Trp-Ile-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OCCYDHCUKXRPSJ-SXNHZJKMSA-N 0.000 description 1
- UKWSFUSPGPBJGU-VFAJRCTISA-N Trp-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O UKWSFUSPGPBJGU-VFAJRCTISA-N 0.000 description 1
- CSOBBJWWODOYGW-ILWGZMRPSA-N Trp-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N)C(=O)O CSOBBJWWODOYGW-ILWGZMRPSA-N 0.000 description 1
- SUGLEXVWEJOCGN-ONUFPDRFSA-N Trp-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N)O SUGLEXVWEJOCGN-ONUFPDRFSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- JONPRIHUYSPIMA-UWJYBYFXSA-N Tyr-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JONPRIHUYSPIMA-UWJYBYFXSA-N 0.000 description 1
- AKFLVKKWVZMFOT-IHRRRGAJSA-N Tyr-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AKFLVKKWVZMFOT-IHRRRGAJSA-N 0.000 description 1
- SEFNTZYRPGBDCY-IHRRRGAJSA-N Tyr-Arg-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N)O SEFNTZYRPGBDCY-IHRRRGAJSA-N 0.000 description 1
- BARBHMSSVWPKPZ-IHRRRGAJSA-N Tyr-Asp-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BARBHMSSVWPKPZ-IHRRRGAJSA-N 0.000 description 1
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 1
- IYHNBRUWVBIVJR-IHRRRGAJSA-N Tyr-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IYHNBRUWVBIVJR-IHRRRGAJSA-N 0.000 description 1
- TWAVEIJGFCBWCG-JYJNAYRXSA-N Tyr-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N TWAVEIJGFCBWCG-JYJNAYRXSA-N 0.000 description 1
- UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 1
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 1
- ADECJAKCRKPSOR-ULQDDVLXSA-N Tyr-His-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O ADECJAKCRKPSOR-ULQDDVLXSA-N 0.000 description 1
- BJCILVZEZRDIDR-PMVMPFDFSA-N Tyr-Leu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 BJCILVZEZRDIDR-PMVMPFDFSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- SBLZVFCEOCWRLS-BPNCWPANSA-N Tyr-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=C(C=C1)O)N SBLZVFCEOCWRLS-BPNCWPANSA-N 0.000 description 1
- VXFXIBCCVLJCJT-JYJNAYRXSA-N Tyr-Pro-Pro Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(O)=O VXFXIBCCVLJCJT-JYJNAYRXSA-N 0.000 description 1
- XGZBEGGGAUQBMB-KJEVXHAQSA-N Tyr-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(C=C2)O)N)O XGZBEGGGAUQBMB-KJEVXHAQSA-N 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- XUIOBCQESNDTDE-FQPOAREZSA-N Tyr-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O XUIOBCQESNDTDE-FQPOAREZSA-N 0.000 description 1
- BIVIUZRBCAUNPW-JRQIVUDYSA-N Tyr-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O BIVIUZRBCAUNPW-JRQIVUDYSA-N 0.000 description 1
- DJSYPCWZPNHQQE-FHWLQOOXSA-N Tyr-Tyr-Gln Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=C(O)C=C1 DJSYPCWZPNHQQE-FHWLQOOXSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- MJUTYRIMFIICKL-JYJNAYRXSA-N Tyr-Val-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MJUTYRIMFIICKL-JYJNAYRXSA-N 0.000 description 1
- ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- SMKXLHVZIFKQRB-GUBZILKMSA-N Val-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N SMKXLHVZIFKQRB-GUBZILKMSA-N 0.000 description 1
- IQQYYFPCWKWUHW-YDHLFZDLSA-N Val-Asn-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N IQQYYFPCWKWUHW-YDHLFZDLSA-N 0.000 description 1
- DBOXBUDEAJVKRE-LSJOCFKGSA-N Val-Asn-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DBOXBUDEAJVKRE-LSJOCFKGSA-N 0.000 description 1
- HIZMLPKDJAXDRG-FXQIFTODSA-N Val-Cys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N HIZMLPKDJAXDRG-FXQIFTODSA-N 0.000 description 1
- CFSSLXZJEMERJY-NRPADANISA-N Val-Gln-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O CFSSLXZJEMERJY-NRPADANISA-N 0.000 description 1
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- PTFPUAXGIKTVNN-ONGXEEELSA-N Val-His-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N PTFPUAXGIKTVNN-ONGXEEELSA-N 0.000 description 1
- HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 1
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- MBGFDZDWMDLXHQ-GUBZILKMSA-N Val-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C(C)C)N MBGFDZDWMDLXHQ-GUBZILKMSA-N 0.000 description 1
- IOETTZIEIBVWBZ-GUBZILKMSA-N Val-Met-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CS)C(=O)O)N IOETTZIEIBVWBZ-GUBZILKMSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 1
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- DLRZGNXCXUGIDG-KKHAAJSZSA-N Val-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O DLRZGNXCXUGIDG-KKHAAJSZSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000231320 Whataroa virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 102000048119 human PDCD1LG2 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000008902 immunological benefit Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010020432 prolyl-prolylisoleucine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220049431 rs587784257 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 바이러스 구조 단백질 및 PD-1 또는 PD-1 의 리간드에서 유래한 항원을 포함하는 바이러스 유사 입자, 및 이를 포함하는 조성물 또는 키트, 면역 반응에서의 이의 용도 등을 제공한다.
Description
관련 출원에 대한 교차 참조
본 출원은 그 전체가 본원에 참조로 포함되는 2013 년 7 월 12 일에 출원한 미국 가출원 번호 61/845,712 에 대해 우선권을 주장한다.
기술 분야
본 발명은 바이러스 구조 단백질 및 PD-1 또는 PD-1 의 리간드에서 유래한 항원을 포함하는 바이러스 유사 입자, 및 이를 포함하는 조성물 또는 키트, 면역 반응에서의 이의 용도 등에 관한 것이다.
세포예정사 (Programmed Cell Death) 1 또는 PD-1 (또한 PDCD1 로서 나타냄) 은 특정 리간드와 상호작용하여 T 세포 항원 수용체 신호전달을 부정적으로 제어하는 CD28 슈퍼패밀리의 50 내지 55 kDa 유형 I 막관통 수용체이며 자체내성의 유지에 있어서 역할을 담당하는 것으로 제시된다.
PD-1 항원은 자가면역, 종양 면역성, 감염 면역성, 이식 면역성, 알레르기 및 면역적 이점을 포함하는 면역 반응의 거의 모든 양태에 관련된다.
PD-1 은 활성화된 T 세포, B 세포 및 대식세포의 표면에서 발현되며 (Y. Agata et al., International Immunology vol.8, No. 5 p765-772, 1996), 이는 면역계에서 또한 중요한 제어 역할을 하는 CTLA-4 와 비교하여, PD-1 이 보다 광범위하게 면역 반응을 부정적으로 제어한다는 것을 제시한다.
일반적으로, 예를 들어 자가면역 질환, 염증 장애, 알레르기, 이식 거부, 암, 면역 결핍 및 기타 면역계 관련 장애와 같은 면역 장애에 대한 안전하고 효과적인 치료 방법이 필요하다. 이러한 장애에 관련된 면역 반응의 조절은 PD-1 경로의 조작에 의해 달성될 수 있다.
PD-1 은 2 개의 리간드, PD-L1 (PDCD1L1 또는 B7-H1 에 대한 예정사 리간드) 및 PD-L2 (PDCD1L2 또는 B7-DC 에 대한 예정사 리간드 2) 를 가지며, 이는 B7 패밀리 리간드의 일원이다.
한 접근 방식에서, PD-1 뿐 아니라 이의 리간드 (PD-L1, PD-L2 또는 둘 모두) 의 상호작용을 차단하는 것은 종양 및 바이러스 면역치료요법에 대한 효과적인 방법을 제공할 수 있다.
US 5,629,204 및 US 5,698,520 은 상기 단백질을 인코딩하는 인간 PD-1 및 DNA 에 관련된 막 단백질에 관한 것이며, PD-1 단백질이 다양한 감염, 면역학적 침체 또는 가속, 또는 종양 등의 치료에 유용할 수 있다는 것을 나타낸다.
US 7,595,048 및 US 2011/0081341 은 PD-1, PD-L1 또는 PD-L2 에 의해 유도된 면역억제 신호를 저해하는 것을 특징으로 하는 면역강화, 암 또는 감염 치료용 조성물, 및 이를 사용하는 치료요법에 관한 것이다.
여러 대규모 제약회사는 시중에서 최초의 것이 되기 위한 경쟁에서 그들의 PD-1 항체를 서로 겨루고 있다. 여기서 3 개의 단일클론 항체 예컨대 PD-1 에 대항하여 작용하는 인간화 단일클론 IgG4 항체인 Merck 의 람브롤리주맙 (Lambrolizumab) (MK-3475), 완전 항 인간 PD-1 항체인 Bristol-Myers Squibb 의 니볼루맙 (Nivolumab) (BMS-936558) 및 PD-1 을 차단하지 않으나 PD-L1 을 차단하는 Roche Genentech 의 MPDL3280A 가 존재한다.
그러나, PD-1 을 표적화하는 보다 강력하고 안전한 화합물이 대단히 필요하다.
바이러스 유사 입자 (VLP) 는 진본 선천적 바이러스의 구조 및 형태를 모방하지만 바이러스 게놈이 결핍되어 있는, 잠재적으로 더 안전하고 저렴한 백신 후보물을 산출해내는 다중단백질 구조이다. 소수의 예방 VLP-기재 백신은 현재 전세계적으로 시판되고 있다: GlaxoSmithKline 의 Engerix® (헤파티티스 B 바이러스) 및 Cervarix® (인간 파필로마바이러스), 및 Merck and Co., Inc. 의 Recombivax HB® (헤파티티스 B 바이러스) 및 Gardasil® (인간 파필로마바이러스) 가 일부 예이다. 다른 VLP-기재 백신 후보물이 임상 시험 중에 있거나 전임상 평가를 거치고 있다 (예컨대 인플루엔자 바이러스, 파보바이러스, 노워크 (Norwalk) 및 각종 키메라 VLP). 많은 기타의 것들은 전임상 시험에서의 성공에도 불구하고 여전히 소규모 기초 연구에 제한되어 있다. 대규모 VLP 제조의 영향은 공정 제어, 모니터링 및 최적화의 맥락에서 토의된다. 주요 업- 및 다운-스트림 기술적 도전 과제가 확인되고 있으며 이에 따라 토의되고 있다. 성공적인 VLP-기재 대규모 백신이 치료 또는 예방 백신을 위한 키메라 VLP-기재 기법에서의 최근 발전 및 임상 시험으로부터의 최신 결과를 수반하여 간략하게 제시되어 있다 (Expert Rev. Vaccines 9(10), 1149-1176, 2010).
치쿤구니야 (Chikungunya) 바이러스 (CHIKV) 는 이러한 알파바이러스가 2004 년도에 케냐에서 재출현한 이래로 아프리카, 유럽 및 아시아에서 백만명을 감염시켰다. 상기 질환의 심각도 및 이러한 유행성 바이러스의 확산은 백신이나 항바이러스 치료요법의 부재 하에서 심각한 공중 위생의 위협을 드러낸다. 유행성 치쿤구니야 바이러스에 대한 VLP 백신이 감염에 대항하여 비-인간 영장류를 보호한다는 것이 보고되어 있다 (Nat Med. 2010 March; 16(3): 334-338). 미국 특허 공개 번호 2012/0003266 은 감염 또는 이의 하나 이상의 증상에 대한 면역력을 유도하는 치쿤구니야에 대한 백신 또는 항원성 조성물을 제형화하는데 유용한 하나 이상의 치쿤구니야 바이러스 구조 단백질을 포함하는 바이러스 유사 입자 (VLP) 를 개시하고 있다. WO2012/106356 은 개질된 알파바이러스 또는 플라비바이러스 바이러스 유사 입자 (VLP) 및 알파바이러스 및 플라비바이러스-매개 질환의 예방 또는 치료에서 사용하기 위해 개질된 VLP 의 제조를 증진시키는 방법을 개시하고 있다 (이러한 인용된 참고문헌은 본원에서 참조로 포함됨).
발명의 개요
제 1 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 제공한다.
제 2 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자를 제공한다.
제 3 양태에서, 본 발명은 약학 조성물 및 약학 조성물을 포함하는 키트를 제공하며, 이때 약학 조성물은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자; 또는 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자; 및 약학적으로 허용가능한 담체를 포함한다.
제 4 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자; 또는 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자의, 대상에서의 면역 반응을 조절하고 암을 치료하거나 감염성 질환을 치료하기 위한 약학 조성물 또는 키트의 제조를 위한 용도를 제공한다.
도 1 은 N-말단 PD-1 (1-167aa) 에 결합하는 항체를 검출한 ELISA 의 결과를 나타낸다.
도 2 는 PD-1-Fc 에 결합하는 항체를 검출한 ELISA 의 결과를 나타낸다.
도 2 는 PD-1-Fc 에 결합하는 항체를 검출한 ELISA 의 결과를 나타낸다.
구현예의 설명
(1) 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자
제 1 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 제공한다.
상기 기재한 입자를 조절함으로써 제조할 수 있는 상기 기재한 입자의 유도체가 또한 본 발명에 의해 제공된다. 개질의 예는 비제한적으로, 하나 이상의 아미노산 잔기의 첨가, 결실 또는 대체를 포함한다.
본 발명에 의해 제공된 입자는 i) 하나 이상의 바이러스 구조 단백질 및 ii) PD-1 에서 유래한 하나 이상의 항원 또는 PD-1 의 리간드에서 유래한 하나 이상의 항원으로 이루어지거나 이를 포함하는 입자일 수 있다. 하나 이상의 바이러스 구조 단백질은 1 종 이상의 단백질 또는 펩티드로 이루어질 수 있으며 자발적으로 어셈블리되어 본 발명에 의해 제공된 입자를 형성할 수 있다. 한 구현예에서, 본 발명에 의해 제공된 입자는 10nm 이상, 예를 들어 20nm 이상, 바람직하게는 50nm 이상의 직경을 갖는다. 한 구현예에서, 입자의 분자량은 100 kDa 내지 100,000 kDa, 바람직하게는 400kDa 내지 30,000kDa 이다.
바람직하게는, 본 발명에 사용한 바이러스 구조 단백질은 알파바이러스 또는 플라비바이러스에서 유래한 바이러스 구조 단백질일 수 있다. 따라서, 본 발명에 의해 제공된 입자는 알파바이러스 또는 플라비바이러스에서 유래한 바이러스 유사 입자를 포함하는 바이러스 유사 입자일 수 있다.
알파바이러스 및 플라비바이러스의 예는 비제한적으로, 아우라 (Aura) 바이러스, 바반키 (Babanki) 바이러스, 바마 삼림 (Barmah Forest) 바이러스 (BFV), 베바루 (Bebaru) 바이러스, 카바수 (Cabassou) 바이러스, 치쿤구니야 바이러스 (CHIKV), 동부 말 뇌염 (Eastern equine encephalitis) 바이러스 (EEEV), 에일랏 (Eilat) 바이러스, 에버글레이즈 (Everglades) 바이러스, 포트 모건 (Fort Morgan) 바이러스, 게타 (Getah) 바이러스, 하이랜드 J 바이러스, 키질라가크 (Kyzylagach) 바이러스, 마야로 (Mayaro) 바이러스, 메 트리 (Me Tri) 바이러스, 미델부르크 (Middelburg) 바이러스, 모소 다스 페드라스 (Mosso das Pedras) 바이러스, 무캄보 (Mucambo) 바이러스, 엔두무 (Ndumu) 바이러스, 오뇽-뇽 (O'nyong-nyong) 바이러스, 픽수나 (Pixuna) 바이러스, 리오 네그로 (Rio Negro) 바이러스, 로스 리버 (Ross River) 바이러스 (RRV), 연어 췌장 질환 (Salmon pancreas disease) 바이러스, 셈리키 삼림 (Semliki Forest) 바이러스, 신드비스 (Sindbis) 바이러스, 남방 바다코끼리 물범 (Southern elephant seal) 바이러스, 토네이트 (Tonate) 바이러스, 트로카라 (Trocara) 바이러스, 우나 (Una) 바이러스, 베네수엘라 말 뇌염 (Venezuelan equine encephalitis) 바이러스 (VEEV), 서부 말 뇌염 (Western equine encephalitis) 바이러스 (WEEV), 화타로아 (Whataroa) 바이러스, 웨스트 나일 (West Nile) 바이러스, 뎅기 (dengue) 바이러스, 진드기 매개 뇌염 (tick-borne encephalitis) 바이러스 및 황열 (yellow fever) 바이러스를 포함한다.
바이러스 구조 단백질은 캡시드 (capsid) 단백질, 외피 단백질, 이의 단편 또는 이의 복합체일 수 있다. 따라서, 본 발명에 사용한 바이러스 구조 단백질은 캡시드 단백질 및/또는 외피 단백질 및/또는 이의 단편으로 이루어지거나 이를 포함할 수 있다. 한 구현예에서, 본 발명에 의해 제공된 바이러스 유사 입자는 캡시드, E2 및 E1 로 이루어지거나 이를 포함한다. 항원은 E2 에 삽입될 수 있다. 예를 들어, 본 발명에 의해 제공된 바이러스 유사 입자는 240 개 캡시드, 240 개 E1 단백질 및 240 개 E2 단백질을 어셈블리하여 형성될 수 있으며, 이때 PD-1 항원이 각각의 E2 단백질에 삽입된다.
본원에서 사용한 바와 같이, 용어 "PD-1 항원" 은 PD-1 에서 유래한 항원을 나타낸다. 바람직하게는, PD-1 은 인간 PD-1 이다. PD-1 에서 유래한 항원은 PD-1 의 단편 또는 PD-1 의 단편의 유도체일 수 있다.
본원에서 사용한 바와 같이, 용어 "PD-1 리간드 항원" 은 PD-1 의 리간드에서 유래한 항원을 나타낸다. PD-1 의 리간드의 예는 비제한적으로, PD-L1 및 PD-L2 를 포함한다. 바람직하게는, PD-1 의 리간드는 인간 PD-L1 또는 인간 PD-L2 이다. PD-L1 에서 유래한 항원은 PD-L1 또는 PD-L2 의 단편; 또는 PD-L1 또는 PD-L2 의 단편의 유도체일 수 있다.
본 발명에 의해 제공된 입자에 함유된 항원에 사용하기 위한 PD-1, PD-L1 또는 PD-L2 의 단편은 PD-1, PD-L1 또는 PD-L2 및/또는 이의 3 차 구조의 아미노산 서열을 기반으로 선택될 수 있다.
예를 들어, 항원에서 사용하기 위한 단편은 PD-1, PD-L1 또는 PD-L2 의 표면에 위치한 단편으로 이루어지거나 이를 포함할 수 있다. 바람직하게는, 본 발명에 의해 제공된 입자에 함유된 항원에 대항하는 항체는 PD-1 및 PD-L1 또는 PD-1 및 PD-L2 사이의 상호작용을 차단한다. 항원에서 사용하기 위한 PD-1, PD-L1 또는 PD-L2 의 단편은 10-300 개 아미노산 잔기 (예를 들어 10-120, 10-30 또는 15-30 개 아미노산 잔기) 의 길이일 수 있다.
한 구현예에서 항원에서 사용하기 위한 단편은, 거리가 항원 또는 항원을 함유하는 자연발생적 단백질 또는 그로부터의 개질된 단백질의 결정에서 측정되는 경우, 항원의 N-말단 잔기와 C-말단 잔기 사이의 공간적 거리가 30Å 이하이도록 선택될 수 있다. 예를 들어, 본 발명에 의해 제공된 입자에 사용된 항원은 PyMOL (예를 들어 PyMOL v0.99: http:/www.pymol.org) 을 포함하는 무료 소프트웨어를 사용하여 설계될 수 있다. 한 구현예에서, 항원의 N-말단 잔기와 C-말단 잔기 사이의 공간적 거리는 30Å (옹스트롬) 이하, 20Å 이하, 또는 10Å 이하 (예를 들어 5Å 내지 15Å, 5Å 내지 12Å, 5Å 내지 11Å, 5Å 내지 10Å, 5Å 내지 8Å, 8Å 내지 15Å, 8Å 내지 13Å, 8Å 내지 12Å, 8Å 내지 11Å, 9Å 내지 12Å, 9Å 내지 11Å, 9Å 내지 10Å 또는 10Å 내지 11Å) 이다.
항원에서 사용하기 위한 PD-1 의 단편의 예는 비제한적으로, lnwyrmspsnqtdklaaf (SEQ ID No.:4), mlnwyrmspsnqtdklaafs (SEQ ID No.:5), vlnwyrmspsnqtdklaafp (SEQ ID No.:6), gaislhpkakiees (SEQ ID No.:7), cgaislhpkakieec (SEQ ID No.:8), VLNWYRMSPSNQTDKLAAF (SEQ ID No.:9), GAISLAPKAQIKES (SEQ ID No.:10), RNDSGTYLCGAISLAPKAQIKESLRAELRVT (SEQ ID No.:11) 및 RNDSGIYLCGAISLHPKAKIEESPGAELVVT (SEQ ID No.:12) 를 포함한다. 항원에서 사용하기 위한 PD-L1 의 단편의 예는 비제한적으로, ciisyggadyc (SEQ ID No.:13), CMISYGGADYC (SEQ ID No.:14), LQDAGVYRCMISYGGADYKRITVKVN (SEQ ID No.:15), LQDAGVYRAMISYGGADYKRITVKVN (SEQ ID No.:16), DLAALIVYWEMEDKNIIQFVH (SEQ ID No.:17), DLAALIVYWEMEDKNIIQFVHGG (SEQ ID No.:18), FTVTVPKDLYVVEYGSNMTIECKFPVE (SEQ ID No.:19), Lqdagvycciisyggadykritlkvn (SEQ ID No.: 20), lqdagvyaaiisyggadykritlkvn (SEQ ID No.:21), dllalvvywekedeqviqfva (SEQ ID No.: 22), dllalvvywekedeqviqfvagg (SEQ ID No.: 23) 및 ftitapkdlyvveygsnvtmecrfpve (SEQ ID No.: 24) 를 포함한다.
PD-1, PD-L1 또는 PD-L2 의 단편의 유도체는 PD-1, PD-L1 또는 PD-L2 의 단편에서의 하나 또는 여러 아미노산 잔기의 첨가, 결실 또는 대체에 의해 제조될 수 있다. 한 구현예에서, PD-1, PD-L1 또는 PD-L2 의 단편의 유도체는 자연발생적 PD-1, PD-L1 또는 PD-L2 의 상응하는 단편에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 갖는다. 한 구현예에서, PD-1, PD-L1 또는 PD-L2 의 단편의 유도체는 자연발생적 PD-1, PD-L1 또는 PD-L2 의 상응하는 단편을 기반으로 최대 10% 의 아미노산이 결실되고, 치환되고/되거나 첨가되는 돌연변이체이다.
본 발명에 의해 제공되는 바와 같은 입자에서, 바이러스 구조 단백질 및 항원은 바이러스 구조 단백질에 존재하는 하나 이상의 제 1 결합 부위 및 항원에 존재하는 하나 이상의 제 2 결합 부위를 통해 연결될 수 있다.
본원에서 사용한 바와 같이, 각각의 "제 1 결합 부위" 및 "제 2 결합 부위" 는 하나 초과의 물질이 서로 연결되는 부위를 나타낸다.
한 구현예에서, 바이러스 구조 단백질 및 항원은 직접적으로 융합된다. 한 구현예에서, 1 또는 2 개의 링커가 항원의 N-말단 잔기와 바이러스 구조 단백질 사이 및/또는 항원의 C-말단 잔기와 바이러스 구조 단백질 사이에 개입될 수 있다.
항원 또는 바이러스 구조 단백질은 절두 (truncated) 될 수 있으며 단길이 링커에 의해 대체될 수 있다. 일부 구현예에서, 항원 또는 바이러스 구조 단백질은 하나 이상의 펩티드 링커를 포함한다. 통상, 링커는 2 내지 25 개 아미노산으로 이루어진다. 보통 이는 2 내지 15 개 아미노산 길이이나, 특정 환경에서는 단 1 개, 예컨대 단일 글리신 잔기일 수 있다.
한 구현예에서, 바이러스 구조 단백질을 인코딩하는 폴리뉴클레오티드가 항원을 인코딩하는 폴리뉴클레오티드와 유전적으로 융합되는 핵산 분자는, 제 1 결합 부위 및 제 2 결합 부위가 펩티드 결합을 통해 연결되도록 숙주 세포에서 발현된다. 이러한 경우, 바이러스 구조 단백질 및 항원은 펩티드 결합을 통해 연결된다. 이러한 구현예에 관련하여, 제 1 결합 부위 및/또는 제 2 결합 부위는 본래 단백질 또는 항원으로부터 유전적으로 개질될 수 있다. 예를 들어, 제 1 결합 부위는 SG, GS, SGG, GGS 및 SGSG 를 포함하는 링커 펩티드를 통해 단백질이 항원과 접합되도록 바이러스 구조 단백질로부터 개질된다.
바이러스 구조 단백질이 항원과 화학적으로 접합되는 경우, 제 1 결합 부위 및 제 2 결합 부위는 화합물인 화학적 가교제를 통해 연결될 수 있다.
가교제의 예는 비제한적으로, SMPH, 술포-MBS, 술포-EMCS, 술포-GMBS, 술포-SIAB, 술포-SMPB, 술포-SMCC, SVSB, SIA 및 Pierce Chemical Company사에서 시판되는 기타 가교제를 포함한다.
바람직하게는, 항원은 유전공학에 의해 생성된 융합 단백질로서 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질에 연결될 수 있다.
본 발명에서 사용한 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질은 치쿤구니야 또는 베네수엘라 말 뇌염 바이러스 외피 단백질 또는 캡시드 또는 하나 이상의 외피 단백질 및/또는 캡시드 단백질의 복합체일 수 있다.
치쿤구니야 바이러스의 예는 비제한적으로, 37997 및 LR2006 OPY-1 의 균주를 포함한다.
베네수엘라 말 뇌염 바이러스의 예는 비제한적으로, TC-83 을 포함한다.
본 발명에서 사용한 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질은 자연발생적 바이러스 구조 단백질 또는 이의 개질된 단백질일 수 있다. 개질된 단백질은 자연발생적 바이러스 구조 단백질의 단편일 수 있다. 한 구현예에서, 개질된 단백질은 자연발생적 바이러스 캡시드 및/또는 외피 단백질에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 갖는다. 한 구현예에서, 개질된 단백질은 자연발생적 바이러스 캡시드 및/또는 외피 단백질을 기반으로 최대 10% 의 아미노산이 결실되고, 치환되고/되거나 첨가되는 돌연변이체이다. 예를 들어, K64A 또는 K64N 돌연변이는 본 발명에서 사용한 베네수엘라 말 뇌염 바이러스 구조 단백질의 캡시드에 도입될 수 있다.
치쿤구니야 또는 베네수엘라 말 뇌염 바이러스 구조 단백질은 캡시드, E2 및 El 로 이루어지거나 이를 포함할 수 있다.
치쿤구니야 바이러스 구조 단백질의 예는 비제한적으로, 치쿤구니야 바이러스 균주 37997 의 캡시드-E2-E1, 및 치쿤구니야 바이러스 LR2006 OPY-1 의 캡시드-E2-E1 을 포함한다.
베네수엘라 말 뇌염 바이러스 구조 단백질의 예는 비제한적으로, 베네수엘라 말 뇌염 바이러스 균주 TC-83 의 캡시드-E2-E1 을 포함한다.
예시적인 치쿤구니야 바이러스 구조 단백질 서열이 Genbank 접근 번호 ABX40006.1 로 제공되며, 하기에 기재된다 (SEQ ID No.:1):
또 다른 예시적인 치쿤구니야 바이러스 구조 단백질 서열이 Genbank 접근 번호 ABX40011.1 로 제공되며, 하기에 기재된다 (SEQ ID No.:2):
예시적인 베네수엘라 말 뇌염 바이러스 구조 단백질이 Genbank 접근 번호 L01443.1 (http:"www.ncbi.nlm.nih.gov/nuccore/L01443.1) 로 제공되며, 하기에 기재된다 (SEQ ID No.:3):
한 구현예에서, 제 1 결합 부위는 아미노기, 바람직하게는 리신 잔기의 아미노기를 포함한다. 한 구현예에서, 제 2 결합 부위는 술프히드릴기, 바람직하게는 시스테인의 술프히드릴기를 포함한다.
본 발명에 따라서, 치쿤구니야 또는 베네수엘라 말 뇌염 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원 {이때 상기 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질 및 항원은 융합 단백질로서 발현됨} 을 포함하는 치쿤구니야 바이러스 유사 입자 또는 베네수엘라 말 뇌염 바이러스 유사 입자가 제공될 수 있다.
PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원은 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질의 임의의 부위와 융합될 수 있다. 예를 들어, PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원은 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질의 N- 또는 C-말단에 직접 또는 간접적으로 연결될 수 있거나, PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원은 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질에 삽입될 수 있다.
한 구현예에서, PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 하나 이상의 항원은 치쿤구니야 바이러스 구조 단백질 또는 베네수엘라 말 뇌염 바이러스 구조 단백질의 E2 에 삽입된다. 예를 들어, 치쿤구니야 바이러스 구조 단백질에 관련하여, PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 하나 이상의 항원은 SEQ ID No.:1 또는 2 의 잔기 519 와 520 사이 (즉, SEQ ID No.:1 또는 2 의 519-위치에서의 G 와 520-위치에서의 Q 사이); SEQ ID No.:1 또는 2 의 잔기 530 과 531 사이 (즉, SEQ ID No.:1 또는 2 의 530-위치에서의 G 와 531-위치에서의 S 사이); SEQ ID No.:1 또는 2 의 잔기 531 과 532 사이 (즉, SEQ ID No.:1 또는 2 의 531-위치에서의 S 와 532-위치에서의 N 사이); SEQ ID No.:1 또는 2 의 잔기 529 와 530 사이 (즉, SEQ ID No.:1 또는 2 의 529-위치에서의 G 와 530-위치에서의 G 사이); 또는 SEQ ID No.:1 또는 2 의 잔기 510 과 511 사이 (즉, SEQ ID No.:1 또는 2 의 510-위치에서의 S 와 511-위치에서의 G 사이); 또는 SEQ ID No.:1 또는 2 의 잔기 511 과 512 사이 (즉, SEQ ID No.:1 또는 2 의 511-위치에서의 G 와 512-위치에서의 N 사이); 또는 SEQ ID No.:1 또는 2 의 잔기 509 와 510 사이 (즉, SEQ ID No.:1 또는 2 의 509-위치에서의 Q 와 510-위치에서의 S 사이) 에 삽입된다. VLP_CHI 532 벡터 (SEQ ID No.: 25) 는 치쿤구니야 바이러스 유사 입자를 제조하는데 사용될 수 있으며, 이때 항원이 SEQ ID No.1 또는 2 의 잔기 531 과 532 사이에 삽입된다.
예를 들어, 베네수엘라 말 뇌염 바이러스 구조 단백질에 관련하여, PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 하나 이상의 항원은 SEQ ID No.:3 의 잔기 517 과 518 사이 (즉, SEQ ID No.:3 의 517-위치에서의 G 와 518-위치에서의 S 사이); SEQ ID No.:3 의 잔기 518 과 519 사이 (즉, SEQ ID No.:3 의 518-위치에서의 S 와 519-위치에서의 S 사이); SEQ ID No.:3 의 잔기 519 와 520 사이 (즉, SEQ ID No.:3 의 519-위치에서의 S 와 520-위치에서의 V 사이); SEQ ID No.:3 의 잔기 515 와 516 사이 (즉, SEQ ID No.:3 의 515-위치에서의 L 과 516-위치에서의 S 사이); SEQ ID No.:3 의 잔기 516 과 517 사이 (즉, SEQ ID No.:3 의 516-위치에서의 S 와 517-위치에서의 G 사이); SEQ ID No.:3 의 잔기 536 과 537 사이 (즉, SEQ ID No.:3 의 536-위치에서의 C 와 537-위치에서의 G 사이); SEQ ID No.:3 의 잔기 537 과 538 사이 (즉, SEQ ID No.:3 의 537-위치에서의 G 와 538-위치에서의 G 사이); SEQ ID No.:3 의 잔기 538 과 539 사이 (즉, SEQ ID No.:3 의 538-위치에서의 G 와 539-위치에서의 T 사이) 에 삽입된다. VLP_VEEV VLP 518 벡터 (SEQ ID No.:26) 는 베네수엘라 말 뇌염 바이러스 유사 입자를 제조하는데 사용될 수 있으며, 이때 항원이 SEQ ID No.3 의 잔기 517 과 518 사이에 삽입된다.
융합 단백질은 당해 기술 분야에서의 종래의 기법을 사용하여 발현될 수 있다. 다양한 발현 시스템을 융합 단백질 발현에 사용할 수 있다. 예를 들어, 융합 단백질은 293 세포, Sf9 세포 또는 대장균 (E.coli) 에서 발현될 수 있다.
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 에서 유래한 단백질은 자연발생적 바이러스 단백질 또는 이의 개질된 단백질일 수 있다.
바이러스에서 유래한 단백질이 항원에서 유래한 단백질과 접합되는 경우, SG, GS, SGG, GGS, SGSG 및 TRGGS 를 포함하는 링커 펩티드가 사용될 수 있다. 바이러스에서 유래한 단백질 (하기에서 "PFV" 로 나타냄) 과 항원에서 유래한 단백질 (하기에서 "PFA" 로 나타냄) 의 접합의 예는 비제한적으로: PFV-SG-PFA-GS-PFV; PFV-SG-PFA-GGS-PFV; PFV-SSG-PFA-GS-PFV; PFV-SGG-PFA-GGS-PFV; PFV-SGSG-PFA-GS-PFV; 및 PFA-SGG-PFA-TRGGS-PFV 를 포함한다.
한 구현예에서, 본 발명은 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 에서 유래한 단백질 및 PD-1 또는 PD-L1 에서 유래한 단백질의 융합 단백질을 포함하는 바이러스 유사 입자를 제공하며, 이때 상기 바이러스 유사 입자는 SEQ ID No.:27-32 로 나타내는 뉴클레오티드 서열을 포함하는 핵산 분자를 포함하는 발현 벡터를 포유류 세포 (예를 들어 293F 세포) 에 트랜스펙션시켜 제조된다. 이러한 구현예에 관련하여, 개질된 융합 단백질은 또한 본 발명에 의해 제공되는 바이러스 유사 입자에 사용될 수 있으며, 이는 SEQ ID No.: 27-32 에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 갖는 뉴클레오티드 서열을 포함하는 핵산 분자를 포함하는 발현 벡터를 포유류 세포 (예를 들어 293F 세포) 에 트랜스펙션시켜 제조될 수 있다.
한 구현예에서, 본 발명은 하기를 포함하거나 이것으로 이루어지는 바이러스 유사 입자를 제공한다:
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 캡시드;
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 E1; 및
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 E2, 이때 PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원은 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 E2 에 삽입된다. 예를 들어, 본 발명은 하기를 포함하거나 이것으로 이루어지는 바이러스 유사 입자를 제공한다:
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 240 개 캡시드;
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 240 개 E1; 및
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 240 개 E2, 이때 PD-1 에서 유래한 항원 및 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 에서 유래한 항원으로 이루어지는 군에서 선택되는 항원은 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 각각의 E2 에 삽입된다.
이러한 구현예에서, 항원이 삽입되는 E2 는 SEQ ID No.:33-36 으로 나타내는 아미노산 서열로 이루어질 수 있고; E1 은 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어질 수 있으며; 캡시드는 SEQ ID No.: 38 로 나타내는 아미노산 서열로 이루어질 수 있고; 또는
항원이 삽입되는 E2 는 SEQ ID No.:39-42 로 나타내는 아미노산 서열로 이루어질 수 있고; E1 은 SEQ ID No.:43 으로 나타내는 아미노산 서열로 이루어질 수 있으며; 캡시드는 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어질 수 있다.
또한 상기 구현예에 관련하여, 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 캡시드, 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 E1 및 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 E2 를 바이러스 유사 입자에 사용할 수 있다. 예를 들어, 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 캡시드는 SEQ ID No.:38 또는 SEQ ID No.:44 로 나타내는 아미노산 서열에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 가질 수 있고; 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 E1 은 SEQ ID No.:37 또는 SEQ ID No.:43 으로 나타내는 아미노산 서열에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 가질 수 있고/있거나; 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 개질된 E2 는 SEQ ID No.:33-36 또는 SEQ ID No.:39-42 로 나타내는 아미노산 서열에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 아미노산 서열 동일성을 가질 수 있다. 또한, 개질된 캡시드, E1 또는 E2 는 SEQ ID No.:38 또는 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어지는 캡시드; SEQ ID No.:37 또는 SEQ ID No.:43 으로 나타내는 아미노산 서열로 이루어지는 E1; 및/또는 SEQ ID No.:33-36 또는 SEQ ID No.:39-42 로 나타내는 아미노산 서열로 이루어지는 E2 를 기반으로 최대 10% 의 아미노산이 결실, 치환 및/또는 첨가되는 돌연변이체일 수 있다.
바이러스 유사 입자는 바이러스 유사 입자를 인코딩하는 뉴클레오티드 서열을 갖는 DNA 분자를 포함하는 발현 벡터를 세포 (예를 들어 293 세포) 에 도입하고, 초원심분리 방법을 사용하여 조건화 배지로부터 상기 바이러스 유사 입자를 회수함으로써 제조될 수 있다.
(2) 뉴클레오티드, 벡터, 숙주 세포
제 2 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 개시된 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자를 제공한다.
본 발명에 의해 제공된 핵산 분자는 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 치쿤구니야 바이러스 유사 입자 또는 베네수엘라 말 뇌염 바이러스 유사 입자를 발현하기 위한 단리된 핵산 분자일 수 있다.
당업자는 SEQ ID No.:63-64 로 나타내는 외피 및/또는 캡시드를 인코딩하는 예시적인 뉴클레오티드 서열을 기반으로 상기 기재한 본 발명에 의해 제공된 핵산 분자를 제조할 수 있다.
예를 들어, 당업자는 PD-1 또는 PD-L1 에서 유래한 항원을 인코딩하는 뉴클레오티드 서열을 치쿤구니야 또는 베네수엘라 말 바이러스 구조 단백질의 E2 를 인코딩하는 뉴클레오티드 서열에 도입하여, 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 치쿤구니야 바이러스 유사 입자 또는 베네수엘라 말 바이러스 유사 입자가 발현되도록 벡터에 도입되는 핵산 분자를 제조할 수 있다. 항원-유래 서열이 상기 기재한 바와 같이 E2 에 도입되는 뉴클레오티드 서열의 예는 비제한적으로, SEQ ID No.:27 또는 29 로 나타내는 뉴클레오티드 서열 (PD-1 항원을 포함하는 치쿤구니야 바이러스 유사 입자 발현을 위함); SEQ ID No.:31 로 나타내는 뉴클레오티드 서열 (PD-L1 항원을 포함하는 치쿤구니야 바이러스 유사 입자 발현을 위함); SEQ ID No.:28 또는 30 으로 나타내는 뉴클레오티드 서열 (PD-1 항원을 포함하는 베네수엘라 말 뇌염 바이러스 유사 입자 발현을 위함); 및 SEQ ID No.:32 로 나타내는 뉴클레오티드 서열 (PD-L1 항원을 포함하는 베네수엘라 말 뇌염 바이러스 유사 입자 발현을 위함) 을 포함한다.
한 구현예에서, 본 발명은 상기 기재한 바와 같이 핵산 분자를 포함하는 벡터를 제공하며, 이때 상기 벡터는 핵산 분자에 작동가능하게 연결된 발현 제어 서열을 임의로 포함한다.
발현 제어 서열의 예는 비제한적으로, 프로모터 예컨대 CMV 프로모터, 파지 람다 PL 프로모터, 대장균 lac, phoA 및 tac 프로모터, SV40 초기 및 후기 프로모터, 및 레트로바이러스 LTR 의 프로모터를 포함한다.
이러한 구현예에서, 상기 기재된 바와 같은 핵산 분자에 작동가능하게 연결된 발현 제어 서열을 포함하는 벡터가 본 발명에 의해 제공된 입자를 제조하기 위한 발현 벡터로서 사용될 수 있다.
발현 벡터는 그 전체가 본원에 참고로 포함되는 WO/2012/006180 을 기반으로 당업자에 의해 제조될 수 있다.
치쿤구니야 바이러스 (CHIKV) 에서 유래한 단백질 및 PD-1 에서 유래한 항원의 융합 단백질을 포함하는 바이러스 유사 입자를 발현하는데 사용할 수 있는 벡터의 예는 VLP31.11 벡터 (SEQ ID No.:45) 및 VLP274.11 벡터 (SEQ ID No.:46) 로 나타낸 벡터를 포함한다.
치쿤구니야 바이러스 (CHIKV) 에서 유래한 단백질 및 PD-L1 에서 유래한 항원의 융합 단백질을 포함하는 바이러스 유사 입자를 발현하는데 사용될 수 있는 벡터의 예는 VLP299.15 벡터 (SEQ ID No.:47) 로 나타낸 벡터를 포함한다.
베네수엘라 말 뇌염 바이러스 (VEEV) 에서 유래한 단백질 및 PD-1 에서 유래한 항원의 융합 단백질을 포함하는 바이러스 유사 입자를 발현하는데 사용될 수 있는 벡터의 예는 VLP31.21 벡터 (SEQ ID No.:48) 및 VLP274.21 벡터 (SEQ ID No.:49) 로 나타낸 벡터를 포함한다.
베네수엘라 말 뇌염 바이러스 (VEEV) 에서 유래한 단백질 및 PD-L1 에서 유래한 항원의 융합 단백질을 포함하는 바이러스 유사 입자를 발현하는데 사용될 수 있는 벡터의 예는 VLP299.25 벡터 (SEQ ID No.:50) 로 나타낸 벡터를 포함한다.
SEQ ID No:45-50 중 어느 하나로 나타내는 뉴클레오티드 서열을 갖는 핵산 분자에 대해 70%, 75%, 80%, 85%, 90%, 95% 또는 98% 이상의 뉴클레오티드 서열 동일성을 갖는 핵산 분자 및 SEQ ID No.:45-50 중 어느 하나로 나타내는 뉴클레오티드 서열을 갖는 핵산 분자를 기반으로 최대 10% 의 아미노산이 결실, 치환 및/또는 첨가되는 돌연변이체일 수 있는 핵산 분자가 또한 본 발명에 의해 제공된다.
또한, 상기 기재한 벡터를 숙주 세포에 도입하여 제조된 재조합체 세포가 본 발명에 의해 제공된다. 예를 들어, CHO 세포 또는 293 세포가 숙주 세포로서 사용된다.
(3) 약학 조성물, 키트
제 3 양태에서, 본 발명은 약학 조성물 및 약학 조성물을 포함하는 키트를 제공하며, 이때 상기 약학 조성물은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자; 또는 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자; 및 약학적으로 허용가능한 담체를 포함한다.
한 구현예에서, 본 발명은 약학 조성물 또는 약학 조성물을 포함하는 키트를 제공하며, 이때 상기 약학 조성물은 상기 기재한 바와 같은 알파바이러스 또는 플라비바이러스 바이러스 유사 입자 (예를 들어 치쿤구니야 바이러스 유사 입자 또는 베네수엘라 말 뇌염 바이러스 유사 입자) 또는 상기 기재한 바와 같은 핵산 분자; 및 약학적으로 허용가능한 담체를 포함한다. 알파바이러스 또는 플라비바이러스 바이러스 유사 입자의 함량 및 핵산 분자의 함량은 약학 조성물의 0.00001-1 w/w% 일 수 있다.
본 발명에 의해 제공된 입자 (예를 들어 CHIKV VLP 또는 VEEV VLP) 의 투약량은 1-500 ㎍/일일 수 있다.
하나 이상의 PD-1 항원 또는 PD-1 리간드 항원을 본 발명에 의해 제공된 하나의 약학 조성물에 사용할 수 있다.
약학 조성물은 아쥬반트 (adjuvant) 를 추가로 포함할 수 있다. 아쥬반트의 예는 비제한적으로, Ribi 용액 (Sigma Adjuvant system, Sigma-Aldrich) 을 포함한다. 본 발명에 의해 제공된 약학 조성물은 완충제 예컨대 이염기성 인산나트륨 수화물, 인산이수소나트륨 및 염화나트륨; 및 보존제 예컨대 티메로살 (thimerosal) 을 함유할 수 있다. 한 구현예에서, 약학 조성물은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 또는 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 0.001-1 w/w% 의 입자 (예를 들어 CHIKV VLP 또는 VEEV VLP), 1-10 w/w% 의 완충제, 0.01-1 w/w% 의 아쥬반트 및 0.00001-0.001 w/w% 의 보존제를 함유하는 수용액이다.
당업자는 종래의 기법을 사용하여 약학 조성물을 제조할 수 있다. 예를 들어, 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 또는 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자 (예를 들어 CHIKV VLP 또는 VEEV VLP) 를 생리학적 pH (예를 들어 pH 5-9, pH 7) 를 갖는 완충액과 혼합하여 본 발명에 의해 제공된 약학 조성물을 제조한다.
한 구현예에서, 약학 조성물은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 포함하는 백신 또는 면역자극제이다. 예를 들어, 본 발명에 의해 제공된 백신 조성물은 면역치료요법 (예를 들어 암 치료) 에 사용될 수 있다.
한 구현예에서, 약학 조성물은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자를 포함하는 DNA 백신이다. 한 구현예에서, 본 발명에 의해 제공된 DNA 백신은 CpG 함유 올리고뉴클레오티드를 포함한다.
본 발명의 제 3 양태에서 제공된 약학 조성물은 1 회 이상 투여될 수 있다. 본 발명의 제 3 양태에서 제공된 약학 조성물은 1 회 초과로 투여되는 경우, 본 발명의 제 1 양태에서 제공된 상이한 입자 (예를 들어 CHIKV VLP 또는 VEEV VLP) 를 각 투여에 사용할 수 있다. 한 구현예에서, 본 발명의 제 1 양태에서 제공된 CHIKV VLP 를 사용하는 면역화 및 본 발명의 제 1 양태에서 제공된 VEEV VLP 를 사용하는 면역화의 조합을 이용한다. 예를 들어, 본 발명의 제 1 앙태에서 제공된 CHIKV VLP 는 1 차 면역화에 사용될 수 있고 본 발명의 제 1 양태에서 제공된 VEEV VLP 는 2 차 면역화에 사용될 수 있거나, 본 발명의 제 1 양태에서 제공된 VEEV VLP 는 1 차 면역화에 사용될 수 있고 본 발명의 제 1 양태에서 제공된 CHIKV VLP 는 2 차 면역화에 사용될 수 있다.
당업자는 본 발명에 의해 제공된 조성물 또는 백신을 사용하는 면역화의 시기를 결정할 수 있다. 예를 들어, 2 차 면역화는 1 차 면역 1, 2, 3, 4, 5, 6, 7, 8, 9 또는 10 주 후에 수행된다.
한 구현예에서, 본 발명은 하기를 포함하는 키트를 제공하며:
(a) 본 발명의 제 1 양태에서 제공된 입자를 포함하는 약학 조성물; 및
(b) 본 발명의 제 1 양태에서 제공된 입자를 포함하는 또 다른 약학 조성물,
이때 (a) 에 포함된 입자는 (b) 에 포함된 입자와 상이한 바이러스 유사 입자이다. 이러한 구현예에서, (a) 에 포함된 입자는 치쿤구니야 바이러스 유사 입자일 수 있고 (b) 에 포함된 입자는 베네수엘라 말 뇌염 바이러스 유사 입자일 수 있다.
한 구현예에서, 본 발명은 하기를 포함하는 키트를 제공하며:
(a) 본 발명의 제 1 양태에서 제공된 입자를 포함하는 약학 조성물; 및
(b) 본 발명의 제 1 양태에서 제공된 입자를 포함하는 또 다른 약학 조성물,
(c) 각각 본 발명의 제 1 양태에서 제공된 입자를 포함하는 하나 이상의 약학 조성물,
이때 (a) 는 면역화 준비에 사용되고 (b) 및 (c) 는 면역화 증강에 사용되며; (a) 에 포함된 입자는 (b) 에 포함된 입자와 상이한 바이러스 유사 입자이고; (c) 에 포함된 입자는 (a) 및 (b) 에 포함된 입자와 상이하거나, (a) 또는 (b) 에 포함된 입자와 동일하다.
상기 기재한 키트에 포함된 각각의 약학 조성물은 동시에, 별도로, 또는 순차적으로 투여될 수 있다.
본 발명의 제 1 양태에서 제공된 알파바이러스 또는 플라비바이러스 바이러스 유사 입자 (예를 들어 치쿤구니야 바이러스 또는 베네수엘라 말 뇌염 바이러스) 또는 본 발명의 제 2 양태에서 제공된 핵산 분자는 본 발명의 제 3 양태에서 제공된 약학 조성물에 사용될 수 있다.
예를 들어, 치쿤구니야 또는 베네수엘라 말 뇌염 바이러스 유사 입자는 하기를 포함하거나 이것으로 이루어진다:
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 (예를 들어 240 개) 캡시드;
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 (예를 들어 240 개) E1; 및
치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 하나 이상의 (예를 들어 240 개) E2, 이때 PD-1 항원은 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 의 E2 에 삽입되어 본 발명의 제 3 양태에서 제공된 조성물 또는 백신을 제조하는데 사용될 수 있다. 항원이 삽입되는 E2 는 SEQ ID No.:33-36 으로 나타내는 아미노산 서열로 이루어질 수 있고; E1 은 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어질 수 있고; 캡시드는 SEQ ID No.:38 로 나타내는 아미노산 서열로 이루어질 수 있고; 또는
항원이 삽입되는 E2 는 SEQ ID No.:39-42 로 나타내는 아미노산 서열로 이루어질 수 있고; E1 은 SEQ ID No.:43 으로 나타내는 아미노산 서열로 이루어질 수 있고; 캡시드는 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어질 수 있다.
(4) 개시된 입자 등의 용도
제 4 양태에서, 본 발명은 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자; 또는 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 핵산 분자의, 암 또는 감염성 질환의 치료 또는 예방; 포유동물 (예를 들어 인간) 에서의 PD-1 또는 PD-1 의 리간드에 대항하는 항체의 생성; 면역 반응의 조절; 면역자극; PD-1 과 PD-1 의 리간드 사이의 상호작용 억제; 또는 PD-1 활성 억제를 위한 약학 조성물 또는 키트의 제조를 위한 용도를 제공한다. 암 또는 감염성 질환을 치료 또는 예방하고; 포유동물 (예를 들어 인간) 에서 PD-1 또는 PD-1 리간드에 대항하는 항체를 생성하고; 면역 반응을 조절하고; 면역자극하고; PD-1 과 PD-1 의 리간드 사이의 상호작용을 억제하거나; PD-1 활성을 억제하는 방법에서 사용되는 본원에 개시된 입자, 약학 조성물 또는 키트가 또한 제공된다.
약학 조성물은 포유동물 (예를 들어 인간) 에게 근육내 (i.m.), 피부내 (i.c.), 피하 (s.c.), 피내 (i.d.) 또는 복강내 (i.p.) 투여될 수 있다.
한 구현예에서, 약학 조성물은 면역치료요법 (예를 들어 암 치료) 에 적용될 수 있는 백신이다.
치료할 수 있는 암의 예는 비제한적으로, 흑색종, 신장암, 전립선암, 유방암, 결장암 및 비-소세포 폐암을 포함한다. 암의 기타 예는 비제한적으로, 골암, 췌장암, 피부암, 두경부 암, 피부 또는 안내 악성 흑색종, 자궁암, 난소암, 직장암, 항문부 암, 위암, 고환암, 나팔관 암종, 자궁내막암종, 자궁경부암종, 질암종, 외음부 암종, 호지킨병, 비-호지킨 림프종, 식도암, 소장암, 내분비계암, 갑상선암, 부갑상선암, 부신암, 연조직의 육종, 요도암, 음경암, 만성 또는 급성 백혈병 예컨대 급성 골수성 백혈병, 만성 골수성 백혈병, 급성 림프구성 백혈병, 만성 림프성 백혈병, 아동기 고형 종양, 림프구성 림프종, 방광암, 신장 또는 요관암, 신우암종, 중추신경계 (CNS) 신생물, 원발성 CNS 림프종, 종양 신생혈관생성, 척추 종양, 뇌간 신경교종, 뇌하수체 선종, 카포시 육종, 유피암, 편평세포암, T-세포 림프종, 석면에 의해 유도된 것들을 포함하는 환경적으로 유도된 암, 및 이의 조합을 포함한다.
치료할 수 있는 감염성 질환의 예는 비제한적으로, HIV, 인플루엔자, 헤르페스, 가르디아 (Guardia), 말라리아, 리슈마니아 (Leishmania), 바이러스 헤파티티스 (A, B 및 C), 헤르페스 바이러스 (예를 들어, VZV, HSV-I, HAV-6, HSV-II, 및 CMV, 엡스타인 바 바이러스), 아데노바이러스, 인플루엔자 바이러스, 플라비바이러스, 에코바이러스, 리노바이러스, 콕사키 (coxsackie) 바이러스, 코르노바이러스, 호흡기 세포융합 바이러스, 볼거리 바이러스, 로타바이러스, 홍역 바이러스, 풍진 바이러스, 파보바이러스, 천연두 바이러스, HTLV 바이러스, 뎅기 바이러스, 파필로마바이러스, 물사마귀 바이러스, 폴리오바이러스, 광견병 바이러스, JC 바이러스 및 아르보바이러스 뇌염 바이러스에 의한 병원성 감염, 박테리아 클라미디아, 리케차 박테리아, 마이코박테리아, 포도상구균, 연쇄상구균, 폐렴구균, 뇌척수막염균 및 코노코쿠스 (conococci), 크렙시엘라, 프로테우스, 세라티아, 슈도모나스, 레지오넬라, 디프테리아, 살모넬라, 바실러스, 콜레라, 파상풍, 보툴리눔 식중독, 탄저병, 흑사병, 렙토스피라증 및 라임병 박테리아에 의한 병원성 감염, 진균 칸디다 (Candida) (알비칸스 (albicans), 크루세이 (krusei), 글라브라타 (glabrata), 트로피칼리스 (tropicalis) 등), 크립토코쿠스 네오포르만스 (Cryptococcus neoformans), 아스페르길루스 (Aspergillus) (푸미가투스 (fumigatus), 니게르 (niger) 등), 털곰팡이 속 (Genus Mucorales) (무코르 (mucor), 압시디아 (absidia), 리조푸스 (rhizophus)), 스포로트릭스 스켄키 (Sporothrix schenkii), 블라스토마이세스 데르마티티디스 (Blastomyces dermatitidis), 파라코키디오이데스 브라실리엔시스 (Paracoccidioides brasiliensis), 코키디오이데스 이미티스 (Coccidioides immitis) 및 히스토플라스마 캡슐라툼 (Histoplasma capsulatum) 에 의한 병원성 감염, 및 기생충 엔타모에바 히스톨리티카 (Entamoeba histolytica), 발란티디움 콜리 (Balantidium coli), 네글레리아파울러리 (Naegleriafowleri), 아칸타모에바 종 (Acanthamoeba sp.), 지아르디아 람비아 (Giardia lambia), 크립토스포리디움 종 (Cryptosporidium sp.), 뉴모시스티스 카리니이 (Pneumocystis carinii), 플라스모디움 비박스 (Plasmodium vivax), 바베시아 마이크로티 (Babesia microti), 트리파노소마 브루세이 (Trypanosoma brucei), 트리파노소마 크루지 (Trypanosoma cruzi), 리슈마니아 도노바니 (Leishmania donovani), 톡소플라스마 곤디 (Toxoplasma gondi) 및 니포스트론길루스 브라실리엔시스 (Nippostrongylus brasiliensis) 에 의한 병원성 감염을 포함한다.
바이러스 구조 단백질 및 PD-1 또는 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 약학 조성물이 포유동물 (예를 들어 인간) 에게 투여되는 경우, PD-1 또는 PD-1 의 리간드에 대항하는 항체는 포유동물의 혈액 중에서 생성된다. 생성된 항체는 면역 반응을 조절할 수 있고; 면역자극 효과를 나타낼 수 있고; PD-1 과 PD-1 의 리간드 (예를 들어 PD-L1, PD-L2) 사이의 상호작용을 억제할 수 있거나; PD-1 활성을 억제할 수 있다.
생성된 항체는 종래의 기법을 사용하여 인간화될 수 있다. 본 발명의 제 1 양태에서 제공된 입자를 사용하여, 단일클론 항체 또는 다클론 항체를 제조할 수 있다. 한 구현예에서, 본 발명은 본 발명의 제 1 양태에서 제공된 입자를 비-인간 포유동물에 투여하고 비-인간 포유동물 생성 항체를 인간화시키는 것을 포함하는, PD-1 또는 PD-1 의 리간드에 대항하는 항체를 생성하는 방법을 제공한다.
본원에서 사용한 바와 같이, 용어 "항체" 는 에피토프 또는 항원 결정자와 결합할 수 있는 분자를 나타낸다. 상기 용어는 전체 항체 및 이의 항원-결합 단편, 예컨대 단일 사슬 항체를 포함하는 것으로 의도된다. 이러한 항체는 인간 항원 결합 항체 단편을 포함하며, 비제한적으로, Fab, Fab' 및 F(ab')2, Fd, 단일 사슬 Fv (scFv), 단일 사슬 항체, 디술피드-연결 Fv (sdFv) 및 VL 또는 VH 도메인을 포함하는 단편을 포함한다. 항체는 조류 및 포유동물을 포함하는 임의의 동물 기원으로부터의 것일 수 있다. 바람직하게는, 항체는 포유류 예를 들어 인간, 쥐과, 토끼, 염소, 기니아 피그, 낙타, 말 등, 또는 기타 적합한 동물 예를 들어 닭으로부터의 것이다. 본원에서 사용한 바와 같이, "인간" 항체는 인간 면역글로불린의 아미노산 서열을 갖는 항체를 포함하며 인간 면역글로불린 라이브러리 또는 하나 이상의 인간 면역글로불린에 대한 트랜스제닉 동물로부터 단리되고 내인성 면역글로불린을 발현하지 않는 항체를 포함한다 (예를 들어, 그 전체가 본원에 참조로 포함되는 미국 특허 번호 5,939,598 에 기재된 바와 같음).
용어 "PD-1 활성" 은 PD-1 과 관련된 하나 이상의 면역조절 활성을 나타낸다. 예를 들어, PD-1 은 TcR/CD28-매개 면역 반응의 부정적 조절자이다. 따라서, 면역 반응 조절의 예는 비제한적으로, TcR/CD28-매개 면역 반응을 증진시키는 것을 포함한다.
한 구현예에서, 본 발명은 입자의 발현을 위해 설계된 벡터를 제조하고; 입자가 발현하도록 벡터로 트랜스펙션된 세포를 배양하고; 입자를 회수하는 것을 포함하는, 본 발명의 제 1 양태에서 제공된 치쿤구니야 또는 베네수엘라 말 뇌염 바이러스 유사 입자를 제조하는 방법을 제공한다. 이러한 구현예에서, 트랜스펙션은 종래의 방법을 사용하여 수행될 수 있다. 트랜스펙션에 사용하는 세포는 293 세포일 수 있다. VLP 를 회수하는 것은, 세포가 벡터로 트랜스펙션된 후 조건화 배지를 수집하는 것을 포함할 수 있으며, 초원심분리를 사용하여 조건화 배지로부터 VLP 를 정제하는 것을 추가로 포함할 수 있다.
하기의 예시적 구현예 (1)-(35) 가 본 발명에 의해 추가로 제공된다:
(1)
바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 하나 이상의 항원을 포함하는 입자;
(2)
(1) 에 따른 입자의 유도체인 입자;
(3)
(1) 또는 (2) 에 있어서, 항원이 PD-1, PD-L1 또는 PD-L2 에서 유래한 항원인 입자;
(4)
(1)-(3) 중 어느 하나에 있어서, 입자를 동물에 투여하는 것이 항원에 대항한 항체를 유도하고 상기 항체가 및 PD-1 및 PD-L1 상호작용 또는 PD-1 및 PD-L2 상호작용을 차단하는 입자;
(5) (1)-(4) 중 어느 하나에 있어서, 상기 입자가 바이러스 유사 입자인 입자;
(6) (1)-(5) 중 어느 하나에 있어서, 상기 입자가 알파바이러스 또는 플라비바이러스에서 유래한 바이러스 유사 입자인 입자;
(7) (1)-(6) 중 어느 하나에 있어서, 상기 입자가 치쿤구니야 바이러스 또는 베네수엘라 말 뇌염 바이러스에서 유래한 바이러스 유사 입자인 입자;
(8)
(1)-(7) 중 어느 하나에 있어서, 바이러스 구조 단백질이 하나 이상의 제 1 결합 부위를 포함하고, 하나 이상의 항원이 하나 이상의 제 2 결합 부위를 포함하고, 바이러스 구조 단백질 및 항원이 하나 이상의 제 1 결합 부위 및 하나 이상의 제 2 결합 부위를 통해 연결되며, 입자가 바이러스 유사 입자인 입자;
(9)
(1)-(8) 중 어느 하나에 있어서, 바이러스 구조 단백질이 캡시드 및/또는 외피 단백질 E1 및 E2 를 포함하는 입자;
(10)
(9) 에 있어서, PD-1 에서 유래한 하나 이상의 항원 또는 PD-L1 에서 유래한 하나 이상의 항원이 외피 단백질의 E2 에 삽입되는 입자;
(11)
(1)-(10) 중 어느 하나에 있어서, 바이러스 구조 단백질이 치쿤구니야 바이러스 (CHIKV) 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 에서 유래한 단백질인 입자;
(12)
(1)-(11) 중 어느 하나에 있어서, 입자가 PD-1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 치쿤구니야 바이러스 유사 입자이며,
PD-1 에서 유래한 항원이 삽입되는 외피 단백질 E2 는 SEQ ID No.:33-35 로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 은 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어지고; 캡시드는 SEQ ID No.:38 로 나타내는 아미노산 서열로 이루어지는 입자;
(13)
(1)-(11) 중 어느 하나에 있어서, 입자가 PD-1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 베네수엘라 말 바이러스 유사 입자이며,
PD-1 에서 유래한 항원이 삽입되는 외피 단백질 E2 는 SEQ ID No.:39-41 로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 은 SEQ ID No.:43 으로 나타내는 아미노산 서열로 이루어지고; 캡시드는 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어지는 입자;
(14)
(1)-(11) 중 어느 하나에 있어서, 입자가 PD-L1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 치쿤구니야 바이러스 유사 입자이며,
PD-L1 에서 유래한 항원이 삽입되는 외피 단백질 E2 는 SEQ ID No.:36 으로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 은 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어지고; 캡시드는 SEQ ID No.:38 로 나타내는 아미노산 서열로 이루어지는 입자;
(15)
(1)-(11) 중 어느 하나에 있어서, 입자가 PD-L1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 베네수엘라 말 바이러스 유사 입자이며, PD-L1 에서 유래한 항원이 삽입되는 외피 단백질 E2 는 SEQ ID No.:42 로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 은 SEQ ID No.:43 로 나타내는 아미노산 서열로 이루어지고; 캡시드는 SEQ ID No.44 로 나타내는 아미노산 서열로 이루어지는 입자;
(16)
(1)-(15) 중 어느 하나에 따른 입자의 아미노산 서열과 90% 이상 (또는 95% 이상) 의 서열 동일성을 갖는 아미노산 서열로 이루어지는 입자;
(17)
(1)-(16) 중 어느 하나에 따른 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 단리된 핵산 분자;
(18)
SEQ ID No.:27-32 중 어느 하나로 나타내는 뉴클레오티드 서열과 90% 이상의 서열 동일성을 갖는 뉴클레오티드 서열로 이루어지는 단리된 핵산 분자;
(19)
(18) 에 있어서, 핵산 분자가 SEQ ID No.:27-32 중 어느 하나로 나타내는 뉴클레오티드 서열로 이루어지는 핵산 분자;
(20)
(17)-(19) 중 어느 하나에 따른 핵산 분자를 포함하는 벡터로서, 상기 벡터가 핵산 분자에 작동가능하게 연결된 발현 제어 서열을 임의로 포함하는 벡터 (예를 들어 SEQ ID No. 45, 46, 47, 48, 49 또는 50 으로 나타내는 뉴클레오티드 서열로 이루어지는 벡터);
(21)
하기를 포함하는 약학 조성물:
(a) (1)-(16) 중 어느 하나에 따른 입자, (17)-(19) 중 어느 하나에 따른 핵산 분자 및/또는 (20) 에 따른 벡터; 및
(b) 약학적으로 허용가능한 담체;
(22)
(21) 에 있어서, 약학 조성물이 (1)-(16) 중 어느 하나에 따른 입자 및 약학적으로 허용가능한 담체를 포함하는 약학 조성물 (예를 들어 백신);
(23)
(1)-(16) 중 어느 하나에 따른 입자, (17)-(19) 중 어느 하나에 따른 핵산 분자 및/또는 (20) 에 따른 벡터의, 암 또는 감염성 질환의 치료 또는 예방; 포유동물에서의 PD-1 또는 PD-1 의 리간드에 대항하는 항체의 생성; 면역 반응의 조절; 면역자극; PD-1 과 PD-1 의 리간드 사이의 상호작용 억제; 또는 PD-1 활성 억제를 위한 약학 조성물 또는 키트의 제조를 위한 용도;
(24)
(23) 에 있어서, 약학 조성물을 투여하여 PD-L1 및/또는 PD-L2 가 PD-1 에 결합하는 것을 억제하는 용도;
(25)
(23) 또는 (24) 에 있어서, 암이 흑색종, 신장암, 전립선암, 유방암, 결장암 또는 비-소세포 폐암인 용도;
(26)
(23) 또는 (24) 에 있어서, 암이 골암, 췌장암, 피부암, 두경부 암, 피부 또는 안내 악성 흑색종, 자궁암, 난소암, 직장암, 항문부 암, 위암, 고환암, 나팔관 암종, 자궁내막암종, 자궁경부암종, 질암종, 외음부 암종, 호지킨병, 비-호지킨 림프종, 식도암, 소장암, 내분비계암, 갑상선암, 부갑상선암, 부신암, 연조직의 육종, 요도암, 음경암, 만성 또는 급성 백혈병 예컨대 급성 골수성 백혈병, 만성 골수성 백혈병, 급성 림프구성 백혈병, 만성 림프성 백혈병, 아동기 고형 종양, 림프구성 림프종, 방광암, 신장 또는 요관암, 신우암종, 중추신경계 (CNS) 신생물, 원발성 CNS 림프종, 종양 신생혈관생성, 척추 종양, 뇌간 신경교종, 뇌하수체 선종, 카포시 육종, 유피암, 편평세포암, T-세포 림프종, 석면에 의해 유도된 것들을 포함하는 환경적으로 유도된 암, 및 이의 조합으로 이루어지는 군에서 선택되는 용도;
(27)
(23) 또는 (24) 에 있어서, 감염성 질환이 HIV, 인플루엔자, 헤르페스, 가르디아 (Guardia), 말라리아, 리슈마니아 (Leishmania), 바이러스 헤파티티스 (A, B 및 C), 헤르페스 바이러스 (예를 들어, VZV, HSV-I, HAV-6, HSV-II, 및 CMV, 엡스타인 바 바이러스), 아데노바이러스, 인플루엔자 바이러스, 플라비바이러스, 에코바이러스, 리노바이러스, 콕사키 (coxsackie) 바이러스, 코르노바이러스, 호흡기 세포융합 바이러스, 볼거리 바이러스, 로타바이러스, 홍역 바이러스, 풍진 바이러스, 파보바이러스, 천연두 바이러스, HTLV 바이러스, 뎅기 바이러스, 파필로마바이러스, 물사마귀 바이러스, 폴리오바이러스, 광견병 바이러스, JC 바이러스 및 아르보바이러스 뇌염 바이러스에 의한 병원성 감염, 박테리아 클라미디아, 리케차 박테리아, 마이코박테리아, 포도상구균, 연쇄상구균, 폐렴구균, 뇌척수막염균 및 코노코쿠스 (conococci), 크렙시엘라, 프로테우스, 세라티아, 슈도모나스, 레지오넬라, 디프테리아, 살모넬라, 바실러스, 콜레라, 파상풍, 보툴리눔 식중독, 탄저병, 흑사병, 렙토스피라증 및 라임병 박테리아에 의한 병원성 감염, 진균 칸디다 (Candida) (알비칸스 (albicans), 크루세이 (krusei), 글라브라타 (glabrata), 트로피칼리스 (tropicalis) 등), 크립토코쿠스 네오포르만스 (Cryptococcus neoformans), 아스페르길루스 (Aspergillus) (푸미가투스 (fumigatus), 니게르 (niger) 등), 털곰팡이 속 (Genus Mucorales) (무코르 (mucor), 압시디아 (absidia), 리조푸스 (rhizophus)), 스포로트릭스 스켄키 (Sporothrix schenkii), 블라스토마이세스 데르마티티디스 (Blastomyces dermatitidis), 파라코키디오이데스 브라실리엔시스 (Paracoccidioides brasiliensis), 코키디오이데스 이미티스 (Coccidioides immitis) 및 히스토플라스마 캡슐라툼 (Histoplasma capsulatum) 에 의한 병원성 감염, 및 기생충 엔타모에바 히스톨리티카 (Entamoeba histolytica), 발란티디움 콜리 (Balantidium coli), 네글레리아파울러리 (Naegleriafowleri), 아칸타모에바 종 (Acanthamoeba sp.), 지아르디아 람비아 (Giardia lambia), 크립토스포리디움 종 (Cryptosporidium sp.), 뉴모시스티스 카리니이 (Pneumocystis carinii), 플라스모디움 비박스 (Plasmodium vivax), 바베시아 마이크로티 (Babesia microti), 트리파노소마 브루세이 (Trypanosoma brucei), 트리파노소마 크루지 (Trypanosoma cruzi), 리슈마니아 도노바니 (Leishmania donovani), 톡소플라스마 곤디 (Toxoplasma gondi) 및 니포스트론길루스 브라실리엔시스 (Nippostrongylus brasiliensis) 에 의한 병원성 감염으로 이루어지는 군에서 선택되는 용도;
(28)
하기를 포함하는 키트로서:
(a) (1)-(16) 중 어느 하나에 따른 입자를 포함하는 약학 조성물; 및
(b) (1)-(16) 중 어느 하나에 따른 입자를 포함하는 또 다른 약학 조성물,
이때, (a) 에 포함된 입자는 (b) 에 포함된 입자와 상이한 바이러스 유사 입자인 키트;
(29)
(28) 에 있어서, (a) 에 포함된 입자가 치쿤구니야 바이러스 유사 입자이고 (b) 에 포함된 입자가 베네수엘라 말 뇌염 바이러스 유사 입자이거나, (a) 에 포함된 입자가 베네수엘라 말 뇌염 바이러스 유사 입자이고 (b) 에 포함된 입자가 치쿤구니야 바이러스 유사 입자인 키트;
(30)
(28) 또는 (29) 에 있어서, (1)-(16) 중 어느 하나에 따른 입자를 각각 포함하는 (c) 하나 이상의 약학 조성물을 추가로 포함하는 키트로서, 이때 (a) 는 면역화 준비에 사용되고 (b) 및 (c) 는 면역화 증강에 사용되며; (c) 에 포함된 입자는 (a) 및 (b) 에 포함된 입자와 상이하거나, (a) 또는 (b) 에 포함된 입자와 동일한 키트;
(31)
(28)-(30) 중 어느 하나에 있어서, 각각의 약학 조성물이 동시에, 별도로, 또는 순차적으로 투여되는 키트;
(32)
암 또는 감염성 질환을 치료 또는 예방하고; 포유동물에서 PD-1 또는 PD-1 의 리간드에 대항하는 항체를 생성하고; 면역 반응을 조절하고; 면역자극하고; PD-1 과 PD-1 의 리간드 사이의 상호작용을 억제하거나; PD-1 활성을 억제하는 방법에서 사용하기 위한, (1)-(16) 중 어느 하나에 따른 입자, (17)-(20) 중 어느 하나에 따른 핵산 분자, (20) 에 따른 벡터, (21) 또는 (22) 에 따른 약학 조성물 또는 (28)-(31) 중 어느 하나에 따른 키트;
(33)
암이 (25) 또는 (26) 에서 기재된 암에서 선택되는, 암을 치료하거나 예방하는 방법에서 사용하기 위한, (1)-(16) 중 어느 하나에 따른 입자, (17)-(20) 중 어느 하나에 따른 핵산 분자, (20) 에 따른 벡터, (21) 또는 (22) 에 따른 약학 조성물 또는 (28)-(31) 중 어느 하나에 따른 키트;
(34)
감염성 질환이 (27) 에서 기재된 감염성 질환에서 선택되는, 감염성 질환을 치료하거나 예방하는 방법에서 사용하기 위한, (1)-(16) 중 어느 하나에 따른 입자, (17)-(20) 중 어느 하나에 따른 핵산 분자, (20) 에 따른 벡터, (21) 또는 (22) 에 따른 약학 조성물 또는 (28)-(31) 중 어느 하나에 따른 키트;
(35)
입자가 발현되도록 (20) 에 따른 벡터로 트랜스펙션되는 세포를 배양하고; 초원심분리를 사용하여 상기 입자를 정제하는 것을 포함하는, 치쿤구니야 바이러스 유사 입자 또는 베네수엘라 말 뇌염 바이러스 유사 입자를 제조하는 방법.
하기 실시예를 참조로 하여 본 발명을 상세히 설명하지만, 이것이 본 발명의 범주를 제한하는 것으로 의도되는 것은 아니다.
실시예
실시예 1: 바이러스 구조 단백질 및 PD-1 항원의 단편을 포함하는 치쿤구니야 바이러스 (CHIKV) 유사 입자의 제조
하기 PD-1 의 폴리뉴클레오티드를 VLP_CHI 532 벡터 (SEQ ID No.:25) 에 삽입되는 것으로 사용하였다. N 말단 링커는 아미노산 서열에서 SGG 이며 (핵 서열에서 TCCGGAGGA) C 말단 링커는 아미노산 서열에서 GGS 이다 (핵 서열에서 GGAGGATCC).
1. VLP31 (PD-1 제 1 번 서열): 항원으로 사용한, PD-1 단편 결합 링커의 서열:
핵 서열
아미노산 서열
2. VLP32 (PD-1 제 2 번 서열): 항원으로 사용한, PD-1 단편 결합 링커의 또 다른 서열:
핵 서열
아미노산 서열
3. VLP33 (PD-1 제 3 번 서열): 항원으로 사용한, PD-1 단편 결합 링커의 또 다른 서열:
핵 서열
아미노산 서열
각각의 폴리뉴클레오티드를 SEQ ID No.2 의 531-위치에서의 Ser 를 인코딩하는 코돈과 532-위치에서의 Asn 을 인코딩하는 코돈 사이에 삽입하여, 개질된 PD-1-유래 펩티드가 치쿤구니야 바이러스 구조 단백질의 E2 에 삽입되는 치쿤구니야 바이러스 유사 입자를 발현하기 위한 플라스미드 (이하, VLP31_11, VLP32_11 또는 VLP33_11 로 나타냄) 를 구축하였다.
293F 세포 (Lifetechnology) 를, PEI (GE Healthcare) 또는 GeneX (ATCC) 를 사용하여 플라스미드로 트랜스펙션하였다. 트랜스펙션 4 일 후, 조건화 배지를 수집하고 3000 rpm 에서 15 분 동안 원심분리하여 세포로부터 이를 분리하였다. 상청액을 0.45 ㎛ 필터를 사용하여 여과하여, 바이러스 유사 입자를 수득하였다. 바이러스 유사 입자를 TFF 컬럼을 사용하여 농축하고 QXL 컬럼 (GE Healthcare) 을 사용하여 정제함으로써, 정제된 바이러스 유사 입자를 수득하였다.
치쿤구니야 바이러스 구조 단백질과 접합된 VLP31, 32 또는 33 을 포함하는 VLP 의 발현을, CHIKV (ATCC: VR-1241AF) 에 대해 특이적인 항체를 사용하여 웨스턴 블롯에 의해 확인하였다.
실시예 2: 바이러스 구조 단백질 및 PD-1 항원의 단편을 포함하는 베네수엘라 말 뇌염 바이러스 (VEEV) 유사 입자의 제조
실시예 1 에서 사용한 PD-1 의 동일한 폴리뉴클레오티드를 VLP_VEEV VLP 518 벡터 (SEQ ID No.:26) 에 삽입되는 것으로 사용하였다. N 말단 링커 및 C 말단 링커는 실시예 1 에서와 동일하다.
각각의 폴리뉴클레오티드를 SEQ ID No.3 의 518-위치에서의 Ser 를 인코딩하는 코돈과 519-위치에서의 Ser 를 인코딩하는 코돈 사이에 삽입하여, 개질된 PD-1-유래 펩티드가 베네수엘라 말 뇌염 구조 단백질의 E2 에 삽입되는 베네수엘라 말 뇌염 바이러스 유사 입자를 발현하기 위한 플라스미드 (이하, VLP31_21, VLP32_21 또는 VLP33_21 로서 나타냄) 를 구축하였다.
293F 세포를 실시예 1 과 같은 플라스미드로 트랜스펙션하였다. 베네수엘라 말 뇌염 바이러스 구조 단백질과 접합된 VLP 31, 32 또는 33 을 포함하는 VLP 의 발현을 VEEV 에 대해 특이적인 항체를 사용하여 웨스턴 블롯에 의해 확인하였다.
실시예 3: 바이러스 구조 단백질 및 PD-1 항원 또는 PD-L1 항원의 단편을 포함하는 치쿤구니야 바이러스 (CHIKV) 유사 입자 및 베네수엘라 말 뇌염 바이러스 (VEEV) 유사 입자의 제조
마우스 PD-1 및 마우스 PD-L1 의 하기의 폴리뉴클레오티드를 VLP_CHI 532 벡터 (SEQ ID No.:25) 에 삽입되거나 VLP_VEEV VLP 518 벡터 (SEQ ID No.:26) 에 삽입되는 것으로 사용하였다. N 말단 링커는 아미노산 서열에서 SGG 이며 (핵 서열에서 TCCGGAGGA) C 말단 링커는 아미노산 서열에서 GGS 이다 (핵 서열에서 GGAGGATCC).
1. VLP299 (마우스PD-L1 서열): 항원으로 사용한, 마우스 PD-L1 도메인3S 부착 링커의 단편의 서열:
핵 서열
아미노산 서열
SGG-ciisyggadyC-GGS (SEQ ID No.:58)
2. VLP274 (마우스PD-1 서열): 항원으로 사용한, 마우스 PD-1 도메인2단길이 부착 링커의 단편의 서열:
핵 서열
아미노산 서열
SGG-gaislhpkakiees-GS (SEQ ID No.:60)
3. VLP275 (마우스PD-1 서열): 항원으로 사용한, 마우스 PD-1 도메인2단길이_v2 부착 링커의 단편의 서열:
핵 서열
아미노산 서열
SGG-cgaislhpkakieeC-GGS (SEQ ID No.:62)
각각의 폴리뉴클레오티드를 SEQ ID No.2 의 531-위치에서의 Ser 를 인코딩하는 코돈과 532-위치에서의 Asn 을 인코딩하는 서열 사이에 삽입하여, 개질된 PD-1-유래 펩티드 또는 개질된 PD-L1-유래 펩티드가 치쿤구니야 바이러스 구조 단백질의 E2 에 삽입되는 치쿤구니야 바이러스 유사 입자를 발현하기 위한 플라스미드 (이하, VLP299-삽입 벡터에 대해서는 VLP299_15, VLP299_25; VLP274-삽입 벡터에 대해서는 VLP274_11, VLP274_15; VLP275-삽입 벡터에 대해서는 VLP275_11, VLP275_15 로 나타냄) 를 구축하였다.
293F 세포를 실시예 1 에서와 같은 플라스미드로 트랜스펙션하였다. 치쿤구니야 바이러스 구조 단백질과 접합된 VLP299, 274 또는 275 를 포함하는 VLP 의 발현을 CHIKV 또는 VEEV 에 대해 특이적인 항체를 사용하여 웨스턴 블롯에 의해 확인하였다.
실시예 4: PD-1 의 면역원성
마우스 PD-1 유전자에서 또한 발견되는 인간 PD-1 의 하기 폴리뉴클레오티드를 VLP_CHI 532 벡터 (SEQ ID No.:25) 에 삽입되거나 VLP_VEEV VLP 518 벡터 (SEQ ID No.:26) 에 삽입되는 것으로 사용하였다. N 말단 링커는 아미노산 서열에서 SGG 이고 (핵 서열에서 TCCGGAGGA) C 말단 링커는 아미노산 서열에서 GGS 이다 (핵 서열에서 GGAGGATCC).
핵 서열
아미노산 서열
폴리뉴클레오티드를 SEQ ID No.:2 의 531-위치에서의 Ser 를 인코딩하는 코돈과 532-위치에서의 Asn 을 인코딩하는 코돈 사이에 삽입하여, 개질된 PD-1-유래 펩티드가 치쿤구니야 바이러스 구조 단백질의 E2 에 삽입되는 치쿤구니야 바이러스 유사 입자를 발현하기 위한 플라스미드 (이하, pCHIKV-hPD-1 로 나타냄) 를 구축하였다. 또한, 폴리뉴클레오티드를 SEQ ID No.:3 의 518-위치에서의 Ser 를 인코딩하는 코돈과 519-위치에서의 Ser 를 인코딩하는 코돈 사이에 삽입하여, 개질된 PD-1-유래 펩티드가 베네수엘라 말 뇌염 구조 단백질의 E2 에 삽입되는 베네수엘라 말 뇌염 바이러스 유사 입자를 발현하기 위한 플라스미드 (이하, pVEEV-hPD-1 로 나타냄) 를 구축하였다.
293F 세포 (Lifetechnology) 를 PEI (GE Healthcare) 또는 GeneX (ATCC) 를 사용하여 플라스미드로 트랜스펙션시켰다. 트랜스펙션 4 일 후, 조건화 배지를 수집하고 3000 rpm 에서 15 분 동안 원심분리하여 세로포부터 이를 분리하였다. 상청액을 0.45 ㎛ 필터를 사용하여 여과함으로써 바이러스 유사 입자를 수득하였다. 바이러스 유사 입자를 TFF 컬럼을 사용하여 농축하고 QXL 컬럼 (GE Healthcare) 을 사용하여 정제함으로써, 정제된 바이러스 유사 입자를 수득하였다. 정제된 바이러스 유사 입자를 회전 컬럼 (분자량-컷오프: 100kDa) 을 사용하여 추가 농축하여, 면역화를 위한 바이러스 유사 입자를 제조하였다 (CHIKV-hPD-1 및 VEEV-hPD-1).
마우스 (4 주령 수컷) 를, 아쥬반트 Ribi 를 근육내 주사하여 VEEV-hPD-1 로 0 및 8 주에서 2 회 (마우스 당 20 ug VLP) 면역화하고, 아쥬반트 Ribi (Sigma Adjuvant system, Sigma-Aldrich) 를 근육내 주사하여 CHIKV-hPD-1 로 4 주에서 1 회 (마우스 당 20 ug VLP) 면역화하였다. 혈액을 제 1 면역화 후 10 주에 채취하였다.
96 웰 ELISA 플레이트를 웰 당 100ul PBS 완충액 중 PD-1 (1-167aa) 또는 PD-1-Fc 접합체의 재조합체 N-말단 단편 50 ng 으로 코팅하였다. 2 시간 인큐베이션 후 플레이트를 0.05% Tween-20 을 함유하는 TBS 완충액으로 3 회 세척하고, 0.05% Tween-20 및 5% 분유를 함유하는 TBS 완충액으로 블로킹하였다. 마우스로부터의 열 불활성화된 희석 혈청을 블로킹 완충액에 첨가하고 1 시간 동안 실온에서 인큐베이션하였다. 3 회 세척 후, 퍼옥시다아제 표지된 염소 항-마우스 IgG 를 1:4000 희석물로 첨가하고 1 시간 동안 실온에서 인큐베이션하였다. 3 회 세척 후, 퍼옥시다아제 기질을 현상을 위해 첨가하고 10 분 동안 인큐베이션하고 2N H2SO4 를 첨가하여 현상을 중단시켰다. 데이터를 Gen5 (BioTek) 및 GraphPad Prism6 (GraphPad software Inc) 을 사용하여 분석하였다.
면역원성을 도 1 및 2 에 나타낸다. 도 1 및 2 에서 나타낸 바와 같이, PD-1 에 대항한 항체의 유도가 CHIKV-PD-1 및 VEEV-PD-1 로 면역화된 마우스의 혈청에서 발견되었다.
실시예 5: 바이러스 구조 단백질 및 PD-1 항원의 단편을 포함하는 치쿤구니야 바이러스 (CHIKV) 유사 입자 또는 베네수엘라 말 뇌염 바이러스 (VEEV) 유사 입자를 포함하는 약학 조성물의 제조
바이러스 구조 단백질 및 PD-1 항원의 단편을 포함하는 치쿤구니야 바이러스 (CHIKV) 유사 입자 및 바이러스 구조 단백질 및 PD-1 항원의 단편을 포함하는 베네수엘라 말 뇌염 바이러스 (VEEV) 유사 입자를 실시예 4 에 따라 제조하였다.
백신 조성물인 약학 조성물을 제조하기 위해, 80 μg 의 각각의 제조된 입자를 1 ml 의 수크로오스 포스페이트 용액 (pH 7.2, 엔도톡신 불포함) (Teknova, SP buffer) 과 혼합하였다.
SEQUENCE LISTING
<110> VLP THERAPEUTICS, LLC
<120> VIRUS LIKE PARTICLE COMPRISING PD-1 ANTIGEN OR PD-1 LIGAND
ANTIGEN
<130> 672050
<150> US 61/845712
<151> 2013-07-12
<160> 64
<170> PatentIn version 3.5
<210> 1
<211> 1248
<212> PRT
<213> Chikungunya virus
<400> 1
Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro
1 5 10 15
Arg Pro Trp Thr Pro Arg Pro Thr Ile Gln Val Ile Arg Pro Arg Pro
20 25 30
Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val
35 40 45
Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn
50 55 60
Arg Lys Asn Lys Lys Gln Lys Gln Lys Gln Gln Ala Pro Gln Asn Asn
65 70 75 80
Thr Asn Gln Lys Lys Gln Pro Pro Lys Lys Lys Pro Ala Gln Lys Lys
85 90 95
Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp
100 105 110
Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Thr Gly Tyr Ala Cys
115 120 125
Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile
130 135 140
Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr
145 150 155 160
Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser
165 170 175
Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly
180 185 190
Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly
195 200 205
Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val
210 215 220
Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu
225 230 235 240
Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu
245 250 255
Gly Ala Glu Glu Trp Ser Leu Ala Ile Pro Val Met Cys Leu Leu Ala
260 265 270
Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr
275 280 285
Glu Lys Glu Pro Glu Glu Thr Leu Arg Met Leu Glu Asp Asn Val Met
290 295 300
Arg Pro Gly Tyr Tyr Gln Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro
305 310 315 320
His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala
325 330 335
Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser
340 345 350
Cys His Ser Pro Val Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp
355 360 365
Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp
370 375 380
Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Asn His Met Pro
385 390 395 400
Ala Asp Ala Glu Arg Ala Gly Leu Phe Val Arg Thr Ser Ala Pro Cys
405 410 415
Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys
420 425 430
Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His
435 440 445
Ser Cys Thr His Pro Phe His His Asp Pro Pro Val Ile Gly Arg Glu
450 455 460
Lys Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr
465 470 475 480
Tyr Val Gln Ser Thr Ala Ala Thr Thr Glu Glu Ile Glu Val His Met
485 490 495
Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Ser Gln Gln Ser Gly Asn
500 505 510
Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys
515 520 525
Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn
530 535 540
Cys Lys Val Asp Gln Cys His Ala Ala Val Thr Asn His Lys Lys Trp
545 550 555 560
Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg
565 570 575
Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg
580 585 590
Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val
595 600 605
Ile Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn
610 615 620
Met Gly Glu Glu Pro Asn Tyr Gln Glu Glu Trp Val Met His Lys Lys
625 630 635 640
Glu Val Val Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly
645 650 655
Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr
660 665 670
Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr
675 680 685
Pro Thr Met Thr Val Val Val Val Ser Val Ala Thr Phe Ile Leu Leu
690 695 700
Ser Met Val Gly Met Ala Ala Gly Met Cys Met Cys Ala Arg Arg Arg
705 710 715 720
Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu
725 730 735
Leu Ser Leu Ile Cys Cys Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln
740 745 750
Glu Ala Ala Ile Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu
755 760 765
Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu
770 775 780
Arg Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met
785 790 795 800
Ser Val Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile
805 810 815
Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly
820 825 830
Tyr Ser Pro Met Val Leu Glu Met Glu Leu Leu Ser Val Thr Leu Glu
835 840 845
Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile
850 855 860
Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys
865 870 875 880
Asn Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe
885 890 895
Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu
900 905 910
Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala
915 920 925
Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val
930 935 940
Leu Tyr Gln Gly Asn Asn Ile Thr Val Thr Ala Tyr Ala Asn Gly Asp
945 950 955 960
His Ala Val Thr Val Lys Asp Ala Lys Phe Ile Val Gly Pro Met Ser
965 970 975
Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp
980 985 990
Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln
995 1000 1005
Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Lys Asp Val Tyr
1010 1015 1020
Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Val Gly Thr Val
1025 1030 1035
His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu
1040 1045 1050
Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys
1055 1060 1065
Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly
1070 1075 1080
Asn Met Pro Ile Ser Ile Asp Ile Pro Glu Ala Ala Phe Thr Arg
1085 1090 1095
Val Val Asp Ala Pro Ser Leu Thr Asp Met Ser Cys Glu Val Pro
1100 1105 1110
Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys
1115 1120 1125
Tyr Ala Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr
1130 1135 1140
Asn Ala Val Thr Ile Arg Glu Ala Glu Ile Glu Val Glu Gly Asn
1145 1150 1155
Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu
1160 1165 1170
Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Glu
1175 1180 1185
Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His
1190 1195 1200
Thr Thr Leu Gly Val Gln Asp Ile Ser Ala Thr Ala Met Ser Trp
1205 1210 1215
Val Gln Lys Ile Thr Gly Gly Val Gly Leu Val Val Ala Val Ala
1220 1225 1230
Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His
1235 1240 1245
<210> 2
<211> 1248
<212> PRT
<213> Chikungunya virus
<400> 2
Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro
1 5 10 15
Arg Pro Trp Ala Pro Arg Pro Thr Ile Gln Val Ile Arg Pro Arg Pro
20 25 30
Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val
35 40 45
Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn
50 55 60
Arg Lys Asn Lys Lys Gln Arg Gln Lys Lys Gln Ala Pro Gln Asn Asp
65 70 75 80
Pro Lys Gln Lys Lys Gln Pro Pro Gln Lys Lys Pro Ala Gln Lys Lys
85 90 95
Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp
100 105 110
Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Met Gly Tyr Ala Cys
115 120 125
Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile
130 135 140
Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr
145 150 155 160
Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser
165 170 175
Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly
180 185 190
Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly
195 200 205
Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val
210 215 220
Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu
225 230 235 240
Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu
245 250 255
Gly Ala Glu Glu Trp Ser Leu Ala Leu Pro Val Leu Cys Leu Leu Ala
260 265 270
Asn Thr Thr Phe Pro Cys Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr
275 280 285
Glu Lys Glu Pro Glu Ser Thr Leu Arg Met Leu Glu Asp Asn Val Met
290 295 300
Arg Pro Gly Tyr Tyr Gln Leu Leu Lys Ala Ser Leu Thr Cys Ser Pro
305 310 315 320
His Arg Gln Arg Arg Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala
325 330 335
Thr Arg Pro Tyr Leu Ala His Cys Pro Asp Cys Gly Glu Gly His Ser
340 345 350
Cys His Ser Pro Ile Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp
355 360 365
Gly Thr Leu Lys Ile Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp
370 375 380
Asp Ser His Asp Trp Thr Lys Leu Arg Tyr Met Asp Ser His Thr Pro
385 390 395 400
Ala Asp Ala Glu Arg Ala Gly Leu Leu Val Arg Thr Ser Ala Pro Cys
405 410 415
Thr Ile Thr Gly Thr Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys
420 425 430
Gly Glu Thr Leu Thr Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His
435 440 445
Thr Cys Thr His Pro Phe His His Glu Pro Pro Val Ile Gly Arg Glu
450 455 460
Arg Phe His Ser Arg Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr
465 470 475 480
Tyr Val Gln Ser Thr Ala Ala Thr Ala Glu Glu Ile Glu Val His Met
485 490 495
Pro Pro Asp Thr Pro Asp Arg Thr Leu Met Thr Gln Gln Ser Gly Asn
500 505 510
Val Lys Ile Thr Val Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys
515 520 525
Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn
530 535 540
Cys Lys Ile Asp Gln Cys His Ala Ala Val Thr Asn His Lys Asn Trp
545 550 555 560
Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg
565 570 575
Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg
580 585 590
Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val
595 600 605
Thr Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn
610 615 620
Met Gly Gln Glu Pro Asn Tyr His Glu Glu Trp Val Thr His Lys Lys
625 630 635 640
Glu Val Thr Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly
645 650 655
Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Met Ser Thr Asn Gly Thr
660 665 670
Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr
675 680 685
Pro Thr Met Thr Val Val Ile Val Ser Val Ala Ser Phe Val Leu Leu
690 695 700
Ser Met Val Gly Thr Ala Val Gly Met Cys Val Cys Ala Arg Arg Arg
705 710 715 720
Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu
725 730 735
Leu Ser Leu Leu Cys Cys Val Arg Thr Thr Lys Ala Ala Thr Tyr Tyr
740 745 750
Glu Ala Ala Ala Tyr Leu Trp Asn Glu Gln Gln Pro Leu Phe Trp Leu
755 760 765
Gln Ala Leu Ile Pro Leu Ala Ala Leu Ile Val Leu Cys Asn Cys Leu
770 775 780
Lys Leu Leu Pro Cys Cys Cys Lys Thr Leu Ala Phe Leu Ala Val Met
785 790 795 800
Ser Ile Gly Ala His Thr Val Ser Ala Tyr Glu His Val Thr Val Ile
805 810 815
Pro Asn Thr Val Gly Val Pro Tyr Lys Thr Leu Val Asn Arg Pro Gly
820 825 830
Tyr Ser Pro Met Val Leu Glu Met Glu Leu Gln Ser Val Thr Leu Glu
835 840 845
Pro Thr Leu Ser Leu Asp Tyr Ile Thr Cys Glu Tyr Lys Thr Val Ile
850 855 860
Pro Ser Pro Tyr Val Lys Cys Cys Gly Thr Ala Glu Cys Lys Asp Lys
865 870 875 880
Ser Leu Pro Asp Tyr Ser Cys Lys Val Phe Thr Gly Val Tyr Pro Phe
885 890 895
Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Ala Glu Asn Thr Gln Leu
900 905 910
Ser Glu Ala His Val Glu Lys Ser Glu Ser Cys Lys Thr Glu Phe Ala
915 920 925
Ser Ala Tyr Arg Ala His Thr Ala Ser Ala Ser Ala Lys Leu Arg Val
930 935 940
Leu Tyr Gln Gly Asn Asn Ile Thr Val Ala Ala Tyr Ala Asn Gly Asp
945 950 955 960
His Ala Val Thr Val Lys Asp Ala Lys Phe Val Val Gly Pro Met Ser
965 970 975
Ser Ala Trp Thr Pro Phe Asp Asn Lys Ile Val Val Tyr Lys Gly Asp
980 985 990
Val Tyr Asn Met Asp Tyr Pro Pro Phe Gly Ala Gly Arg Pro Gly Gln
995 1000 1005
Phe Gly Asp Ile Gln Ser Arg Thr Pro Glu Ser Lys Asp Val Tyr
1010 1015 1020
Ala Asn Thr Gln Leu Val Leu Gln Arg Pro Ala Ala Gly Thr Val
1025 1030 1035
His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe Lys Tyr Trp Leu
1040 1045 1050
Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro Phe Gly Cys
1055 1060 1065
Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala Val Gly
1070 1075 1080
Asn Ile Pro Ile Ser Ile Asp Ile Pro Asp Ala Ala Phe Thr Arg
1085 1090 1095
Val Val Asp Ala Pro Ser Val Thr Asp Met Ser Cys Glu Val Pro
1100 1105 1110
Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys
1115 1120 1125
Tyr Thr Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr
1130 1135 1140
Asn Ala Val Thr Ile Arg Glu Ala Asp Val Glu Val Glu Gly Asn
1145 1150 1155
Ser Gln Leu Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu
1160 1165 1170
Phe Arg Val Gln Val Cys Ser Thr Gln Val His Cys Ala Ala Ala
1175 1180 1185
Cys His Pro Pro Lys Asp His Ile Val Asn Tyr Pro Ala Ser His
1190 1195 1200
Thr Thr Leu Gly Val Gln Asp Ile Ser Thr Thr Ala Met Ser Trp
1205 1210 1215
Val Gln Lys Ile Thr Gly Gly Val Gly Leu Ile Val Ala Val Ala
1220 1225 1230
Ala Leu Ile Leu Ile Val Val Leu Cys Val Ser Phe Ser Arg His
1235 1240 1245
<210> 3
<211> 1255
<212> PRT
<213> Venesuelan equine encephalitis virus
<400> 3
Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg
1 5 10 15
Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro
20 25 30
Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu
35 40 45
Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Ala
50 55 60
Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly
65 70 75 80
Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro
85 90 95
Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro
100 105 110
Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe
115 120 125
Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly
130 135 140
Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp
145 150 155 160
Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu
165 170 175
Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr
180 185 190
His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln
195 200 205
Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly
210 215 220
Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile
225 230 235 240
Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val
245 250 255
Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys
260 265 270
Glu Gln Trp Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr
275 280 285
Phe Pro Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu
290 295 300
Thr Leu Ala Met Leu Ser Val Asn Val Asp Asn Pro Gly Tyr Asp Glu
305 310 315 320
Leu Leu Glu Ala Ala Val Lys Cys Pro Gly Arg Lys Arg Arg Ser Thr
325 330 335
Glu Glu Leu Phe Asn Glu Tyr Lys Leu Thr Arg Pro Tyr Met Ala Arg
340 345 350
Cys Ile Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala Ile Glu
355 360 365
Ala Val Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln Thr Ser
370 375 380
Ser Gln Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg Thr Met
385 390 395 400
Arg Tyr Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His Gln Val
405 410 415
Ser Leu Tyr Thr Ser Arg Pro Cys His Ile Val Asp Gly His Gly Tyr
420 425 430
Phe Leu Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met Glu Phe
435 440 445
Lys Lys Asp Ser Val Arg His Ser Cys Ser Val Pro Tyr Glu Val Lys
450 455 460
Phe Asn Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu His Gly
465 470 475 480
Val Glu Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn Arg Gly
485 490 495
Ala Tyr Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser Ser Leu
500 505 510
Val Ser Leu Ser Gly Ser Ser Val Thr Val Thr Pro Pro Asp Gly Thr
515 520 525
Ser Ala Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile Ser Glu Thr
530 535 540
Ile Asn Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys
545 550 555 560
Arg Ala Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys
565 570 575
Leu Pro Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu His Val Pro
580 585 590
Phe Leu Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala Pro Glu Pro
595 600 605
Met Ile Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu His Pro Lys
610 615 620
Asn Pro Thr Tyr Leu Ile Thr Arg Gln Leu Ala Asp Glu Pro His Tyr
625 630 635 640
Thr His Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe Thr Val Thr
645 650 655
Glu Lys Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro Lys Arg Phe
660 665 670
Trp Ala Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu Pro His Glu
675 680 685
Val Ile Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr Ile Leu Gly
690 695 700
Leu Ser Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala Ala Ser Thr
705 710 715 720
Trp Leu Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu
725 730 735
Thr Pro Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu Cys Cys Ala
740 745 750
Arg Thr Ala Arg Ala Glu Thr Thr Trp Glu Ser Leu Asp His Leu Trp
755 760 765
Asn Asn Asn Gln Gln Met Phe Trp Ile Gln Leu Leu Ile Pro Leu Ala
770 775 780
Ala Leu Ile Val Val Thr Arg Leu Leu Arg Cys Val Cys Cys Val Val
785 790 795 800
Pro Phe Leu Val Met Ala Gly Ala Ala Gly Ala Gly Ala Tyr Glu His
805 810 815
Ala Thr Thr Met Pro Ser Gln Ala Gly Ile Ser Tyr Asn Thr Ile Val
820 825 830
Asn Arg Ala Gly Tyr Ala Pro Leu Pro Ile Ser Ile Thr Pro Thr Lys
835 840 845
Ile Lys Leu Ile Pro Thr Val Asn Leu Glu Tyr Val Thr Cys His Tyr
850 855 860
Lys Thr Gly Met Asp Ser Pro Ala Ile Lys Cys Cys Gly Ser Gln Glu
865 870 875 880
Cys Thr Pro Thr Tyr Arg Pro Asp Glu Gln Cys Lys Val Phe Thr Gly
885 890 895
Val Tyr Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Thr Glu
900 905 910
Asn Thr Gln Val Ser Lys Ala Tyr Val Met Lys Ser Asp Asp Cys Leu
915 920 925
Ala Asp His Ala Glu Ala Tyr Lys Ala His Thr Ala Ser Val Gln Ala
930 935 940
Phe Leu Asn Ile Thr Val Gly Glu His Ser Ile Val Thr Thr Val Tyr
945 950 955 960
Val Asn Gly Glu Thr Pro Val Asn Phe Asn Gly Val Lys Ile Thr Ala
965 970 975
Gly Pro Leu Ser Thr Ala Trp Thr Pro Phe Asp Arg Lys Ile Val Gln
980 985 990
Tyr Ala Gly Glu Ile Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Gly
995 1000 1005
Gln Pro Gly Ala Phe Gly Asp Ile Gln Ser Arg Thr Val Ser Ser
1010 1015 1020
Ser Asp Leu Tyr Ala Asn Thr Asn Leu Val Leu Gln Arg Pro Lys
1025 1030 1035
Ala Gly Ala Ile His Val Pro Tyr Thr Gln Ala Pro Ser Gly Phe
1040 1045 1050
Glu Gln Trp Lys Lys Asp Lys Ala Pro Ser Leu Lys Phe Thr Ala
1055 1060 1065
Pro Phe Gly Cys Glu Ile Tyr Thr Asn Pro Ile Arg Ala Glu Asn
1070 1075 1080
Cys Ala Val Gly Ser Ile Pro Leu Ala Phe Asp Ile Pro Asp Ala
1085 1090 1095
Leu Phe Thr Arg Val Ser Glu Thr Pro Thr Leu Ser Ala Ala Glu
1100 1105 1110
Cys Thr Leu Asn Glu Cys Val Tyr Ser Ser Asp Phe Gly Gly Ile
1115 1120 1125
Ala Thr Val Lys Tyr Ser Ala Ser Lys Ser Gly Lys Cys Ala Val
1130 1135 1140
His Val Pro Ser Gly Thr Ala Thr Leu Lys Glu Ala Ala Val Glu
1145 1150 1155
Leu Thr Glu Gln Gly Ser Ala Thr Ile His Phe Ser Thr Ala Asn
1160 1165 1170
Ile His Pro Glu Phe Arg Leu Gln Ile Cys Thr Ser Tyr Val Thr
1175 1180 1185
Cys Lys Gly Asp Cys His Pro Pro Lys Asp His Ile Val Thr His
1190 1195 1200
Pro Gln Tyr His Ala Gln Thr Phe Thr Ala Ala Val Ser Lys Thr
1205 1210 1215
Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly Ser Ala Val Ile
1220 1225 1230
Ile Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala Met Tyr Val
1235 1240 1245
Leu Thr Asn Gln Lys His Asn
1250 1255
<210> 4
<211> 18
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 4
Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
1 5 10 15
Ala Phe
<210> 5
<211> 20
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 5
Met Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu
1 5 10 15
Ala Ala Phe Ser
20
<210> 6
<211> 20
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 6
Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu
1 5 10 15
Ala Ala Phe Pro
20
<210> 7
<211> 14
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 7
Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu Glu Ser
1 5 10
<210> 8
<211> 15
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 8
Cys Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu Glu Cys
1 5 10 15
<210> 9
<211> 19
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 9
Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu
1 5 10 15
Ala Ala Phe
<210> 10
<211> 14
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 10
Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu Ser
1 5 10
<210> 11
<211> 31
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 11
Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro
1 5 10 15
Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr
20 25 30
<210> 12
<211> 31
<212> PRT
<213> Artificial
<220>
<223> PD-1 antigen
<400> 12
Arg Asn Asp Ser Gly Ile Tyr Leu Cys Gly Ala Ile Ser Leu His Pro
1 5 10 15
Lys Ala Lys Ile Glu Glu Ser Pro Gly Ala Glu Leu Val Val Thr
20 25 30
<210> 13
<211> 11
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 13
Cys Ile Ile Ser Tyr Gly Gly Ala Asp Tyr Cys
1 5 10
<210> 14
<211> 11
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 14
Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Cys
1 5 10
<210> 15
<211> 26
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 15
Leu Gln Asp Ala Gly Val Tyr Arg Cys Met Ile Ser Tyr Gly Gly Ala
1 5 10 15
Asp Tyr Lys Arg Ile Thr Val Lys Val Asn
20 25
<210> 16
<211> 26
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 16
Leu Gln Asp Ala Gly Val Tyr Arg Ala Met Ile Ser Tyr Gly Gly Ala
1 5 10 15
Asp Tyr Lys Arg Ile Thr Val Lys Val Asn
20 25
<210> 17
<211> 21
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 17
Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
1 5 10 15
Ile Gln Phe Val His
20
<210> 18
<211> 23
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 18
Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
1 5 10 15
Ile Gln Phe Val His Gly Gly
20
<210> 19
<211> 27
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 19
Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser
1 5 10 15
Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu
20 25
<210> 20
<211> 26
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 20
Leu Gln Asp Ala Gly Val Tyr Cys Cys Ile Ile Ser Tyr Gly Gly Ala
1 5 10 15
Asp Tyr Lys Arg Ile Thr Leu Lys Val Asn
20 25
<210> 21
<211> 26
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 21
Leu Gln Asp Ala Gly Val Tyr Ala Ala Ile Ile Ser Tyr Gly Gly Ala
1 5 10 15
Asp Tyr Lys Arg Ile Thr Leu Lys Val Asn
20 25
<210> 22
<211> 21
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 22
Asp Leu Leu Ala Leu Val Val Tyr Trp Glu Lys Glu Asp Glu Gln Val
1 5 10 15
Ile Gln Phe Val Ala
20
<210> 23
<211> 23
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 23
Asp Leu Leu Ala Leu Val Val Tyr Trp Glu Lys Glu Asp Glu Gln Val
1 5 10 15
Ile Gln Phe Val Ala Gly Gly
20
<210> 24
<211> 27
<212> PRT
<213> Artificial
<220>
<223> PD-L1 antigen
<400> 24
Phe Thr Ile Thr Ala Pro Lys Asp Leu Tyr Val Val Glu Tyr Gly Ser
1 5 10 15
Asn Val Thr Met Glu Cys Arg Phe Pro Val Glu
20 25
<210> 25
<211> 8410
<212> DNA
<213> Artificial
<220>
<223> VLP_CHI 532 vector
<400> 25
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgga gttcatcccg acgcaaactt tctataacag aaggtaccaa ccccgaccct 960
gggccccacg ccctacaatt caagtaatta gacctagacc acgtccacag aggcaggctg 1020
ggcaactcgc ccagctgatc tccgcagtca acaaattgac catgcgcgcg gtacctcaac 1080
agaagcctcg cagaaatcgg aaaaacaaga agcaaaggca gaagaagcag gcgccgcaaa 1140
acgacccaaa gcaaaagaag caaccaccac aaaagaagcc ggctcaaaag aagaagaaac 1200
caggccgtag ggagagaatg tgcatgaaaa ttgaaaatga ttgcatcttc gaagtcaagc 1260
atgaaggcaa agtgatgggc tacgcatgcc tggtggggga taaagtaatg aaaccagcac 1320
atgtgaaggg aactatcgac aatgccgatc tggctaaact ggcctttaag cggtcgtcta 1380
aatacgatct tgaatgtgca cagataccgg tgcacatgaa gtctgatgcc tcgaagttta 1440
cccacgagaa acccgagggg tactataact ggcatcacgg agcagtgcag tattcaggag 1500
gccggttcac tatcccgacg ggtgcaggca agccgggaga cagcggcaga ccgatcttcg 1560
acaacaaagg acgggtggtg gccatcgtcc taggaggggc caacgaaggt gcccgcacgg 1620
ccctctccgt ggtgacgtgg aacaaagaca tcgtcacaaa aattacccct gagggagccg 1680
aagagtggag cctcgccctc ccggtcttgt gcctgttggc aaacactaca ttcccctgct 1740
ctcagccgcc ttgcacaccc tgctgctacg aaaaggaacc ggaaagcacc ttgcgcatgc 1800
ttgaggacaa cgtgatgaga cccggatact accagctact aaaagcatcg ctgacttgct 1860
ctccccaccg ccaaagacgc agtactaagg acaattttaa tgtctataaa gccacaagac 1920
catatctagc tcattgtcct gactgcggag aagggcattc gtgccacagc cctatcgcat 1980
tggagcgcat cagaaatgaa gcaacggacg gaacgctgaa aatccaggtc tctttgcaga 2040
tcgggataaa gacagatgac agccacgatt ggaccaagct gcgctatatg gatagccata 2100
cgccagcgga cgcggagcga gccggattgc ttgtaaggac ttcagcaccg tgcacgatca 2160
ccgggaccat gggacacttt attctcgccc gatgcccgaa aggagagacg ctgacagtgg 2220
gatttacgga cagcagaaag atcagccaca catgcacaca cccgttccat catgaaccac 2280
ctgtgatagg tagggagagg ttccactctc gaccacaaca tggtaaagag ttaccttgca 2340
gcacgtacgt gcagagcacc gctgccactg ctgaggagat agaggtgcat atgcccccag 2400
atactcctga ccgcacgctg atgacgcagc agtctggcaa cgtgaagatc acagttaatg 2460
ggcagacggt gcggtacaag tgcaactgcg gtggctccgg aagtggatcc aacgagggac 2520
tgacaaccac agacaaagtg atcaataact gcaaaattga tcagtgccat gctgcagtca 2580
ctaatcacaa gaattggcaa tacaactccc ctttagtccc gcgcaacgct gaactcgggg 2640
accgtaaagg aaagatccac atcccattcc cattggcaaa cgtgacttgc agagtgccaa 2700
aagcaagaaa ccctacagta acttacggaa aaaaccaagt caccatgctg ctgtatcctg 2760
accatccgac actcttgtct taccgtaaca tgggacagga accaaattac cacgaggagt 2820
gggtgacaca caagaaggag gttaccttga ccgtgcctac tgagggtctg gaggtcactt 2880
ggggcaacaa cgaaccatac aagtactggc cgcagatgtc tacgaacggt actgctcatg 2940
gtcacccaca tgagataatc ttgtactatt atgagctgta ccccactatg actgtagtca 3000
ttgtgtcggt ggcctcgttc gtgcttctgt cgatggtggg cacagcagtg ggaatgtgtg 3060
tgtgcgcacg gcgcagatgc attacaccat atgaattaac accaggagcc actgttccct 3120
tcctgctcag cctgctatgc tgcgtcagaa cgaccaaggc ggccacatat tacgaggctg 3180
cggcatatct atggaacgaa cagcagcccc tgttctggtt gcaggctctt atcccgctgg 3240
ccgccttgat cgtcctgtgc aactgtctga aactcttgcc atgctgctgt aagaccctgg 3300
cttttttagc cgtaatgagc atcggtgccc acactgtgag cgcgtacgaa cacgtaacag 3360
tgatcccgaa cacggtggga gtaccgtata agactcttgt caacagaccg ggttacagcc 3420
ccatggtgtt ggagatggag ctacaatcag tcaccttgga accaacactg tcacttgact 3480
acatcacgtg cgagtacaaa actgtcatcc cctccccgta cgtgaagtgc tgtggtacag 3540
cagagtgcaa ggacaagagc ctaccagact acagctgcaa ggtctttact ggagtctacc 3600
catttatgtg gggcggcgcc tactgctttt gcgacgccga aaatacgcaa ttgagcgagg 3660
cacatgtaga gaaatctgaa tcttgcaaaa cagagtttgc atcggcctac agagcccaca 3720
ccgcatcggc gtcggcgaag ctccgcgtcc tttaccaagg aaacaacatt accgtagctg 3780
cctacgctaa cggtgaccat gccgtcacag taaaggacgc caagtttgtc gtgggcccaa 3840
tgtcctccgc ctggacacct tttgacaaca aaatcgtggt gtacaaaggc gacgtctaca 3900
acatggacta cccacctttt ggcgcaggaa gaccaggaca atttggtgac attcaaagtc 3960
gtacaccgga aagtaaagac gtttatgcca acactcagtt ggtactacag aggccagcag 4020
caggcacggt acatgtacca tactctcagg caccatctgg cttcaagtat tggctgaagg 4080
aacgaggagc atcgctacag cacacggcac cgttcggttg ccagattgcg acaaacccgg 4140
taagagctgt aaattgcgct gtggggaaca taccaatttc catcgacata ccggatgcgg 4200
cctttactag ggttgtcgat gcaccctctg taacggacat gtcatgcgaa gtaccagcct 4260
gcactcactc ctccgacttt gggggcgtcg ccatcatcaa atacacagct agcaagaaag 4320
gtaaatgtgc agtacattcg atgaccaacg ccgttaccat tcgagaagcc gacgtagaag 4380
tagaggggaa ctcccagctg caaatatcct tctcaacagc cctggcaagc gccgagtttc 4440
gcgtgcaagt gtgctccaca caagtacact gcgcagccgc atgccaccct ccaaaggacc 4500
acatagtcaa ttacccagca tcacacacca cccttggggt ccaggatata tccacaacgg 4560
caatgtcttg ggtgcagaag attacgggag gagtaggatt aattgttgct gttgctgcct 4620
taattttaat tgtggtgcta tgcgtgtcgt ttagcaggca ctaaggatct agatctgctg 4680
tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg 4740
aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga 4800
gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg 4860
aagacaatag caggcatgct ggggatgcgg tgggctctat gggtacccag gtgctgaaga 4920
attgacccgg ttcctcctgg gccagaaaga agcaggcaca tccccttctc tgtgacacac 4980
cctgtccacg cccctggttc ttagttccag ccccactcat aggacactca tagctcagga 5040
gggctccgcc ttcaatccca cccgctaaag tacttggagc ggtctctccc tccctcatca 5100
gcccaccaaa ccaaacctag cctccaagag tgggaagaaa ttaaagcaag ataggctatt 5160
aagtgcagag ggagagaaaa tgcctccaac atgtgaggaa gtaatgagag aaatcataga 5220
attttaaggc catgatttaa ggccatcatg gcctaagctt gaaaggagat aggatccaag 5280
cttggcgtaa tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc 5340
acacaacata cgagccggaa gcataaagtg taaagcctgg ggtgcctaat gagtgagcta 5400
actcacatta attgcgttgc gctcactgcc cgctttccag tcgggaaacc tgtcgtgcca 5460
gctgcattaa tgaatcggcc aacgcgcggg gagaggcggt ttgcgtattg ggcgctcttc 5520
cgcttcctcg ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc 5580
tcactcaaag gcggtaatac ggttatccac agaatcaggg gataacgcag gaaagaacat 5640
gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt 5700
ccataggctc cgcccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg 5760
aaacccgaca ggactataaa gataccaggc gtttccccct ggaagctccc tcgtgcgctc 5820
tcctgttccg accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt 5880
ggcgctttct catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa 5940
gctgggctgt gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccggtaacta 6000
tcgtcttgag tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa 6060
caggattagc agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa 6120
ctacggctac actagaagaa cagtatttgg tatctgcgct ctgctgaagc cagttacctt 6180
cggaaaaaga gttggtagct cttgatccgg caaacaaacc accgctggta gcggtggttt 6240
ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat 6300
cttttctacg gggtctgacg ctcagtggaa cgaaaactca cgttaaggga ttttggtcat 6360
gagattatca aaaaggatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc 6420
aatctaaagt atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc 6480
acctatctca gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta 6540
gataactacg atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga 6600
accacgctca ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg 6660
cagaagtggt cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc 6720
tagagtaagt agttcgccag ttaatagttt gcgcaacgtt gttgccattg ctacaggcat 6780
cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc tccggttccc aacgatcaag 6840
gcgagttaca tgatccccca tgttgtgcaa aaaagcggtt agctccttcg gtcctccgat 6900
cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa 6960
ttctcttact gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa 7020
gtcattctga gaatagtgta tgcggcgacc gagttgctct tgcccggcgt caatacggga 7080
taataccgcg ccacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg 7140
gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc 7200
acccaactga tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg 7260
aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact 7320
cttccttttt caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat 7380
atttgaatgt atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt 7440
gccacctgac gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat 7500
cacgaggccc tttcgggtcg cgcgtttcgg tgatgacggt gaaaacctct gacacatgca 7560
gctcccgttg acggtcacag cttgtctgta agcggatgcc gggagcagac aagcccgtca 7620
gggcgcgtca gcgggtgttg gcgggtgtcg gggctggctt aactatgcgg catcagagca 7680
gattgtactg agagtgcacc ataaaattgt aaacgttaat attttgttaa aattcgcgtt 7740
aaatttttgt taaatcagct cattttttaa ccaataggcc gaaatcggca aaatccctta 7800
taaatcaaaa gaatagcccg agatagggtt gagtgttgtt ccagtttgga acaagagtcc 7860
actattaaag aacgtggact ccaacgtcaa agggcgaaaa accgtctatc agggcgatgg 7920
cccactacgt gaaccatcac ccaaatcaag ttttttgggg tcgaggtgcc gtaaagcact 7980
aaatcggaac cctaaaggga gcccccgatt tagagcttga cggggaaagc cggcgaacgt 8040
ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct agggcgctgg caagtgtagc 8100
ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat gcgccgctac agggcgcgta 8160
ctatggttgc tttgacgtat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac 8220
cgcatcaggc gccattcgcc attcaggctg cgcaactgtt gggaagggcg atcggtgcgg 8280
gcctcttcgc tattacgcca gctggcgaaa gggggatgtg ctgcaaggcg attaagttgg 8340
gtaacgccag ggttttccca gtcacgacgt tgtaaaacga cggccagtga attccatggt 8400
ctcaactttc 8410
<210> 26
<211> 8431
<212> DNA
<213> Artificial
<220>
<223> VLP_VEEV VLP 518 vector
<400> 26
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgtt cccgttccag ccaatgtatc cgatgcagcc aatgccctat cgcaacccgt 960
tcgcggcccc gcgcaggccc tggttcccca gaaccgaccc ttttctggcg atgcaggtgc 1020
aggaattaac ccgctcgatg gctaacctga cgttcaagca acgccgggac gcgccacctg 1080
aggggccatc cgctaataaa ccgaagaagg aggcctcgca aaaacagaaa gggggaggcc 1140
aagggaagaa gaagaagaac caagggaaga agaaggctaa gacagggccg cctaatccga 1200
aggcacagaa tggaaacaag aagaagacca acaagaaacc aggcaagaga cagcgcatgg 1260
tcatgaaatt ggaatctgac aagacgttcc caatcatgtt ggaagggaag ataaacggct 1320
acgcttgtgt ggtcggaggg aagttattca ggccgatgca tgtggaaggc aagatcgaca 1380
acgacgttct ggccgcgctt aagacgaaga aagcatccaa atacgatctt gagtatgcag 1440
atgtgccaca gaacatgcgg gccgatacat tcaaatacac ccatgagaaa ccccaaggct 1500
attacagctg gcatcatgga gcagtccaat atgaaaatgg gcgtttcacg gtgccgaaag 1560
gagttggggc caagggagac agcggacgac ccattctgga taaccaggga cgggtggtcg 1620
ctattgtgct gggaggtgtg aatgaaggat ctaggacagc cctttcagtc gtcatgtgga 1680
acgagaaggg agttaccgtg aagtatactc cagagaactg cgagcaatgg tcactagtga 1740
ccaccatgtg tctgctcgcc aatgtgacgt tcccatgtgc tcaaccacca atttgctacg 1800
acagaaaacc agcagagact ttggccatgc tcagcgttaa cgttgacaac ccgggctacg 1860
atgagctgct ggaagcagct gttaagtgcc ccggaaggaa aaggagatcc accgaggagc 1920
tgtttaatga gtataagcta acgcgccctt acatggccag atgcatcaga tgtgcagttg 1980
ggagctgcca tagtccaata gcaatcgagg cagtaaagag cgacgggcac gacggttatg 2040
ttagacttca gacttcctcg cagtatggcc tggattcctc cggcaactta aagggcagga 2100
ccatgcggta tgacatgcac gggaccatta aagagatacc actacatcaa gtgtcactct 2160
atacatctcg cccgtgtcac attgtggatg ggcacggtta tttcctgctt gccaggtgcc 2220
cggcagggga ctccatcacc atggaattta agaaagattc cgtcagacac tcctgctcgg 2280
tgccgtatga agtgaaattt aatcctgtag gcagagaact ctatactcat cccccagaac 2340
acggagtaga gcaagcgtgc caagtctacg cacatgatgc acagaacaga ggagcttatg 2400
tcgagatgca cctcccgggc tcagaagtgg acagcagttt ggtttccttg agcggctccg 2460
gaggatccag ttcagtcacc gtgacacctc ctgatgggac tagcgccctg gtggaatgcg 2520
agtgtggcgg cacaaagatc tccgagacca tcaacaagac aaaacagttc agccagtgca 2580
caaagaagga gcagtgcaga gcatatcggc tgcagaacga taagtgggtg tataattctg 2640
acaaactgcc caaagcagcg ggagccacct taaaaggaaa actgcatgtc ccattcttgc 2700
tggcagacgg caaatgcacc gtgcctctag caccagaacc tatgataacc ttcggtttca 2760
gatcagtgtc actgaaactg caccctaaga atcccacata tctaatcacc cgccaacttg 2820
ctgatgagcc tcactacacg cacgagctca tatctgaacc agctgttagg aattttaccg 2880
tcaccgaaaa agggtgggag tttgtatggg gaaaccaccc gccgaaaagg ttttgggcac 2940
aggaaacagc acccggaaat ccacatgggc taccgcacga ggtgataact cattattacc 3000
acagataccc tatgtccacc atcctgggtt tgtcaatttg tgccgccatt gcaaccgttt 3060
ccgttgcagc gtctacctgg ctgttttgca gatcaagagt tgcgtgccta actccttacc 3120
ggctaacacc taacgctagg ataccatttt gtctggctgt gctttgctgc gcccgcactg 3180
cccgggccga gaccacctgg gagtccttgg atcacctatg gaacaataac caacagatgt 3240
tctggattca attgctgatc cctctggccg ccttgatcgt agtgactcgc ctgctcaggt 3300
gcgtgtgctg tgtcgtgcct tttttagtca tggccggcgc cgcaggcgcc ggcgcctacg 3360
agcacgcgac cacgatgccg agccaagcgg gaatctcgta taacactata gtcaacagag 3420
caggctacgc accactccct atcagcataa caccaacaaa gatcaagctg atacctacag 3480
tgaacttgga gtacgtcacc tgccactaca aaacaggaat ggattcacca gccatcaaat 3540
gctgcggatc tcaggaatgc actccaactt acaggcctga tgaacagtgc aaagtcttca 3600
caggggttta cccgttcatg tggggtggtg catattgctt ttgcgacact gagaacaccc 3660
aagtcagcaa ggcctacgta atgaaatctg acgactgcct tgcggatcat gctgaagcat 3720
ataaagcgca cacagcctca gtgcaggcgt tcctcaacat cacagtggga gaacactcta 3780
ttgtgactac cgtgtatgtg aatggagaaa ctcctgtgaa tttcaatggg gtcaaaataa 3840
ctgcaggtcc gctttccaca gcttggacac cctttgatcg caaaatcgtg cagtatgccg 3900
gggagatcta taattatgat tttcctgagt atggggcagg acaaccagga gcatttggag 3960
atatacaatc cagaacagtc tcaagctctg atctgtatgc caataccaac ctagtgctgc 4020
agagacccaa agcaggagcg atccacgtgc catacactca ggcaccttcg ggttttgagc 4080
aatggaagaa agataaagct ccatcattga aatttaccgc ccctttcgga tgcgaaatat 4140
atacaaaccc cattcgcgcc gaaaactgtg ctgtagggtc aattccatta gcctttgaca 4200
ttcccgacgc cttgttcacc agggtgtcag aaacaccgac actttcagcg gccgaatgca 4260
ctcttaacga gtgcgtgtat tcttccgact ttggtgggat cgccacggtc aagtactcgg 4320
ccagcaagtc aggcaagtgc gcagtccatg tgccatcagg gactgctacc ctaaaagaag 4380
cagcagtcga gctaaccgag caagggtcgg cgactatcca tttctcgacc gcaaatatcc 4440
acccggagtt caggctccaa atatgcacat catatgttac gtgcaaaggt gattgtcacc 4500
ccccgaaaga ccatattgtg acacaccctc agtatcacgc ccaaacattt acagccgcgg 4560
tgtcaaaaac cgcgtggacg tggttaacat ccctgctggg aggatcagcc gtaattatta 4620
taattggctt ggtgctggct actattgtgg ccatgtacgt gctgaccaac cagaaacata 4680
attaaggatc tagatctgct gtgccttcta gttgccagcc atctgttgtt tgcccctccc 4740
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 4800
aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 4860
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 4920
tgggtaccca ggtgctgaag aattgacccg gttcctcctg ggccagaaag aagcaggcac 4980
atccccttct ctgtgacaca ccctgtccac gcccctggtt cttagttcca gccccactca 5040
taggacactc atagctcagg agggctccgc cttcaatccc acccgctaaa gtacttggag 5100
cggtctctcc ctccctcatc agcccaccaa accaaaccta gcctccaaga gtgggaagaa 5160
attaaagcaa gataggctat taagtgcaga gggagagaaa atgcctccaa catgtgagga 5220
agtaatgaga gaaatcatag aattttaagg ccatgattta aggccatcat ggcctaagct 5280
tgaaaggaga taggatcaaa gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa 5340
ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg 5400
gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca 5460
gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg 5520
tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg 5580
gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg 5640
ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 5700
ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg 5760
acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc 5820
tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc 5880
ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc 5940
ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg 6000
ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc 6060
actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 6120
gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc 6180
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac 6240
caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg 6300
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 6360
acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa 6420
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta 6480
ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt 6540
tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag 6600
tgctgcaatg ataccgcgag aaccacgctc accggctcca gatttatcag caataaacca 6660
gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc 6720
tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 6780
tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 6840
ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt 6900
tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat 6960
ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 7020
gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc 7080
ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat 7140
cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 7200
ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 7260
ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 7320
gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta 7380
ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc 7440
gcgcacattt ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt 7500
aacctataaa aataggcgta tcacgaggcc ctttcgggtc gcgcgtttcg gtgatgacgg 7560
tgaaaacctc tgacacatgc agctcccgtt gacggtcaca gcttgtctgt aagcggatgc 7620
cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc ggggctggct 7680
taactatgcg gcatcagagc agattgtact gagagtgcac cataaaattg taaacgttaa 7740
tattttgtta aaattcgcgt taaatttttg ttaaatcagc tcatttttta accaataggc 7800
cgaaatcggc aaaatccctt ataaatcaaa agaatagccc gagatagggt tgagtgttgt 7860
tccagtttgg aacaagagtc cactattaaa gaacgtggac tccaacgtca aagggcgaaa 7920
aaccgtctat cagggcgatg gcccactacg tgaaccatca cccaaatcaa gttttttggg 7980
gtcgaggtgc cgtaaagcac taaatcggaa ccctaaaggg agcccccgat ttagagcttg 8040
acggggaaag ccggcgaacg tggcgagaaa ggaagggaag aaagcgaaag gagcgggcgc 8100
tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc accacacccg ccgcgcttaa 8160
tgcgccgcta cagggcgcgt actatggttg ctttgacgta tgcggtgtga aataccgcac 8220
agatgcgtaa ggagaaaata ccgcatcagg cgccattcgc cattcaggct gcgcaactgt 8280
tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc agctggcgaa agggggatgt 8340
gctgcaaggc gattaagttg ggtaacgcca gggttttccc agtcacgacg ttgtaaaacg 8400
acggccagtg aattccatgg tctcaacttt c 8431
<210> 27
<211> 3813
<212> DNA
<213> Artificial
<220>
<223> VLP31_11 (CHI_VLP_532 PD-1-1) nucleotide sequence (VLP region)
<400> 27
atggagttca tcccgacgca aactttctat aacagaaggt accaaccccg accctgggcc 60
ccacgcccta caattcaagt aattagacct agaccacgtc cacagaggca ggctgggcaa 120
ctcgcccagc tgatctccgc agtcaacaaa ttgaccatgc gcgcggtacc tcaacagaag 180
cctcgcagaa atcggaaaaa caagaagcaa aggcagaaga agcaggcgcc gcaaaacgac 240
ccaaagcaaa agaagcaacc accacaaaag aagccggctc aaaagaagaa gaaaccaggc 300
cgtagggaga gaatgtgcat gaaaattgaa aatgattgca tcttcgaagt caagcatgaa 360
ggcaaagtga tgggctacgc atgcctggtg ggggataaag taatgaaacc agcacatgtg 420
aagggaacta tcgacaatgc cgatctggct aaactggcct ttaagcggtc gtctaaatac 480
gatcttgaat gtgcacagat accggtgcac atgaagtctg atgcctcgaa gtttacccac 540
gagaaacccg aggggtacta taactggcat cacggagcag tgcagtattc aggaggccgg 600
ttcactatcc cgacgggtgc aggcaagccg ggagacagcg gcagaccgat cttcgacaac 660
aaaggacggg tggtggccat cgtcctagga ggggccaacg aaggtgcccg cacggccctc 720
tccgtggtga cgtggaacaa agacatcgtc acaaaaatta cccctgaggg agccgaagag 780
tggagcctcg ccctcccggt cttgtgcctg ttggcaaaca ctacattccc ctgctctcag 840
ccgccttgca caccctgctg ctacgaaaag gaaccggaaa gcaccttgcg catgcttgag 900
gacaacgtga tgagacccgg atactaccag ctactaaaag catcgctgac ttgctctccc 960
caccgccaaa gacgcagtac taaggacaat tttaatgtct ataaagccac aagaccatat 1020
ctagctcatt gtcctgactg cggagaaggg cattcgtgcc acagccctat cgcattggag 1080
cgcatcagaa atgaagcaac ggacggaacg ctgaaaatcc aggtctcttt gcagatcggg 1140
ataaagacag atgacagcca cgattggacc aagctgcgct atatggatag ccatacgcca 1200
gcggacgcgg agcgagccgg attgcttgta aggacttcag caccgtgcac gatcaccggg 1260
accatgggac actttattct cgcccgatgc ccgaaaggag agacgctgac agtgggattt 1320
acggacagca gaaagatcag ccacacatgc acacacccgt tccatcatga accacctgtg 1380
ataggtaggg agaggttcca ctctcgacca caacatggta aagagttacc ttgcagcacg 1440
tacgtgcaga gcaccgctgc cactgctgag gagatagagg tgcatatgcc cccagatact 1500
cctgaccgca cgctgatgac gcagcagtct ggcaacgtga agatcacagt taatgggcag 1560
acggtgcggt acaagtgcaa ctgcggtggc tccggaggac taaactggta ccgcatgagc 1620
cccagcaacc agacggacaa gctggccgcc ttcggaggat ccaacgaggg actgacaacc 1680
acagacaaag tgatcaataa ctgcaaaatt gatcagtgcc atgctgcagt cactaatcac 1740
aagaattggc aatacaactc ccctttagtc ccgcgcaacg ctgaactcgg ggaccgtaaa 1800
ggaaagatcc acatcccatt cccattggca aacgtgactt gcagagtgcc aaaagcaaga 1860
aaccctacag taacttacgg aaaaaaccaa gtcaccatgc tgctgtatcc tgaccatccg 1920
acactcttgt cttaccgtaa catgggacag gaaccaaatt accacgagga gtgggtgaca 1980
cacaagaagg aggttacctt gaccgtgcct actgagggtc tggaggtcac ttggggcaac 2040
aacgaaccat acaagtactg gccgcagatg tctacgaacg gtactgctca tggtcaccca 2100
catgagataa tcttgtacta ttatgagctg taccccacta tgactgtagt cattgtgtcg 2160
gtggcctcgt tcgtgcttct gtcgatggtg ggcacagcag tgggaatgtg tgtgtgcgca 2220
cggcgcagat gcattacacc atatgaatta acaccaggag ccactgttcc cttcctgctc 2280
agcctgctat gctgcgtcag aacgaccaag gcggccacat attacgaggc tgcggcatat 2340
ctatggaacg aacagcagcc cctgttctgg ttgcaggctc ttatcccgct ggccgccttg 2400
atcgtcctgt gcaactgtct gaaactcttg ccatgctgct gtaagaccct ggctttttta 2460
gccgtaatga gcatcggtgc ccacactgtg agcgcgtacg aacacgtaac agtgatcccg 2520
aacacggtgg gagtaccgta taagactctt gtcaacagac cgggttacag ccccatggtg 2580
ttggagatgg agctacaatc agtcaccttg gaaccaacac tgtcacttga ctacatcacg 2640
tgcgagtaca aaactgtcat cccctccccg tacgtgaagt gctgtggtac agcagagtgc 2700
aaggacaaga gcctaccaga ctacagctgc aaggtcttta ctggagtcta cccatttatg 2760
tggggcggcg cctactgctt ttgcgacgcc gaaaatacgc aattgagcga ggcacatgta 2820
gagaaatctg aatcttgcaa aacagagttt gcatcggcct acagagccca caccgcatcg 2880
gcgtcggcga agctccgcgt cctttaccaa ggaaacaaca ttaccgtagc tgcctacgct 2940
aacggtgacc atgccgtcac agtaaaggac gccaagtttg tcgtgggccc aatgtcctcc 3000
gcctggacac cttttgacaa caaaatcgtg gtgtacaaag gcgacgtcta caacatggac 3060
tacccacctt ttggcgcagg aagaccagga caatttggtg acattcaaag tcgtacaccg 3120
gaaagtaaag acgtttatgc caacactcag ttggtactac agaggccagc agcaggcacg 3180
gtacatgtac catactctca ggcaccatct ggcttcaagt attggctgaa ggaacgagga 3240
gcatcgctac agcacacggc accgttcggt tgccagattg cgacaaaccc ggtaagagct 3300
gtaaattgcg ctgtggggaa cataccaatt tccatcgaca taccggatgc ggcctttact 3360
agggttgtcg atgcaccctc tgtaacggac atgtcatgcg aagtaccagc ctgcactcac 3420
tcctccgact ttgggggcgt cgccatcatc aaatacacag ctagcaagaa aggtaaatgt 3480
gcagtacatt cgatgaccaa cgccgttacc attcgagaag ccgacgtaga agtagagggg 3540
aactcccagc tgcaaatatc cttctcaaca gccctggcaa gcgccgagtt tcgcgtgcaa 3600
gtgtgctcca cacaagtaca ctgcgcagcc gcatgccacc ctccaaagga ccacatagtc 3660
aattacccag catcacacac cacccttggg gtccaggata tatccacaac ggcaatgtct 3720
tgggtgcaga agattacggg aggagtagga ttaattgttg ctgttgctgc cttaatttta 3780
attgtggtgc tatgcgtgtc gtttagcagg cac 3813
<210> 28
<211> 3837
<212> DNA
<213> Artificial
<220>
<223> VLP31_21 (VEEV 519 vector PD-1-1) nucleotide sequence (VLP
region)
<400> 28
atgttcccgt tccagccaat gtatccgatg cagccaatgc cctatcgcaa cccgttcgcg 60
gccccgcgca ggccctggtt ccccagaacc gacccttttc tggcgatgca ggtgcaggaa 120
ttaacccgct cgatggctaa cctgacgttc aagcaacgcc gggacgcgcc acctgagggg 180
ccatccgcta ataaaccgaa gaaggaggcc tcgcaaaaac agaaaggggg aggccaaggg 240
aagaagaaga agaaccaagg gaagaagaag gctaagacag ggccgcctaa tccgaaggca 300
cagaatggaa acaagaagaa gaccaacaag aaaccaggca agagacagcg catggtcatg 360
aaattggaat ctgacaagac gttcccaatc atgttggaag ggaagataaa cggctacgct 420
tgtgtggtcg gagggaagtt attcaggccg atgcatgtgg aaggcaagat cgacaacgac 480
gttctggccg cgcttaagac gaagaaagca tccaaatacg atcttgagta tgcagatgtg 540
ccacagaaca tgcgggccga tacattcaaa tacacccatg agaaacccca aggctattac 600
agctggcatc atggagcagt ccaatatgaa aatgggcgtt tcacggtgcc gaaaggagtt 660
ggggccaagg gagacagcgg acgacccatt ctggataacc agggacgggt ggtcgctatt 720
gtgctgggag gtgtgaatga aggatctagg acagcccttt cagtcgtcat gtggaacgag 780
aagggagtta ccgtgaagta tactccagag aactgcgagc aatggtcact agtgaccacc 840
atgtgtctgc tcgccaatgt gacgttccca tgtgctcaac caccaatttg ctacgacaga 900
aaaccagcag agactttggc catgctcagc gttaacgttg acaacccggg ctacgatgag 960
ctgctggaag cagctgttaa gtgccccgga aggaaaagga gatccaccga ggagctgttt 1020
aatgagtata agctaacgcg cccttacatg gccagatgca tcagatgtgc agttgggagc 1080
tgccatagtc caatagcaat cgaggcagta aagagcgacg ggcacgacgg ttatgttaga 1140
cttcagactt cctcgcagta tggcctggat tcctccggca acttaaaggg caggaccatg 1200
cggtatgaca tgcacgggac cattaaagag ataccactac atcaagtgtc actctataca 1260
tctcgcccgt gtcacattgt ggatgggcac ggttatttcc tgcttgccag gtgcccggca 1320
ggggactcca tcaccatgga atttaagaaa gattccgtca gacactcctg ctcggtgccg 1380
tatgaagtga aatttaatcc tgtaggcaga gaactctata ctcatccccc agaacacgga 1440
gtagagcaag cgtgccaagt ctacgcacat gatgcacaga acagaggagc ttatgtcgag 1500
atgcacctcc cgggctcaga agtggacagc agtttggttt ccttgagcgg cagttccgga 1560
ggactaaact ggtaccgcat gagccccagc aaccagacgg acaagctggc cgccttcgga 1620
ggatcctcag tcaccgtgac acctcctgat gggactagcg ccctggtgga atgcgagtgt 1680
ggcggcacaa agatctccga gaccatcaac aagacaaaac agttcagcca gtgcacaaag 1740
aaggagcagt gcagagcata tcggctgcag aacgataagt gggtgtataa ttctgacaaa 1800
ctgcccaaag cagcgggagc caccttaaaa ggaaaactgc atgtcccatt cttgctggca 1860
gacggcaaat gcaccgtgcc tctagcacca gaacctatga taaccttcgg tttcagatca 1920
gtgtcactga aactgcaccc taagaatccc acatatctaa tcacccgcca acttgctgat 1980
gagcctcact acacgcacga gctcatatct gaaccagctg ttaggaattt taccgtcacc 2040
gaaaaagggt gggagtttgt atggggaaac cacccgccga aaaggttttg ggcacaggaa 2100
acagcacccg gaaatccaca tgggctaccg cacgaggtga taactcatta ttaccacaga 2160
taccctatgt ccaccatcct gggtttgtca atttgtgccg ccattgcaac cgtttccgtt 2220
gcagcgtcta cctggctgtt ttgcagatca agagttgcgt gcctaactcc ttaccggcta 2280
acacctaacg ctaggatacc attttgtctg gctgtgcttt gctgcgcccg cactgcccgg 2340
gccgagacca cctgggagtc cttggatcac ctatggaaca ataaccaaca gatgttctgg 2400
attcaattgc tgatccctct ggccgccttg atcgtagtga ctcgcctgct caggtgcgtg 2460
tgctgtgtcg tgcctttttt agtcatggcc ggcgccgcag gcgccggcgc ctacgagcac 2520
gcgaccacga tgccgagcca agcgggaatc tcgtataaca ctatagtcaa cagagcaggc 2580
tacgcaccac tccctatcag cataacacca acaaagatca agctgatacc tacagtgaac 2640
ttggagtacg tcacctgcca ctacaaaaca ggaatggatt caccagccat caaatgctgc 2700
ggatctcagg aatgcactcc aacttacagg cctgatgaac agtgcaaagt cttcacaggg 2760
gtttacccgt tcatgtgggg tggtgcatat tgcttttgcg acactgagaa cacccaagtc 2820
agcaaggcct acgtaatgaa atctgacgac tgccttgcgg atcatgctga agcatataaa 2880
gcgcacacag cctcagtgca ggcgttcctc aacatcacag tgggagaaca ctctattgtg 2940
actaccgtgt atgtgaatgg agaaactcct gtgaatttca atggggtcaa aataactgca 3000
ggtccgcttt ccacagcttg gacacccttt gatcgcaaaa tcgtgcagta tgccggggag 3060
atctataatt atgattttcc tgagtatggg gcaggacaac caggagcatt tggagatata 3120
caatccagaa cagtctcaag ctctgatctg tatgccaata ccaacctagt gctgcagaga 3180
cccaaagcag gagcgatcca cgtgccatac actcaggcac cttcgggttt tgagcaatgg 3240
aagaaagata aagctccatc attgaaattt accgcccctt tcggatgcga aatatataca 3300
aaccccattc gcgccgaaaa ctgtgctgta gggtcaattc cattagcctt tgacattccc 3360
gacgccttgt tcaccagggt gtcagaaaca ccgacacttt cagcggccga atgcactctt 3420
aacgagtgcg tgtattcttc cgactttggt gggatcgcca cggtcaagta ctcggccagc 3480
aagtcaggca agtgcgcagt ccatgtgcca tcagggactg ctaccctaaa agaagcagca 3540
gtcgagctaa ccgagcaagg gtcggcgact atccatttct cgaccgcaaa tatccacccg 3600
gagttcaggc tccaaatatg cacatcatat gttacgtgca aaggtgattg tcaccccccg 3660
aaagaccata ttgtgacaca ccctcagtat cacgcccaaa catttacagc cgcggtgtca 3720
aaaaccgcgt ggacgtggtt aacatccctg ctgggaggat cagccgtaat tattataatt 3780
ggcttggtgc tggctactat tgtggccatg tacgtgctga ccaaccagaa acataat 3837
<210> 29
<211> 3798
<212> DNA
<213> Artificial
<220>
<223> VLP274_11 (CHI_VLP_532 PD-1-1) nucleotide sequence (VLP region)
<400> 29
atggagttca tcccgacgca aactttctat aacagaaggt accaaccccg accctgggcc 60
ccacgcccta caattcaagt aattagacct agaccacgtc cacagaggca ggctgggcaa 120
ctcgcccagc tgatctccgc agtcaacaaa ttgaccatgc gcgcggtacc tcaacagaag 180
cctcgcagaa atcggaaaaa caagaagcaa aggcagaaga agcaggcgcc gcaaaacgac 240
ccaaagcaaa agaagcaacc accacaaaag aagccggctc aaaagaagaa gaaaccaggc 300
cgtagggaga gaatgtgcat gaaaattgaa aatgattgca tcttcgaagt caagcatgaa 360
ggcaaagtga tgggctacgc atgcctggtg ggggataaag taatgaaacc agcacatgtg 420
aagggaacta tcgacaatgc cgatctggct aaactggcct ttaagcggtc gtctaaatac 480
gatcttgaat gtgcacagat accggtgcac atgaagtctg atgcctcgaa gtttacccac 540
gagaaacccg aggggtacta taactggcat cacggagcag tgcagtattc aggaggccgg 600
ttcactatcc cgacgggtgc aggcaagccg ggagacagcg gcagaccgat cttcgacaac 660
aaaggacggg tggtggccat cgtcctagga ggggccaacg aaggtgcccg cacggccctc 720
tccgtggtga cgtggaacaa agacatcgtc acaaaaatta cccctgaggg agccgaagag 780
tggagcctcg ccctcccggt cttgtgcctg ttggcaaaca ctacattccc ctgctctcag 840
ccgccttgca caccctgctg ctacgaaaag gaaccggaaa gcaccttgcg catgcttgag 900
gacaacgtga tgagacccgg atactaccag ctactaaaag catcgctgac ttgctctccc 960
caccgccaaa gacgcagtac taaggacaat tttaatgtct ataaagccac aagaccatat 1020
ctagctcatt gtcctgactg cggagaaggg cattcgtgcc acagccctat cgcattggag 1080
cgcatcagaa atgaagcaac ggacggaacg ctgaaaatcc aggtctcttt gcagatcggg 1140
ataaagacag atgacagcca cgattggacc aagctgcgct atatggatag ccatacgcca 1200
gcggacgcgg agcgagccgg attgcttgta aggacttcag caccgtgcac gatcaccggg 1260
accatgggac actttattct cgcccgatgc ccgaaaggag agacgctgac agtgggattt 1320
acggacagca gaaagatcag ccacacatgc acacacccgt tccatcatga accacctgtg 1380
ataggtaggg agaggttcca ctctcgacca caacatggta aagagttacc ttgcagcacg 1440
tacgtgcaga gcaccgctgc cactgctgag gagatagagg tgcatatgcc cccagatact 1500
cctgaccgca cgctgatgac gcagcagtct ggcaacgtga agatcacagt taatgggcag 1560
acggtgcggt acaagtgcaa ctgcggtggc tccggaggcg gcgccatcag cctgcacccc 1620
aaggccaaga tcgaggaatc tggatccaac gagggactga caaccacaga caaagtgatc 1680
aataactgca aaattgatca gtgccatgct gcagtcacta atcacaagaa ttggcaatac 1740
aactcccctt tagtcccgcg caacgctgaa ctcggggacc gtaaaggaaa gatccacatc 1800
ccattcccat tggcaaacgt gacttgcaga gtgccaaaag caagaaaccc tacagtaact 1860
tacggaaaaa accaagtcac catgctgctg tatcctgacc atccgacact cttgtcttac 1920
cgtaacatgg gacaggaacc aaattaccac gaggagtggg tgacacacaa gaaggaggtt 1980
accttgaccg tgcctactga gggtctggag gtcacttggg gcaacaacga accatacaag 2040
tactggccgc agatgtctac gaacggtact gctcatggtc acccacatga gataatcttg 2100
tactattatg agctgtaccc cactatgact gtagtcattg tgtcggtggc ctcgttcgtg 2160
cttctgtcga tggtgggcac agcagtggga atgtgtgtgt gcgcacggcg cagatgcatt 2220
acaccatatg aattaacacc aggagccact gttcccttcc tgctcagcct gctatgctgc 2280
gtcagaacga ccaaggcggc cacatattac gaggctgcgg catatctatg gaacgaacag 2340
cagcccctgt tctggttgca ggctcttatc ccgctggccg ccttgatcgt cctgtgcaac 2400
tgtctgaaac tcttgccatg ctgctgtaag accctggctt ttttagccgt aatgagcatc 2460
ggtgcccaca ctgtgagcgc gtacgaacac gtaacagtga tcccgaacac ggtgggagta 2520
ccgtataaga ctcttgtcaa cagaccgggt tacagcccca tggtgttgga gatggagcta 2580
caatcagtca ccttggaacc aacactgtca cttgactaca tcacgtgcga gtacaaaact 2640
gtcatcccct ccccgtacgt gaagtgctgt ggtacagcag agtgcaagga caagagccta 2700
ccagactaca gctgcaaggt ctttactgga gtctacccat ttatgtgggg cggcgcctac 2760
tgcttttgcg acgccgaaaa tacgcaattg agcgaggcac atgtagagaa atctgaatct 2820
tgcaaaacag agtttgcatc ggcctacaga gcccacaccg catcggcgtc ggcgaagctc 2880
cgcgtccttt accaaggaaa caacattacc gtagctgcct acgctaacgg tgaccatgcc 2940
gtcacagtaa aggacgccaa gtttgtcgtg ggcccaatgt cctccgcctg gacacctttt 3000
gacaacaaaa tcgtggtgta caaaggcgac gtctacaaca tggactaccc accttttggc 3060
gcaggaagac caggacaatt tggtgacatt caaagtcgta caccggaaag taaagacgtt 3120
tatgccaaca ctcagttggt actacagagg ccagcagcag gcacggtaca tgtaccatac 3180
tctcaggcac catctggctt caagtattgg ctgaaggaac gaggagcatc gctacagcac 3240
acggcaccgt tcggttgcca gattgcgaca aacccggtaa gagctgtaaa ttgcgctgtg 3300
gggaacatac caatttccat cgacataccg gatgcggcct ttactagggt tgtcgatgca 3360
ccctctgtaa cggacatgtc atgcgaagta ccagcctgca ctcactcctc cgactttggg 3420
ggcgtcgcca tcatcaaata cacagctagc aagaaaggta aatgtgcagt acattcgatg 3480
accaacgccg ttaccattcg agaagccgac gtagaagtag aggggaactc ccagctgcaa 3540
atatccttct caacagccct ggcaagcgcc gagtttcgcg tgcaagtgtg ctccacacaa 3600
gtacactgcg cagccgcatg ccaccctcca aaggaccaca tagtcaatta cccagcatca 3660
cacaccaccc ttggggtcca ggatatatcc acaacggcaa tgtcttgggt gcagaagatt 3720
acgggaggag taggattaat tgttgctgtt gctgccttaa ttttaattgt ggtgctatgc 3780
gtgtcgttta gcaggcac 3798
<210> 30
<211> 3822
<212> DNA
<213> Artificial
<220>
<223> VLP274_21 (VEEV 519 vector PD-1-1) nucleotide sequence (VLP
region)
<400> 30
atgttcccgt tccagccaat gtatccgatg cagccaatgc cctatcgcaa cccgttcgcg 60
gccccgcgca ggccctggtt ccccagaacc gacccttttc tggcgatgca ggtgcaggaa 120
ttaacccgct cgatggctaa cctgacgttc aagcaacgcc gggacgcgcc acctgagggg 180
ccatccgcta ataaaccgaa gaaggaggcc tcgcaaaaac agaaaggggg aggccaaggg 240
aagaagaaga agaaccaagg gaagaagaag gctaagacag ggccgcctaa tccgaaggca 300
cagaatggaa acaagaagaa gaccaacaag aaaccaggca agagacagcg catggtcatg 360
aaattggaat ctgacaagac gttcccaatc atgttggaag ggaagataaa cggctacgct 420
tgtgtggtcg gagggaagtt attcaggccg atgcatgtgg aaggcaagat cgacaacgac 480
gttctggccg cgcttaagac gaagaaagca tccaaatacg atcttgagta tgcagatgtg 540
ccacagaaca tgcgggccga tacattcaaa tacacccatg agaaacccca aggctattac 600
agctggcatc atggagcagt ccaatatgaa aatgggcgtt tcacggtgcc gaaaggagtt 660
ggggccaagg gagacagcgg acgacccatt ctggataacc agggacgggt ggtcgctatt 720
gtgctgggag gtgtgaatga aggatctagg acagcccttt cagtcgtcat gtggaacgag 780
aagggagtta ccgtgaagta tactccagag aactgcgagc aatggtcact agtgaccacc 840
atgtgtctgc tcgccaatgt gacgttccca tgtgctcaac caccaatttg ctacgacaga 900
aaaccagcag agactttggc catgctcagc gttaacgttg acaacccggg ctacgatgag 960
ctgctggaag cagctgttaa gtgccccgga aggaaaagga gatccaccga ggagctgttt 1020
aatgagtata agctaacgcg cccttacatg gccagatgca tcagatgtgc agttgggagc 1080
tgccatagtc caatagcaat cgaggcagta aagagcgacg ggcacgacgg ttatgttaga 1140
cttcagactt cctcgcagta tggcctggat tcctccggca acttaaaggg caggaccatg 1200
cggtatgaca tgcacgggac cattaaagag ataccactac atcaagtgtc actctataca 1260
tctcgcccgt gtcacattgt ggatgggcac ggttatttcc tgcttgccag gtgcccggca 1320
ggggactcca tcaccatgga atttaagaaa gattccgtca gacactcctg ctcggtgccg 1380
tatgaagtga aatttaatcc tgtaggcaga gaactctata ctcatccccc agaacacgga 1440
gtagagcaag cgtgccaagt ctacgcacat gatgcacaga acagaggagc ttatgtcgag 1500
atgcacctcc cgggctcaga agtggacagc agtttggttt ccttgagcgg cagttccgga 1560
ggcggcgcca tcagcctgca ccccaaggcc aagatcgagg aatctggatc ctcagtcacc 1620
gtgacacctc ctgatgggac tagcgccctg gtggaatgcg agtgtggcgg cacaaagatc 1680
tccgagacca tcaacaagac aaaacagttc agccagtgca caaagaagga gcagtgcaga 1740
gcatatcggc tgcagaacga taagtgggtg tataattctg acaaactgcc caaagcagcg 1800
ggagccacct taaaaggaaa actgcatgtc ccattcttgc tggcagacgg caaatgcacc 1860
gtgcctctag caccagaacc tatgataacc ttcggtttca gatcagtgtc actgaaactg 1920
caccctaaga atcccacata tctaatcacc cgccaacttg ctgatgagcc tcactacacg 1980
cacgagctca tatctgaacc agctgttagg aattttaccg tcaccgaaaa agggtgggag 2040
tttgtatggg gaaaccaccc gccgaaaagg ttttgggcac aggaaacagc acccggaaat 2100
ccacatgggc taccgcacga ggtgataact cattattacc acagataccc tatgtccacc 2160
atcctgggtt tgtcaatttg tgccgccatt gcaaccgttt ccgttgcagc gtctacctgg 2220
ctgttttgca gatcaagagt tgcgtgccta actccttacc ggctaacacc taacgctagg 2280
ataccatttt gtctggctgt gctttgctgc gcccgcactg cccgggccga gaccacctgg 2340
gagtccttgg atcacctatg gaacaataac caacagatgt tctggattca attgctgatc 2400
cctctggccg ccttgatcgt agtgactcgc ctgctcaggt gcgtgtgctg tgtcgtgcct 2460
tttttagtca tggccggcgc cgcaggcgcc ggcgcctacg agcacgcgac cacgatgccg 2520
agccaagcgg gaatctcgta taacactata gtcaacagag caggctacgc accactccct 2580
atcagcataa caccaacaaa gatcaagctg atacctacag tgaacttgga gtacgtcacc 2640
tgccactaca aaacaggaat ggattcacca gccatcaaat gctgcggatc tcaggaatgc 2700
actccaactt acaggcctga tgaacagtgc aaagtcttca caggggttta cccgttcatg 2760
tggggtggtg catattgctt ttgcgacact gagaacaccc aagtcagcaa ggcctacgta 2820
atgaaatctg acgactgcct tgcggatcat gctgaagcat ataaagcgca cacagcctca 2880
gtgcaggcgt tcctcaacat cacagtggga gaacactcta ttgtgactac cgtgtatgtg 2940
aatggagaaa ctcctgtgaa tttcaatggg gtcaaaataa ctgcaggtcc gctttccaca 3000
gcttggacac cctttgatcg caaaatcgtg cagtatgccg gggagatcta taattatgat 3060
tttcctgagt atggggcagg acaaccagga gcatttggag atatacaatc cagaacagtc 3120
tcaagctctg atctgtatgc caataccaac ctagtgctgc agagacccaa agcaggagcg 3180
atccacgtgc catacactca ggcaccttcg ggttttgagc aatggaagaa agataaagct 3240
ccatcattga aatttaccgc ccctttcgga tgcgaaatat atacaaaccc cattcgcgcc 3300
gaaaactgtg ctgtagggtc aattccatta gcctttgaca ttcccgacgc cttgttcacc 3360
agggtgtcag aaacaccgac actttcagcg gccgaatgca ctcttaacga gtgcgtgtat 3420
tcttccgact ttggtgggat cgccacggtc aagtactcgg ccagcaagtc aggcaagtgc 3480
gcagtccatg tgccatcagg gactgctacc ctaaaagaag cagcagtcga gctaaccgag 3540
caagggtcgg cgactatcca tttctcgacc gcaaatatcc acccggagtt caggctccaa 3600
atatgcacat catatgttac gtgcaaaggt gattgtcacc ccccgaaaga ccatattgtg 3660
acacaccctc agtatcacgc ccaaacattt acagccgcgg tgtcaaaaac cgcgtggacg 3720
tggttaacat ccctgctggg aggatcagcc gtaattatta taattggctt ggtgctggct 3780
actattgtgg ccatgtacgt gctgaccaac cagaaacata at 3822
<210> 31
<211> 3792
<212> DNA
<213> Artificial
<220>
<223> VLP299_15 (CHI_VLP_532 PD-L1-1) nucleotide sequence (VLP region)
<400> 31
atggagttca tcccgacgca aactttctat aacagaaggt accaaccccg accctgggcc 60
ccacgcccta caattcaagt aattagacct agaccacgtc cacagaggca ggctgggcaa 120
ctcgcccagc tgatctccgc agtcaacaaa ttgaccatgc gcgcggtacc tcaacagaag 180
cctcgcagaa atcggaaaaa caagaagcaa aggcagaaga agcaggcgcc gcaaaacgac 240
ccaaagcaaa agaagcaacc accacaaaag aagccggctc aaaagaagaa gaaaccaggc 300
cgtagggaga gaatgtgcat gaaaattgaa aatgattgca tcttcgaagt caagcatgaa 360
ggcaaagtga tgggctacgc atgcctggtg ggggataaag taatgaaacc agcacatgtg 420
aagggaacta tcgacaatgc cgatctggct aaactggcct ttaagcggtc gtctaaatac 480
gatcttgaat gtgcacagat accggtgcac atgaagtctg atgcctcgaa gtttacccac 540
gagaaacccg aggggtacta taactggcat cacggagcag tgcagtattc aggaggccgg 600
ttcactatcc cgacgggtgc aggcaagccg ggagacagcg gcagaccgat cttcgacaac 660
aaaggacggg tggtggccat cgtcctagga ggggccaacg aaggtgcccg cacggccctc 720
tccgtggtga cgtggaacaa agacatcgtc acaaaaatta cccctgaggg agccgaagag 780
tggagcctcg ccctcccggt cttgtgcctg ttggcaaaca ctacattccc ctgctctcag 840
ccgccttgca caccctgctg ctacgaaaag gaaccggaaa gcaccttgcg catgcttgag 900
gacaacgtga tgagacccgg atactaccag ctactaaaag catcgctgac ttgctctccc 960
caccgccaaa gacgcagtac taaggacaat tttaatgtct ataaagccac aagaccatat 1020
ctagctcatt gtcctgactg cggagaaggg cattcgtgcc acagccctat cgcattggag 1080
cgcatcagaa atgaagcaac ggacggaacg ctgaaaatcc aggtctcttt gcagatcggg 1140
ataaagacag atgacagcca cgattggacc aagctgcgct atatggatag ccatacgcca 1200
gcggacgcgg agcgagccgg attgcttgta aggacttcag caccgtgcac gatcaccggg 1260
accatgggac actttattct cgcccgatgc ccgaaaggag agacgctgac agtgggattt 1320
acggacagca gaaagatcag ccacacatgc acacacccgt tccatcatga accacctgtg 1380
ataggtaggg agaggttcca ctctcgacca caacatggta aagagttacc ttgcagcacg 1440
tacgtgcaga gcaccgctgc cactgctgag gagatagagg tgcatatgcc cccagatact 1500
cctgaccgca cgctgatgac gcagcagtct ggcaacgtga agatcacagt taatgggcag 1560
acggtgcggt acaagtgcaa ctgcggtggc tccggaggct gcatcatcag ctacggcgga 1620
gccgactact gcggcggatc caacgaggga ctgacaacca cagacaaagt gatcaataac 1680
tgcaaaattg atcagtgcca tgctgcagtc actaatcaca agaattggca atacaactcc 1740
cctttagtcc cgcgcaacgc tgaactcggg gaccgtaaag gaaagatcca catcccattc 1800
ccattggcaa acgtgacttg cagagtgcca aaagcaagaa accctacagt aacttacgga 1860
aaaaaccaag tcaccatgct gctgtatcct gaccatccga cactcttgtc ttaccgtaac 1920
atgggacagg aaccaaatta ccacgaggag tgggtgacac acaagaagga ggttaccttg 1980
accgtgccta ctgagggtct ggaggtcact tggggcaaca acgaaccata caagtactgg 2040
ccgcagatgt ctacgaacgg tactgctcat ggtcacccac atgagataat cttgtactat 2100
tatgagctgt accccactat gactgtagtc attgtgtcgg tggcctcgtt cgtgcttctg 2160
tcgatggtgg gcacagcagt gggaatgtgt gtgtgcgcac ggcgcagatg cattacacca 2220
tatgaattaa caccaggagc cactgttccc ttcctgctca gcctgctatg ctgcgtcaga 2280
acgaccaagg cggccacata ttacgaggct gcggcatatc tatggaacga acagcagccc 2340
ctgttctggt tgcaggctct tatcccgctg gccgccttga tcgtcctgtg caactgtctg 2400
aaactcttgc catgctgctg taagaccctg gcttttttag ccgtaatgag catcggtgcc 2460
cacactgtga gcgcgtacga acacgtaaca gtgatcccga acacggtggg agtaccgtat 2520
aagactcttg tcaacagacc gggttacagc cccatggtgt tggagatgga gctacaatca 2580
gtcaccttgg aaccaacact gtcacttgac tacatcacgt gcgagtacaa aactgtcatc 2640
ccctccccgt acgtgaagtg ctgtggtaca gcagagtgca aggacaagag cctaccagac 2700
tacagctgca aggtctttac tggagtctac ccatttatgt ggggcggcgc ctactgcttt 2760
tgcgacgccg aaaatacgca attgagcgag gcacatgtag agaaatctga atcttgcaaa 2820
acagagtttg catcggccta cagagcccac accgcatcgg cgtcggcgaa gctccgcgtc 2880
ctttaccaag gaaacaacat taccgtagct gcctacgcta acggtgacca tgccgtcaca 2940
gtaaaggacg ccaagtttgt cgtgggccca atgtcctccg cctggacacc ttttgacaac 3000
aaaatcgtgg tgtacaaagg cgacgtctac aacatggact acccaccttt tggcgcagga 3060
agaccaggac aatttggtga cattcaaagt cgtacaccgg aaagtaaaga cgtttatgcc 3120
aacactcagt tggtactaca gaggccagca gcaggcacgg tacatgtacc atactctcag 3180
gcaccatctg gcttcaagta ttggctgaag gaacgaggag catcgctaca gcacacggca 3240
ccgttcggtt gccagattgc gacaaacccg gtaagagctg taaattgcgc tgtggggaac 3300
ataccaattt ccatcgacat accggatgcg gcctttacta gggttgtcga tgcaccctct 3360
gtaacggaca tgtcatgcga agtaccagcc tgcactcact cctccgactt tgggggcgtc 3420
gccatcatca aatacacagc tagcaagaaa ggtaaatgtg cagtacattc gatgaccaac 3480
gccgttacca ttcgagaagc cgacgtagaa gtagagggga actcccagct gcaaatatcc 3540
ttctcaacag ccctggcaag cgccgagttt cgcgtgcaag tgtgctccac acaagtacac 3600
tgcgcagccg catgccaccc tccaaaggac cacatagtca attacccagc atcacacacc 3660
acccttgggg tccaggatat atccacaacg gcaatgtctt gggtgcagaa gattacggga 3720
ggagtaggat taattgttgc tgttgctgcc ttaattttaa ttgtggtgct atgcgtgtcg 3780
tttagcaggc ac 3792
<210> 32
<211> 3816
<212> DNA
<213> Artificial
<220>
<223> VLP299_25 (VEEV 519 vector PD-L1-1) nucleotide sequence (VLP
region)
<400> 32
atgttcccgt tccagccaat gtatccgatg cagccaatgc cctatcgcaa cccgttcgcg 60
gccccgcgca ggccctggtt ccccagaacc gacccttttc tggcgatgca ggtgcaggaa 120
ttaacccgct cgatggctaa cctgacgttc aagcaacgcc gggacgcgcc acctgagggg 180
ccatccgcta ataaaccgaa gaaggaggcc tcgcaaaaac agaaaggggg aggccaaggg 240
aagaagaaga agaaccaagg gaagaagaag gctaagacag ggccgcctaa tccgaaggca 300
cagaatggaa acaagaagaa gaccaacaag aaaccaggca agagacagcg catggtcatg 360
aaattggaat ctgacaagac gttcccaatc atgttggaag ggaagataaa cggctacgct 420
tgtgtggtcg gagggaagtt attcaggccg atgcatgtgg aaggcaagat cgacaacgac 480
gttctggccg cgcttaagac gaagaaagca tccaaatacg atcttgagta tgcagatgtg 540
ccacagaaca tgcgggccga tacattcaaa tacacccatg agaaacccca aggctattac 600
agctggcatc atggagcagt ccaatatgaa aatgggcgtt tcacggtgcc gaaaggagtt 660
ggggccaagg gagacagcgg acgacccatt ctggataacc agggacgggt ggtcgctatt 720
gtgctgggag gtgtgaatga aggatctagg acagcccttt cagtcgtcat gtggaacgag 780
aagggagtta ccgtgaagta tactccagag aactgcgagc aatggtcact agtgaccacc 840
atgtgtctgc tcgccaatgt gacgttccca tgtgctcaac caccaatttg ctacgacaga 900
aaaccagcag agactttggc catgctcagc gttaacgttg acaacccggg ctacgatgag 960
ctgctggaag cagctgttaa gtgccccgga aggaaaagga gatccaccga ggagctgttt 1020
aatgagtata agctaacgcg cccttacatg gccagatgca tcagatgtgc agttgggagc 1080
tgccatagtc caatagcaat cgaggcagta aagagcgacg ggcacgacgg ttatgttaga 1140
cttcagactt cctcgcagta tggcctggat tcctccggca acttaaaggg caggaccatg 1200
cggtatgaca tgcacgggac cattaaagag ataccactac atcaagtgtc actctataca 1260
tctcgcccgt gtcacattgt ggatgggcac ggttatttcc tgcttgccag gtgcccggca 1320
ggggactcca tcaccatgga atttaagaaa gattccgtca gacactcctg ctcggtgccg 1380
tatgaagtga aatttaatcc tgtaggcaga gaactctata ctcatccccc agaacacgga 1440
gtagagcaag cgtgccaagt ctacgcacat gatgcacaga acagaggagc ttatgtcgag 1500
atgcacctcc cgggctcaga agtggacagc agtttggttt ccttgagcgg cagttccgga 1560
ggctgcatca tcagctacgg cggagccgac tactgcggcg gatcctcagt caccgtgaca 1620
cctcctgatg ggactagcgc cctggtggaa tgcgagtgtg gcggcacaaa gatctccgag 1680
accatcaaca agacaaaaca gttcagccag tgcacaaaga aggagcagtg cagagcatat 1740
cggctgcaga acgataagtg ggtgtataat tctgacaaac tgcccaaagc agcgggagcc 1800
accttaaaag gaaaactgca tgtcccattc ttgctggcag acggcaaatg caccgtgcct 1860
ctagcaccag aacctatgat aaccttcggt ttcagatcag tgtcactgaa actgcaccct 1920
aagaatccca catatctaat cacccgccaa cttgctgatg agcctcacta cacgcacgag 1980
ctcatatctg aaccagctgt taggaatttt accgtcaccg aaaaagggtg ggagtttgta 2040
tggggaaacc acccgccgaa aaggttttgg gcacaggaaa cagcacccgg aaatccacat 2100
gggctaccgc acgaggtgat aactcattat taccacagat accctatgtc caccatcctg 2160
ggtttgtcaa tttgtgccgc cattgcaacc gtttccgttg cagcgtctac ctggctgttt 2220
tgcagatcaa gagttgcgtg cctaactcct taccggctaa cacctaacgc taggatacca 2280
ttttgtctgg ctgtgctttg ctgcgcccgc actgcccggg ccgagaccac ctgggagtcc 2340
ttggatcacc tatggaacaa taaccaacag atgttctgga ttcaattgct gatccctctg 2400
gccgccttga tcgtagtgac tcgcctgctc aggtgcgtgt gctgtgtcgt gcctttttta 2460
gtcatggccg gcgccgcagg cgccggcgcc tacgagcacg cgaccacgat gccgagccaa 2520
gcgggaatct cgtataacac tatagtcaac agagcaggct acgcaccact ccctatcagc 2580
ataacaccaa caaagatcaa gctgatacct acagtgaact tggagtacgt cacctgccac 2640
tacaaaacag gaatggattc accagccatc aaatgctgcg gatctcagga atgcactcca 2700
acttacaggc ctgatgaaca gtgcaaagtc ttcacagggg tttacccgtt catgtggggt 2760
ggtgcatatt gcttttgcga cactgagaac acccaagtca gcaaggccta cgtaatgaaa 2820
tctgacgact gccttgcgga tcatgctgaa gcatataaag cgcacacagc ctcagtgcag 2880
gcgttcctca acatcacagt gggagaacac tctattgtga ctaccgtgta tgtgaatgga 2940
gaaactcctg tgaatttcaa tggggtcaaa ataactgcag gtccgctttc cacagcttgg 3000
acaccctttg atcgcaaaat cgtgcagtat gccggggaga tatataatta tgattttcct 3060
gagtatgggg caggacaacc aggagcattt ggagatatac aatccagaac agtctcaagc 3120
tctgatctgt atgccaatac caacctagtg ctgcagagac ccaaagcagg agcgatccac 3180
gtgccataca ctcaggcacc ttcgggtttt gagcaatgga agaaagataa agctccatca 3240
ttgaaattta ccgccccttt cggatgcgaa atatatacaa accccattcg cgccgaaaac 3300
tgtgctgtag ggtcaattcc attagccttt gacattcccg acgccttgtt caccagggtg 3360
tcagaaacac cgacactttc agcggccgaa tgcactctta acgagtgcgt gtattcttcc 3420
gactttggtg ggatcgccac ggtcaagtac tcggccagca agtcaggcaa gtgcgcagtc 3480
catgtgccat cagggactgc taccctaaaa gaagcagcag tcgagctaac cgagcaaggg 3540
tcggcgacta tccatttctc gaccgcaaat atccacccgg agttcaggct ccaaatatgc 3600
acatcatatg ttacgtgcaa aggtgattgt caccccccga aagaccatat tgtgacacac 3660
cctcagtatc acgcccaaac atttacagcc gcggtgtcaa aaaccgcgtg gacgtggtta 3720
acatccctgc tgggaggatc agccgtaatt attataattg gcttggtgct ggctactatt 3780
gtggccatgt acgtgctgac caaccagaaa cataat 3816
<210> 33
<211> 446
<212> PRT
<213> Artificial
<220>
<223> 31_11 human PD-1 inserted E2 CHIKV amino acid
<400> 33
Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu
1 5 10 15
Ala His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Ile
20 25 30
Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile
35 40 45
Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp
50 55 60
Thr Lys Leu Arg Tyr Met Asp Ser His Thr Pro Ala Asp Ala Glu Arg
65 70 75 80
Ala Gly Leu Leu Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr
85 90 95
Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr
100 105 110
Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His Thr Cys Thr His Pro
115 120 125
Phe His His Glu Pro Pro Val Ile Gly Arg Glu Arg Phe His Ser Arg
130 135 140
Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr
145 150 155 160
Ala Ala Thr Ala Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro
165 170 175
Asp Arg Thr Leu Met Thr Gln Gln Ser Gly Asn Val Lys Ile Thr Val
180 185 190
Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Gly Gly
195 200 205
Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
210 215 220
Ala Phe Gly Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile
225 230 235 240
Asn Asn Cys Lys Ile Asp Gln Cys His Ala Ala Val Thr Asn His Lys
245 250 255
Asn Trp Gln Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly
260 265 270
Asp Arg Lys Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr
275 280 285
Cys Arg Val Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn
290 295 300
Gln Val Thr Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr
305 310 315 320
Arg Asn Met Gly Gln Glu Pro Asn Tyr His Glu Glu Trp Val Thr His
325 330 335
Lys Lys Glu Val Thr Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr
340 345 350
Trp Gly Asn Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Met Ser Thr Asn
355 360 365
Gly Thr Ala His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu
370 375 380
Leu Tyr Pro Thr Met Thr Val Val Ile Val Ser Val Ala Ser Phe Val
385 390 395 400
Leu Leu Ser Met Val Gly Thr Ala Val Gly Met Cys Val Cys Ala Arg
405 410 415
Arg Arg Cys Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro
420 425 430
Phe Leu Leu Ser Leu Leu Cys Cys Val Arg Thr Thr Lys Ala
435 440 445
<210> 34
<211> 440
<212> PRT
<213> Artificial
<220>
<223> 274_11 mouse PD-1 inserted into E2 CHIKV amino acid
<400> 34
Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu
1 5 10 15
Ala His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Ile
20 25 30
Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile
35 40 45
Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp
50 55 60
Thr Lys Leu Arg Tyr Met Asp Ser His Thr Pro Ala Asp Ala Glu Arg
65 70 75 80
Ala Gly Leu Leu Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr
85 90 95
Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr
100 105 110
Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His Thr Cys Thr His Pro
115 120 125
Phe His His Glu Pro Pro Val Ile Gly Arg Glu Arg Phe His Ser Arg
130 135 140
Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr
145 150 155 160
Ala Ala Thr Ala Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro
165 170 175
Asp Arg Thr Leu Met Thr Gln Gln Ser Gly Asn Val Lys Ile Thr Val
180 185 190
Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Gly Gly
195 200 205
Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu Glu Ser Gly Ser
210 215 220
Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Ile
225 230 235 240
Asp Gln Cys His Ala Ala Val Thr Asn His Lys Asn Trp Gln Tyr Asn
245 250 255
Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys
260 265 270
Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys
275 280 285
Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Thr Met Leu
290 295 300
Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Gln
305 310 315 320
Glu Pro Asn Tyr His Glu Glu Trp Val Thr His Lys Lys Glu Val Thr
325 330 335
Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu
340 345 350
Pro Tyr Lys Tyr Trp Pro Gln Met Ser Thr Asn Gly Thr Ala His Gly
355 360 365
His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met
370 375 380
Thr Val Val Ile Val Ser Val Ala Ser Phe Val Leu Leu Ser Met Val
385 390 395 400
Gly Thr Ala Val Gly Met Cys Val Cys Ala Arg Arg Arg Cys Ile Thr
405 410 415
Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu
420 425 430
Leu Cys Cys Val Arg Thr Thr Lys
435 440
<210> 35
<211> 443
<212> PRT
<213> Artificial
<220>
<223> 275_11 human PD-1 inserted E2 CHIKV amino acid
<400> 35
Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu
1 5 10 15
Ala His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Ile
20 25 30
Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile
35 40 45
Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp
50 55 60
Thr Lys Leu Arg Tyr Met Asp Ser His Thr Pro Ala Asp Ala Glu Arg
65 70 75 80
Ala Gly Leu Leu Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr
85 90 95
Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr
100 105 110
Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His Thr Cys Thr His Pro
115 120 125
Phe His His Glu Pro Pro Val Ile Gly Arg Glu Arg Phe His Ser Arg
130 135 140
Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr
145 150 155 160
Ala Ala Thr Ala Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro
165 170 175
Asp Arg Thr Leu Met Thr Gln Gln Ser Gly Asn Val Lys Ile Thr Val
180 185 190
Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Gly Gly
195 200 205
Cys Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu Glu Cys Gly
210 215 220
Gly Ser Asn Glu Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys
225 230 235 240
Lys Ile Asp Gln Cys His Ala Ala Val Thr Asn His Lys Asn Trp Gln
245 250 255
Tyr Asn Ser Pro Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys
260 265 270
Gly Lys Ile His Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val
275 280 285
Pro Lys Ala Arg Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Thr
290 295 300
Met Leu Leu Tyr Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met
305 310 315 320
Gly Gln Glu Pro Asn Tyr His Glu Glu Trp Val Thr His Lys Lys Glu
325 330 335
Val Thr Leu Thr Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn
340 345 350
Asn Glu Pro Tyr Lys Tyr Trp Pro Gln Met Ser Thr Asn Gly Thr Ala
355 360 365
His Gly His Pro His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro
370 375 380
Thr Met Thr Val Val Ile Val Ser Val Ala Ser Phe Val Leu Leu Ser
385 390 395 400
Met Val Gly Thr Ala Val Gly Met Cys Val Cys Ala Arg Arg Arg Cys
405 410 415
Ile Thr Pro Tyr Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu
420 425 430
Ser Leu Leu Cys Cys Val Arg Thr Thr Lys Ala
435 440
<210> 36
<211> 439
<212> PRT
<213> Artificial
<220>
<223> 299_15 human PD-L1 inserted E2 CHIKV amino acid
<400> 36
Ser Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu
1 5 10 15
Ala His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Ile
20 25 30
Ala Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile
35 40 45
Gln Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp
50 55 60
Thr Lys Leu Arg Tyr Met Asp Ser His Thr Pro Ala Asp Ala Glu Arg
65 70 75 80
Ala Gly Leu Leu Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr
85 90 95
Met Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr
100 105 110
Val Gly Phe Thr Asp Ser Arg Lys Ile Ser His Thr Cys Thr His Pro
115 120 125
Phe His His Glu Pro Pro Val Ile Gly Arg Glu Arg Phe His Ser Arg
130 135 140
Pro Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr
145 150 155 160
Ala Ala Thr Ala Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro
165 170 175
Asp Arg Thr Leu Met Thr Gln Gln Ser Gly Asn Val Lys Ile Thr Val
180 185 190
Asn Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Gly Gly
195 200 205
Cys Ile Ile Ser Tyr Gly Gly Ala Asp Tyr Cys Gly Gly Ser Asn Glu
210 215 220
Gly Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Ile Asp Gln
225 230 235 240
Cys His Ala Ala Val Thr Asn His Lys Asn Trp Gln Tyr Asn Ser Pro
245 250 255
Leu Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His
260 265 270
Ile Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg
275 280 285
Asn Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Thr Met Leu Leu Tyr
290 295 300
Pro Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Gln Glu Pro
305 310 315 320
Asn Tyr His Glu Glu Trp Val Thr His Lys Lys Glu Val Thr Leu Thr
325 330 335
Val Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr
340 345 350
Lys Tyr Trp Pro Gln Met Ser Thr Asn Gly Thr Ala His Gly His Pro
355 360 365
His Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val
370 375 380
Val Ile Val Ser Val Ala Ser Phe Val Leu Leu Ser Met Val Gly Thr
385 390 395 400
Ala Val Gly Met Cys Val Cys Ala Arg Arg Arg Cys Ile Thr Pro Tyr
405 410 415
Glu Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Leu Cys
420 425 430
Cys Val Arg Thr Thr Lys Ala
435
<210> 37
<211> 439
<212> PRT
<213> Chikungunya virus
<400> 37
Tyr Glu His Val Thr Val Ile Pro Asn Thr Val Gly Val Pro Tyr Lys
1 5 10 15
Thr Leu Val Asn Arg Pro Gly Tyr Ser Pro Met Val Leu Glu Met Glu
20 25 30
Leu Gln Ser Val Thr Leu Glu Pro Thr Leu Ser Leu Asp Tyr Ile Thr
35 40 45
Cys Glu Tyr Lys Thr Val Ile Pro Ser Pro Tyr Val Lys Cys Cys Gly
50 55 60
Thr Ala Glu Cys Lys Asp Lys Ser Leu Pro Asp Tyr Ser Cys Lys Val
65 70 75 80
Phe Thr Gly Val Tyr Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys
85 90 95
Asp Ala Glu Asn Thr Gln Leu Ser Glu Ala His Val Glu Lys Ser Glu
100 105 110
Ser Cys Lys Thr Glu Phe Ala Ser Ala Tyr Arg Ala His Thr Ala Ser
115 120 125
Ala Ser Ala Lys Leu Arg Val Leu Tyr Gln Gly Asn Asn Ile Thr Val
130 135 140
Ala Ala Tyr Ala Asn Gly Asp His Ala Val Thr Val Lys Asp Ala Lys
145 150 155 160
Phe Val Val Gly Pro Met Ser Ser Ala Trp Thr Pro Phe Asp Asn Lys
165 170 175
Ile Val Val Tyr Lys Gly Asp Val Tyr Asn Met Asp Tyr Pro Pro Phe
180 185 190
Gly Ala Gly Arg Pro Gly Gln Phe Gly Asp Ile Gln Ser Arg Thr Pro
195 200 205
Glu Ser Lys Asp Val Tyr Ala Asn Thr Gln Leu Val Leu Gln Arg Pro
210 215 220
Ala Ala Gly Thr Val His Val Pro Tyr Ser Gln Ala Pro Ser Gly Phe
225 230 235 240
Lys Tyr Trp Leu Lys Glu Arg Gly Ala Ser Leu Gln His Thr Ala Pro
245 250 255
Phe Gly Cys Gln Ile Ala Thr Asn Pro Val Arg Ala Val Asn Cys Ala
260 265 270
Val Gly Asn Ile Pro Ile Ser Ile Asp Ile Pro Asp Ala Ala Phe Thr
275 280 285
Arg Val Val Asp Ala Pro Ser Val Thr Asp Met Ser Cys Glu Val Pro
290 295 300
Ala Cys Thr His Ser Ser Asp Phe Gly Gly Val Ala Ile Ile Lys Tyr
305 310 315 320
Thr Ala Ser Lys Lys Gly Lys Cys Ala Val His Ser Met Thr Asn Ala
325 330 335
Val Thr Ile Arg Glu Ala Asp Val Glu Val Glu Gly Asn Ser Gln Leu
340 345 350
Gln Ile Ser Phe Ser Thr Ala Leu Ala Ser Ala Glu Phe Arg Val Gln
355 360 365
Val Cys Ser Thr Gln Val His Cys Ala Ala Ala Cys His Pro Pro Lys
370 375 380
Asp His Ile Val Asn Tyr Pro Ala Ser His Thr Thr Leu Gly Val Gln
385 390 395 400
Asp Ile Ser Thr Thr Ala Met Ser Trp Val Gln Lys Ile Thr Gly Gly
405 410 415
Val Gly Leu Ile Val Ala Val Ala Ala Leu Ile Leu Ile Val Val Leu
420 425 430
Cys Val Ser Phe Ser Arg His
435
<210> 38
<211> 261
<212> PRT
<213> Chikungunya virus
<400> 38
Met Glu Phe Ile Pro Thr Gln Thr Phe Tyr Asn Arg Arg Tyr Gln Pro
1 5 10 15
Arg Pro Trp Ala Pro Arg Pro Thr Ile Gln Val Ile Arg Pro Arg Pro
20 25 30
Arg Pro Gln Arg Gln Ala Gly Gln Leu Ala Gln Leu Ile Ser Ala Val
35 40 45
Asn Lys Leu Thr Met Arg Ala Val Pro Gln Gln Lys Pro Arg Arg Asn
50 55 60
Arg Lys Asn Lys Lys Gln Arg Gln Lys Lys Gln Ala Pro Gln Asn Asp
65 70 75 80
Pro Lys Gln Lys Lys Gln Pro Pro Gln Lys Lys Pro Ala Gln Lys Lys
85 90 95
Lys Lys Pro Gly Arg Arg Glu Arg Met Cys Met Lys Ile Glu Asn Asp
100 105 110
Cys Ile Phe Glu Val Lys His Glu Gly Lys Val Met Gly Tyr Ala Cys
115 120 125
Leu Val Gly Asp Lys Val Met Lys Pro Ala His Val Lys Gly Thr Ile
130 135 140
Asp Asn Ala Asp Leu Ala Lys Leu Ala Phe Lys Arg Ser Ser Lys Tyr
145 150 155 160
Asp Leu Glu Cys Ala Gln Ile Pro Val His Met Lys Ser Asp Ala Ser
165 170 175
Lys Phe Thr His Glu Lys Pro Glu Gly Tyr Tyr Asn Trp His His Gly
180 185 190
Ala Val Gln Tyr Ser Gly Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly
195 200 205
Lys Pro Gly Asp Ser Gly Arg Pro Ile Phe Asp Asn Lys Gly Arg Val
210 215 220
Val Ala Ile Val Leu Gly Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu
225 230 235 240
Ser Val Val Thr Trp Asn Lys Asp Ile Val Thr Lys Ile Thr Pro Glu
245 250 255
Gly Ala Glu Glu Trp
260
<210> 39
<211> 447
<212> PRT
<213> Artificial
<220>
<223> 31_21 human PD-1 inserted E2 VEEV amino acid
<400> 39
Ser Thr Glu Glu Leu Phe Asn Glu Tyr Lys Leu Thr Arg Pro Tyr Met
1 5 10 15
Ala Arg Cys Ile Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala
20 25 30
Ile Glu Ala Val Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln
35 40 45
Thr Ser Ser Gln Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg
50 55 60
Thr Met Arg Tyr Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His
65 70 75 80
Gln Val Ser Leu Tyr Thr Ser Arg Pro Cys His Ile Val Asp Gly His
85 90 95
Gly Tyr Phe Leu Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met
100 105 110
Glu Phe Lys Lys Asp Ser Val Arg His Ser Cys Ser Val Pro Tyr Glu
115 120 125
Val Lys Phe Asn Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu
130 135 140
His Gly Val Glu Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn
145 150 155 160
Arg Gly Ala Tyr Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser
165 170 175
Ser Leu Val Ser Leu Ser Gly Ser Ser Gly Gly Leu Asn Trp Tyr Arg
180 185 190
Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Gly Gly Ser
195 200 205
Ser Val Thr Val Thr Pro Pro Asp Gly Thr Ser Ala Leu Val Glu Cys
210 215 220
Glu Cys Gly Gly Thr Lys Ile Ser Glu Thr Ile Asn Lys Thr Lys Gln
225 230 235 240
Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys Arg Ala Tyr Arg Leu Gln
245 250 255
Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys Leu Pro Lys Ala Ala Gly
260 265 270
Ala Thr Leu Lys Gly Lys Leu His Val Pro Phe Leu Leu Ala Asp Gly
275 280 285
Lys Cys Thr Val Pro Leu Ala Pro Glu Pro Met Ile Thr Phe Gly Phe
290 295 300
Arg Ser Val Ser Leu Lys Leu His Pro Lys Asn Pro Thr Tyr Leu Ile
305 310 315 320
Thr Arg Gln Leu Ala Asp Glu Pro His Tyr Thr His Glu Leu Ile Ser
325 330 335
Glu Pro Ala Val Arg Asn Phe Thr Val Thr Glu Lys Gly Trp Glu Phe
340 345 350
Val Trp Gly Asn His Pro Pro Lys Arg Phe Trp Ala Gln Glu Thr Ala
355 360 365
Pro Gly Asn Pro His Gly Leu Pro His Glu Val Ile Thr His Tyr Tyr
370 375 380
His Arg Tyr Pro Met Ser Thr Ile Leu Gly Leu Ser Ile Cys Ala Ala
385 390 395 400
Ile Ala Thr Val Ser Val Ala Ala Ser Thr Trp Leu Phe Cys Arg Ser
405 410 415
Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu Thr Pro Asn Ala Arg Ile
420 425 430
Pro Phe Cys Leu Ala Val Leu Cys Cys Ala Arg Thr Ala Arg Ala
435 440 445
<210> 40
<211> 442
<212> PRT
<213> Artificial
<220>
<223> 274_21 human PD-1 inserted E2 VEEV amino acid
<400> 40
Ser Thr Glu Glu Leu Phe Asn Glu Tyr Lys Leu Thr Arg Pro Tyr Met
1 5 10 15
Ala Arg Cys Ile Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala
20 25 30
Ile Glu Ala Val Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln
35 40 45
Thr Ser Ser Gln Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg
50 55 60
Thr Met Arg Tyr Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His
65 70 75 80
Gln Val Ser Leu Tyr Thr Ser Arg Pro Cys His Ile Val Asp Gly His
85 90 95
Gly Tyr Phe Leu Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met
100 105 110
Glu Phe Lys Lys Asp Ser Val Arg His Ser Cys Ser Val Pro Tyr Glu
115 120 125
Val Lys Phe Asn Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu
130 135 140
His Gly Val Glu Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn
145 150 155 160
Arg Gly Ala Tyr Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser
165 170 175
Ser Leu Val Ser Leu Ser Gly Ser Ser Gly Gly Gly Ala Ile Ser Leu
180 185 190
His Pro Lys Ala Lys Ile Glu Glu Ser Gly Ser Ser Val Thr Val Thr
195 200 205
Pro Pro Asp Gly Thr Ser Ala Leu Val Glu Cys Glu Cys Gly Gly Thr
210 215 220
Lys Ile Ser Glu Thr Ile Asn Lys Thr Lys Gln Phe Ser Gln Cys Thr
225 230 235 240
Lys Lys Glu Gln Cys Arg Ala Tyr Arg Leu Gln Asn Asp Lys Trp Val
245 250 255
Tyr Asn Ser Asp Lys Leu Pro Lys Ala Ala Gly Ala Thr Leu Lys Gly
260 265 270
Lys Leu His Val Pro Phe Leu Leu Ala Asp Gly Lys Cys Thr Val Pro
275 280 285
Leu Ala Pro Glu Pro Met Ile Thr Phe Gly Phe Arg Ser Val Ser Leu
290 295 300
Lys Leu His Pro Lys Asn Pro Thr Tyr Leu Ile Thr Arg Gln Leu Ala
305 310 315 320
Asp Glu Pro His Tyr Thr His Glu Leu Ile Ser Glu Pro Ala Val Arg
325 330 335
Asn Phe Thr Val Thr Glu Lys Gly Trp Glu Phe Val Trp Gly Asn His
340 345 350
Pro Pro Lys Arg Phe Trp Ala Gln Glu Thr Ala Pro Gly Asn Pro His
355 360 365
Gly Leu Pro His Glu Val Ile Thr His Tyr Tyr His Arg Tyr Pro Met
370 375 380
Ser Thr Ile Leu Gly Leu Ser Ile Cys Ala Ala Ile Ala Thr Val Ser
385 390 395 400
Val Ala Ala Ser Thr Trp Leu Phe Cys Arg Ser Arg Val Ala Cys Leu
405 410 415
Thr Pro Tyr Arg Leu Thr Pro Asn Ala Arg Ile Pro Phe Cys Leu Ala
420 425 430
Val Leu Cys Cys Ala Arg Thr Ala Arg Ala
435 440
<210> 41
<211> 444
<212> PRT
<213> Artificial
<220>
<223> 275_21 human PD-1 inserted E2 VEEV amino acid
<400> 41
Ser Thr Glu Glu Leu Phe Asn Glu Tyr Lys Leu Thr Arg Pro Tyr Met
1 5 10 15
Ala Arg Cys Ile Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala
20 25 30
Ile Glu Ala Val Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln
35 40 45
Thr Ser Ser Gln Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg
50 55 60
Thr Met Arg Tyr Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His
65 70 75 80
Gln Val Ser Leu Tyr Thr Ser Arg Pro Cys His Ile Val Asp Gly His
85 90 95
Gly Tyr Phe Leu Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met
100 105 110
Glu Phe Lys Lys Asp Ser Val Arg His Ser Cys Ser Val Pro Tyr Glu
115 120 125
Val Lys Phe Asn Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu
130 135 140
His Gly Val Glu Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn
145 150 155 160
Arg Gly Ala Tyr Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser
165 170 175
Ser Leu Val Ser Leu Ser Gly Ser Ser Gly Gly Cys Gly Ala Ile Ser
180 185 190
Leu His Pro Lys Ala Lys Ile Glu Glu Cys Gly Gly Ser Ser Val Thr
195 200 205
Val Thr Pro Pro Asp Gly Thr Ser Ala Leu Val Glu Cys Glu Cys Gly
210 215 220
Gly Thr Lys Ile Ser Glu Thr Ile Asn Lys Thr Lys Gln Phe Ser Gln
225 230 235 240
Cys Thr Lys Lys Glu Gln Cys Arg Ala Tyr Arg Leu Gln Asn Asp Lys
245 250 255
Trp Val Tyr Asn Ser Asp Lys Leu Pro Lys Ala Ala Gly Ala Thr Leu
260 265 270
Lys Gly Lys Leu His Val Pro Phe Leu Leu Ala Asp Gly Lys Cys Thr
275 280 285
Val Pro Leu Ala Pro Glu Pro Met Ile Thr Phe Gly Phe Arg Ser Val
290 295 300
Ser Leu Lys Leu His Pro Lys Asn Pro Thr Tyr Leu Ile Thr Arg Gln
305 310 315 320
Leu Ala Asp Glu Pro His Tyr Thr His Glu Leu Ile Ser Glu Pro Ala
325 330 335
Val Arg Asn Phe Thr Val Thr Glu Lys Gly Trp Glu Phe Val Trp Gly
340 345 350
Asn His Pro Pro Lys Arg Phe Trp Ala Gln Glu Thr Ala Pro Gly Asn
355 360 365
Pro His Gly Leu Pro His Glu Val Ile Thr His Tyr Tyr His Arg Tyr
370 375 380
Pro Met Ser Thr Ile Leu Gly Leu Ser Ile Cys Ala Ala Ile Ala Thr
385 390 395 400
Val Ser Val Ala Ala Ser Thr Trp Leu Phe Cys Arg Ser Arg Val Ala
405 410 415
Cys Leu Thr Pro Tyr Arg Leu Thr Pro Asn Ala Arg Ile Pro Phe Cys
420 425 430
Leu Ala Val Leu Cys Cys Ala Arg Thr Ala Arg Ala
435 440
<210> 42
<211> 440
<212> PRT
<213> Artificial
<220>
<223> 299_25 human PD-L1 inserted E2 VEEV amino acid
<400> 42
Ser Thr Glu Glu Leu Phe Asn Glu Tyr Lys Leu Thr Arg Pro Tyr Met
1 5 10 15
Ala Arg Cys Ile Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala
20 25 30
Ile Glu Ala Val Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln
35 40 45
Thr Ser Ser Gln Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg
50 55 60
Thr Met Arg Tyr Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His
65 70 75 80
Gln Val Ser Leu Tyr Thr Ser Arg Pro Cys His Ile Val Asp Gly His
85 90 95
Gly Tyr Phe Leu Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met
100 105 110
Glu Phe Lys Lys Asp Ser Val Arg His Ser Cys Ser Val Pro Tyr Glu
115 120 125
Val Lys Phe Asn Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu
130 135 140
His Gly Val Glu Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn
145 150 155 160
Arg Gly Ala Tyr Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser
165 170 175
Ser Leu Val Ser Leu Ser Gly Ser Ser Gly Gly Cys Ile Ile Ser Tyr
180 185 190
Gly Gly Ala Asp Tyr Cys Gly Gly Ser Ser Val Thr Val Thr Pro Pro
195 200 205
Asp Gly Thr Ser Ala Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile
210 215 220
Ser Glu Thr Ile Asn Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys
225 230 235 240
Glu Gln Cys Arg Ala Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn
245 250 255
Ser Asp Lys Leu Pro Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu
260 265 270
His Val Pro Phe Leu Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala
275 280 285
Pro Glu Pro Met Ile Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu
290 295 300
His Pro Lys Asn Pro Thr Tyr Leu Ile Thr Arg Gln Leu Ala Asp Glu
305 310 315 320
Pro His Tyr Thr His Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe
325 330 335
Thr Val Thr Glu Lys Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro
340 345 350
Lys Arg Phe Trp Ala Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu
355 360 365
Pro His Glu Val Ile Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr
370 375 380
Ile Leu Gly Leu Ser Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala
385 390 395 400
Ala Ser Thr Trp Leu Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro
405 410 415
Tyr Arg Leu Thr Pro Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu
420 425 430
Cys Cys Ala Arg Thr Ala Arg Ala
435 440
<210> 43
<211> 442
<212> PRT
<213> Venezuelan equine encephalitis virus
<400> 43
Tyr Glu His Ala Thr Thr Met Pro Ser Gln Ala Gly Ile Ser Tyr Asn
1 5 10 15
Thr Ile Val Asn Arg Ala Gly Tyr Ala Pro Leu Pro Ile Ser Ile Thr
20 25 30
Pro Thr Lys Ile Lys Leu Ile Pro Thr Val Asn Leu Glu Tyr Val Thr
35 40 45
Cys His Tyr Lys Thr Gly Met Asp Ser Pro Ala Ile Lys Cys Cys Gly
50 55 60
Ser Gln Glu Cys Thr Pro Thr Tyr Arg Pro Asp Glu Gln Cys Lys Val
65 70 75 80
Phe Thr Gly Val Tyr Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys
85 90 95
Asp Thr Glu Asn Thr Gln Val Ser Lys Ala Tyr Val Met Lys Ser Asp
100 105 110
Asp Cys Leu Ala Asp His Ala Glu Ala Tyr Lys Ala His Thr Ala Ser
115 120 125
Val Gln Ala Phe Leu Asn Ile Thr Val Gly Glu His Ser Ile Val Thr
130 135 140
Thr Val Tyr Val Asn Gly Glu Thr Pro Val Asn Phe Asn Gly Val Lys
145 150 155 160
Ile Thr Ala Gly Pro Leu Ser Thr Ala Trp Thr Pro Phe Asp Arg Lys
165 170 175
Ile Val Gln Tyr Ala Gly Glu Ile Tyr Asn Tyr Asp Phe Pro Glu Tyr
180 185 190
Gly Ala Gly Gln Pro Gly Ala Phe Gly Asp Ile Gln Ser Arg Thr Val
195 200 205
Ser Ser Ser Asp Leu Tyr Ala Asn Thr Asn Leu Val Leu Gln Arg Pro
210 215 220
Lys Ala Gly Ala Ile His Val Pro Tyr Thr Gln Ala Pro Ser Gly Phe
225 230 235 240
Glu Gln Trp Lys Lys Asp Lys Ala Pro Ser Leu Lys Phe Thr Ala Pro
245 250 255
Phe Gly Cys Glu Ile Tyr Thr Asn Pro Ile Arg Ala Glu Asn Cys Ala
260 265 270
Val Gly Ser Ile Pro Leu Ala Phe Asp Ile Pro Asp Ala Leu Phe Thr
275 280 285
Arg Val Ser Glu Thr Pro Thr Leu Ser Ala Ala Glu Cys Thr Leu Asn
290 295 300
Glu Cys Val Tyr Ser Ser Asp Phe Gly Gly Ile Ala Thr Val Lys Tyr
305 310 315 320
Ser Ala Ser Lys Ser Gly Lys Cys Ala Val His Val Pro Ser Gly Thr
325 330 335
Ala Thr Leu Lys Glu Ala Ala Val Glu Leu Thr Glu Gln Gly Ser Ala
340 345 350
Thr Ile His Phe Ser Thr Ala Asn Ile His Pro Glu Phe Arg Leu Gln
355 360 365
Ile Cys Thr Ser Tyr Val Thr Cys Lys Gly Asp Cys His Pro Pro Lys
370 375 380
Asp His Ile Val Thr His Pro Gln Tyr His Ala Gln Thr Phe Thr Ala
385 390 395 400
Ala Val Ser Lys Thr Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly
405 410 415
Ser Ala Val Ile Ile Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala
420 425 430
Met Tyr Val Leu Thr Asn Gln Lys His Asn
435 440
<210> 44
<211> 275
<212> PRT
<213> Venezuelan equine encephalitis virus
<400> 44
Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg
1 5 10 15
Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro
20 25 30
Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu
35 40 45
Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Asn
50 55 60
Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly
65 70 75 80
Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro
85 90 95
Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro
100 105 110
Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe
115 120 125
Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly
130 135 140
Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp
145 150 155 160
Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu
165 170 175
Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr
180 185 190
His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln
195 200 205
Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly
210 215 220
Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile
225 230 235 240
Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val
245 250 255
Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys
260 265 270
Glu Gln Trp
275
<210> 45
<211> 8467
<212> DNA
<213> Artificial
<220>
<223> VLP31.11 vector
<400> 45
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgga gttcatcccg acgcaaactt tctataacag aaggtaccaa ccccgaccct 960
gggccccacg ccctacaatt caagtaatta gacctagacc acgtccacag aggcaggctg 1020
ggcaactcgc ccagctgatc tccgcagtca acaaattgac catgcgcgcg gtacctcaac 1080
agaagcctcg cagaaatcgg aaaaacaaga agcaaaggca gaagaagcag gcgccgcaaa 1140
acgacccaaa gcaaaagaag caaccaccac aaaagaagcc ggctcaaaag aagaagaaac 1200
caggccgtag ggagagaatg tgcatgaaaa ttgaaaatga ttgcatcttc gaagtcaagc 1260
atgaaggcaa agtgatgggc tacgcatgcc tggtggggga taaagtaatg aaaccagcac 1320
atgtgaaggg aactatcgac aatgccgatc tggctaaact ggcctttaag cggtcgtcta 1380
aatacgatct tgaatgtgca cagataccgg tgcacatgaa gtctgatgcc tcgaagttta 1440
cccacgagaa acccgagggg tactataact ggcatcacgg agcagtgcag tattcaggag 1500
gccggttcac tatcccgacg ggtgcaggca agccgggaga cagcggcaga ccgatcttcg 1560
acaacaaagg acgggtggtg gccatcgtcc taggaggggc caacgaaggt gcccgcacgg 1620
ccctctccgt ggtgacgtgg aacaaagaca tcgtcacaaa aattacccct gagggagccg 1680
aagagtggag cctcgccctc ccggtcttgt gcctgttggc aaacactaca ttcccctgct 1740
ctcagccgcc ttgcacaccc tgctgctacg aaaaggaacc ggaaagcacc ttgcgcatgc 1800
ttgaggacaa cgtgatgaga cccggatact accagctact aaaagcatcg ctgacttgct 1860
ctccccaccg ccaaagacgc agtactaagg acaattttaa tgtctataaa gccacaagac 1920
catatctagc tcattgtcct gactgcggag aagggcattc gtgccacagc cctatcgcat 1980
tggagcgcat cagaaatgaa gcaacggacg gaacgctgaa aatccaggtc tctttgcaga 2040
tcgggataaa gacagatgac agccacgatt ggaccaagct gcgctatatg gatagccata 2100
cgccagcgga cgcggagcga gccggattgc ttgtaaggac ttcagcaccg tgcacgatca 2160
ccgggaccat gggacacttt attctcgccc gatgcccgaa aggagagacg ctgacagtgg 2220
gatttacgga cagcagaaag atcagccaca catgcacaca cccgttccat catgaaccac 2280
ctgtgatagg tagggagagg ttccactctc gaccacaaca tggtaaagag ttaccttgca 2340
gcacgtacgt gcagagcacc gctgccactg ctgaggagat agaggtgcat atgcccccag 2400
atactcctga ccgcacgctg atgacgcagc agtctggcaa cgtgaagatc acagttaatg 2460
ggcagacggt gcggtacaag tgcaactgcg gtggctccgg aggactaaac tggtaccgca 2520
tgagccccag caaccagacg gacaagctgg ccgccttcgg aggatccaac gagggactga 2580
caaccacaga caaagtgatc aataactgca aaattgatca gtgccatgct gcagtcacta 2640
atcacaagaa ttggcaatac aactcccctt tagtcccgcg caacgctgaa ctcggggacc 2700
gtaaaggaaa gatccacatc ccattcccat tggcaaacgt gacttgcaga gtgccaaaag 2760
caagaaaccc tacagtaact tacggaaaaa accaagtcac catgctgctg tatcctgacc 2820
atccgacact cttgtcttac cgtaacatgg gacaggaacc aaattaccac gaggagtggg 2880
tgacacacaa gaaggaggtt accttgaccg tgcctactga gggtctggag gtcacttggg 2940
gcaacaacga accatacaag tactggccgc agatgtctac gaacggtact gctcatggtc 3000
acccacatga gataatcttg tactattatg agctgtaccc cactatgact gtagtcattg 3060
tgtcggtggc ctcgttcgtg cttctgtcga tggtgggcac agcagtggga atgtgtgtgt 3120
gcgcacggcg cagatgcatt acaccatatg aattaacacc aggagccact gttcccttcc 3180
tgctcagcct gctatgctgc gtcagaacga ccaaggcggc cacatattac gaggctgcgg 3240
catatctatg gaacgaacag cagcccctgt tctggttgca ggctcttatc ccgctggccg 3300
ccttgatcgt cctgtgcaac tgtctgaaac tcttgccatg ctgctgtaag accctggctt 3360
ttttagccgt aatgagcatc ggtgcccaca ctgtgagcgc gtacgaacac gtaacagtga 3420
tcccgaacac ggtgggagta ccgtataaga ctcttgtcaa cagaccgggt tacagcccca 3480
tggtgttgga gatggagcta caatcagtca ccttggaacc aacactgtca cttgactaca 3540
tcacgtgcga gtacaaaact gtcatcccct ccccgtacgt gaagtgctgt ggtacagcag 3600
agtgcaagga caagagccta ccagactaca gctgcaaggt ctttactgga gtctacccat 3660
ttatgtgggg cggcgcctac tgcttttgcg acgccgaaaa tacgcaattg agcgaggcac 3720
atgtagagaa atctgaatct tgcaaaacag agtttgcatc ggcctacaga gcccacaccg 3780
catcggcgtc ggcgaagctc cgcgtccttt accaaggaaa caacattacc gtagctgcct 3840
acgctaacgg tgaccatgcc gtcacagtaa aggacgccaa gtttgtcgtg ggcccaatgt 3900
cctccgcctg gacacctttt gacaacaaaa tcgtggtgta caaaggcgac gtctacaaca 3960
tggactaccc accttttggc gcaggaagac caggacaatt tggtgacatt caaagtcgta 4020
caccggaaag taaagacgtt tatgccaaca ctcagttggt actacagagg ccagcagcag 4080
gcacggtaca tgtaccatac tctcaggcac catctggctt caagtattgg ctgaaggaac 4140
gaggagcatc gctacagcac acggcaccgt tcggttgcca gattgcgaca aacccggtaa 4200
gagctgtaaa ttgcgctgtg gggaacatac caatttccat cgacataccg gatgcggcct 4260
ttactagggt tgtcgatgca ccctctgtaa cggacatgtc atgcgaagta ccagcctgca 4320
ctcactcctc cgactttggg ggcgtcgcca tcatcaaata cacagctagc aagaaaggta 4380
aatgtgcagt acattcgatg accaacgccg ttaccattcg agaagccgac gtagaagtag 4440
aggggaactc ccagctgcaa atatccttct caacagccct ggcaagcgcc gagtttcgcg 4500
tgcaagtgtg ctccacacaa gtacactgcg cagccgcatg ccaccctcca aaggaccaca 4560
tagtcaatta cccagcatca cacaccaccc ttggggtcca ggatatatcc acaacggcaa 4620
tgtcttgggt gcagaagatt acgggaggag taggattaat tgttgctgtt gctgccttaa 4680
ttttaattgt ggtgctatgc gtgtcgttta gcaggcacta aggatctaga tctgctgtgc 4740
cttctagttg ccagccatct gttgtttgcc cctcccccgt gccttccttg accctggaag 4800
gtgccactcc cactgtcctt tcctaataaa atgaggaaat tgcatcgcat tgtctgagta 4860
ggtgtcattc tattctgggg ggtggggtgg ggcaggacag caagggggag gattgggaag 4920
acaatagcag gcatgctggg gatgcggtgg gctctatggg tacccaggtg ctgaagaatt 4980
gacccggttc ctcctgggcc agaaagaagc aggcacatcc ccttctctgt gacacaccct 5040
gtccacgccc ctggttctta gttccagccc cactcatagg acactcatag ctcaggaggg 5100
ctccgccttc aatcccaccc gctaaagtac ttggagcggt ctctccctcc ctcatcagcc 5160
caccaaacca aacctagcct ccaagagtgg gaagaaatta aagcaagata ggctattaag 5220
tgcagaggga gagaaaatgc ctccaacatg tgaggaagta atgagagaaa tcatagaatt 5280
ttaaggccat gatttaaggc catcatggcc taagcttgaa aggagatagg atcaaagctt 5340
ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccaca 5400
caacatacga gccggaagca taaagtgtaa agcctggggt gcctaatgag tgagctaact 5460
cacattaatt gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt cgtgccagct 5520
gcattaatga atcggccaac gcgcggggag aggcggtttg cgtattgggc gctcttccgc 5580
ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca 5640
ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg 5700
agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca 5760
taggctccgc ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa 5820
cccgacagga ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc 5880
tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc 5940
gctttctcat agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct 6000
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg 6060
tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag 6120
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta 6180
cggctacact agaagaacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg 6240
aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt 6300
tgtttgcaag cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt 6360
ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag 6420
attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat 6480
ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc 6540
tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactccccg tcgtgtagat 6600
aactacgata cgggagggct taccatctgg ccccagtgct gcaatgatac cgcgagaacc 6660
acgctcaccg gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgcag 6720
aagtggtcct gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaagctag 6780
agtaagtagt tcgccagtta atagtttgcg caacgttgtt gccattgcta caggcatcgt 6840
ggtgtcacgc tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg 6900
agttacatga tcccccatgt tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt 6960
tgtcagaagt aagttggccg cagtgttatc actcatggtt atggcagcac tgcataattc 7020
tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc 7080
attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa 7140
taccgcgcca catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg 7200
aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc 7260
caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag 7320
gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt 7380
cctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt 7440
tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc 7500
acctgacgtc taagaaacca ttattatcat gacattaacc tataaaaata ggcgtatcac 7560
gaggcccttt cgggtcgcgc gtttcggtga tgacggtgaa aacctctgac acatgcagct 7620
cccgttgacg gtcacagctt gtctgtaagc ggatgccggg agcagacaag cccgtcaggg 7680
cgcgtcagcg ggtgttggcg ggtgtcgggg ctggcttaac tatgcggcat cagagcagat 7740
tgtactgaga gtgcaccata aaattgtaaa cgttaatatt ttgttaaaat tcgcgttaaa 7800
tttttgttaa atcagctcat tttttaacca ataggccgaa atcggcaaaa tcccttataa 7860
atcaaaagaa tagcccgaga tagggttgag tgttgttcca gtttggaaca agagtccact 7920
attaaagaac gtggactcca acgtcaaagg gcgaaaaacc gtctatcagg gcgatggccc 7980
actacgtgaa ccatcaccca aatcaagttt tttggggtcg aggtgccgta aagcactaaa 8040
tcggaaccct aaagggagcc cccgatttag agcttgacgg ggaaagccgg cgaacgtggc 8100
gagaaaggaa gggaagaaag cgaaaggagc gggcgctagg gcgctggcaa gtgtagcggt 8160
cacgctgcgc gtaaccacca cacccgccgc gcttaatgcg ccgctacagg gcgcgtacta 8220
tggttgcttt gacgtatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc 8280
atcaggcgcc attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc 8340
tcttcgctat tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta 8400
acgccagggt tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt ccatggtctc 8460
aactttc 8467
<210> 46
<211> 8452
<212> DNA
<213> Artificial
<220>
<223> VLP274.11 vector
<400> 46
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgga gttcatcccg acgcaaactt tctataacag aaggtaccaa ccccgaccct 960
gggccccacg ccctacaatt caagtaatta gacctagacc acgtccacag aggcaggctg 1020
ggcaactcgc ccagctgatc tccgcagtca acaaattgac catgcgcgcg gtacctcaac 1080
agaagcctcg cagaaatcgg aaaaacaaga agcaaaggca gaagaagcag gcgccgcaaa 1140
acgacccaaa gcaaaagaag caaccaccac aaaagaagcc ggctcaaaag aagaagaaac 1200
caggccgtag ggagagaatg tgcatgaaaa ttgaaaatga ttgcatcttc gaagtcaagc 1260
atgaaggcaa agtgatgggc tacgcatgcc tggtggggga taaagtaatg aaaccagcac 1320
atgtgaaggg aactatcgac aatgccgatc tggctaaact ggcctttaag cggtcgtcta 1380
aatacgatct tgaatgtgca cagataccgg tgcacatgaa gtctgatgcc tcgaagttta 1440
cccacgagaa acccgagggg tactataact ggcatcacgg agcagtgcag tattcaggag 1500
gccggttcac tatcccgacg ggtgcaggca agccgggaga cagcggcaga ccgatcttcg 1560
acaacaaagg acgggtggtg gccatcgtcc taggaggggc caacgaaggt gcccgcacgg 1620
ccctctccgt ggtgacgtgg aacaaagaca tcgtcacaaa aattacccct gagggagccg 1680
aagagtggag cctcgccctc ccggtcttgt gcctgttggc aaacactaca ttcccctgct 1740
ctcagccgcc ttgcacaccc tgctgctacg aaaaggaacc ggaaagcacc ttgcgcatgc 1800
ttgaggacaa cgtgatgaga cccggatact accagctact aaaagcatcg ctgacttgct 1860
ctccccaccg ccaaagacgc agtactaagg acaattttaa tgtctataaa gccacaagac 1920
catatctagc tcattgtcct gactgcggag aagggcattc gtgccacagc cctatcgcat 1980
tggagcgcat cagaaatgaa gcaacggacg gaacgctgaa aatccaggtc tctttgcaga 2040
tcgggataaa gacagatgac agccacgatt ggaccaagct gcgctatatg gatagccata 2100
cgccagcgga cgcggagcga gccggattgc ttgtaaggac ttcagcaccg tgcacgatca 2160
ccgggaccat gggacacttt attctcgccc gatgcccgaa aggagagacg ctgacagtgg 2220
gatttacgga cagcagaaag atcagccaca catgcacaca cccgttccat catgaaccac 2280
ctgtgatagg tagggagagg ttccactctc gaccacaaca tggtaaagag ttaccttgca 2340
gcacgtacgt gcagagcacc gctgccactg ctgaggagat agaggtgcat atgcccccag 2400
atactcctga ccgcacgctg atgacgcagc agtctggcaa cgtgaagatc acagttaatg 2460
ggcagacggt gcggtacaag tgcaactgcg gtggctccgg aggcggcgcc atcagcctgc 2520
accccaaggc caagatcgag gaatctggat ccaacgaggg actgacaacc acagacaaag 2580
tgatcaataa ctgcaaaatt gatcagtgcc atgctgcagt cactaatcac aagaattggc 2640
aatacaactc ccctttagtc ccgcgcaacg ctgaactcgg ggaccgtaaa ggaaagatcc 2700
acatcccatt cccattggca aacgtgactt gcagagtgcc aaaagcaaga aaccctacag 2760
taacttacgg aaaaaaccaa gtcaccatgc tgctgtatcc tgaccatccg acactcttgt 2820
cttaccgtaa catgggacag gaaccaaatt accacgagga gtgggtgaca cacaagaagg 2880
aggttacctt gaccgtgcct actgagggtc tggaggtcac ttggggcaac aacgaaccat 2940
acaagtactg gccgcagatg tctacgaacg gtactgctca tggtcaccca catgagataa 3000
tcttgtacta ttatgagctg taccccacta tgactgtagt cattgtgtcg gtggcctcgt 3060
tcgtgcttct gtcgatggtg ggcacagcag tgggaatgtg tgtgtgcgca cggcgcagat 3120
gcattacacc atatgaatta acaccaggag ccactgttcc cttcctgctc agcctgctat 3180
gctgcgtcag aacgaccaag gcggccacat attacgaggc tgcggcatat ctatggaacg 3240
aacagcagcc cctgttctgg ttgcaggctc ttatcccgct ggccgccttg atcgtcctgt 3300
gcaactgtct gaaactcttg ccatgctgct gtaagaccct ggctttttta gccgtaatga 3360
gcatcggtgc ccacactgtg agcgcgtacg aacacgtaac agtgatcccg aacacggtgg 3420
gagtaccgta taagactctt gtcaacagac cgggttacag ccccatggtg ttggagatgg 3480
agctacaatc agtcaccttg gaaccaacac tgtcacttga ctacatcacg tgcgagtaca 3540
aaactgtcat cccctccccg tacgtgaagt gctgtggtac agcagagtgc aaggacaaga 3600
gcctaccaga ctacagctgc aaggtcttta ctggagtcta cccatttatg tggggcggcg 3660
cctactgctt ttgcgacgcc gaaaatacgc aattgagcga ggcacatgta gagaaatctg 3720
aatcttgcaa aacagagttt gcatcggcct acagagccca caccgcatcg gcgtcggcga 3780
agctccgcgt cctttaccaa ggaaacaaca ttaccgtagc tgcctacgct aacggtgacc 3840
atgccgtcac agtaaaggac gccaagtttg tcgtgggccc aatgtcctcc gcctggacac 3900
cttttgacaa caaaatcgtg gtgtacaaag gcgacgtcta caacatggac tacccacctt 3960
ttggcgcagg aagaccagga caatttggtg acattcaaag tcgtacaccg gaaagtaaag 4020
acgtttatgc caacactcag ttggtactac agaggccagc agcaggcacg gtacatgtac 4080
catactctca ggcaccatct ggcttcaagt attggctgaa ggaacgagga gcatcgctac 4140
agcacacggc accgttcggt tgccagattg cgacaaaccc ggtaagagct gtaaattgcg 4200
ctgtggggaa cataccaatt tccatcgaca taccggatgc ggcctttact agggttgtcg 4260
atgcaccctc tgtaacggac atgtcatgcg aagtaccagc ctgcactcac tcctccgact 4320
ttgggggcgt cgccatcatc aaatacacag ctagcaagaa aggtaaatgt gcagtacatt 4380
cgatgaccaa cgccgttacc attcgagaag ccgacgtaga agtagagggg aactcccagc 4440
tgcaaatatc cttctcaaca gccctggcaa gcgccgagtt tcgcgtgcaa gtgtgctcca 4500
cacaagtaca ctgcgcagcc gcatgccacc ctccaaagga ccacatagtc aattacccag 4560
catcacacac cacccttggg gtccaggata tatccacaac ggcaatgtct tgggtgcaga 4620
agattacggg aggagtagga ttaattgttg ctgttgctgc cttaatttta attgtggtgc 4680
tatgcgtgtc gtttagcagg cactaaggat ctagatctgc tgtgccttct agttgccagc 4740
catctgttgt ttgcccctcc cccgtgcctt ccttgaccct ggaaggtgcc actcccactg 4800
tcctttccta ataaaatgag gaaattgcat cgcattgtct gagtaggtgt cattctattc 4860
tggggggtgg ggtggggcag gacagcaagg gggaggattg ggaagacaat agcaggcatg 4920
ctggggatgc ggtgggctct atgggtaccc aggtgctgaa gaattgaccc ggttcctcct 4980
gggccagaaa gaagcaggca catccccttc tctgtgacac accctgtcca cgcccctggt 5040
tcttagttcc agccccactc ataggacact catagctcag gagggctccg ccttcaatcc 5100
cacccgctaa agtacttgga gcggtctctc cctccctcat cagcccacca aaccaaacct 5160
agcctccaag agtgggaaga aattaaagca agataggcta ttaagtgcag agggagagaa 5220
aatgcctcca acatgtgagg aagtaatgag agaaatcata gaattttaag gccatgattt 5280
aaggccatca tggcctaagc ttgaaaggag ataggatcaa agcttggcgt aatcatggtc 5340
atagctgttt cctgtgtgaa attgttatcc gctcacaatt ccacacaaca tacgagccgg 5400
aagcataaag tgtaaagcct ggggtgccta atgagtgagc taactcacat taattgcgtt 5460
gcgctcactg cccgctttcc agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg 5520
ccaacgcgcg gggagaggcg gtttgcgtat tgggcgctct tccgcttcct cgctcactga 5580
ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca gctcactcaa aggcggtaat 5640
acggttatcc acagaatcag gggataacgc aggaaagaac atgtgagcaa aaggccagca 5700
aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc 5760
tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata 5820
aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 5880
gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc 5940
acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga 6000
accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 6060
ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag 6120
gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag 6180
aacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag 6240
ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca 6300
gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga 6360
cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat caaaaaggat 6420
cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga 6480
gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg 6540
tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta cgatacggga 6600
gggcttacca tctggcccca gtgctgcaat gataccgcga gaaccacgct caccggctcc 6660
agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac 6720
tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 6780
agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc 6840
gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc 6900
catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt 6960
ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc 7020
atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg 7080
tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag 7140
cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat 7200
cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc 7260
atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa 7320
aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 7380
ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa 7440
aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtctaaga 7500
aaccattatt atcatgacat taacctataa aaataggcgt atcacgaggc cctttcgggt 7560
cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgt tgacggtcac 7620
agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgt cagcgggtgt 7680
tggcgggtgt cggggctggc ttaactatgc ggcatcagag cagattgtac tgagagtgca 7740
ccataaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag 7800
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagcc 7860
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 7920
ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc 7980
acccaaatca agttttttgg ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg 8040
gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa 8100
gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac 8160
caccacaccc gccgcgctta atgcgccgct acagggcgcg tactatggtt gctttgacgt 8220
atgcggtgtg aaataccgca cagatgcgta aggagaaaat accgcatcag gcgccattcg 8280
ccattcaggc tgcgcaactg ttgggaaggg cgatcggtgc gggcctcttc gctattacgc 8340
cagctggcga aagggggatg tgctgcaagg cgattaagtt gggtaacgcc agggttttcc 8400
cagtcacgac gttgtaaaac gacggccagt gaattccatg gtctcaactt tc 8452
<210> 47
<211> 7290
<212> DNA
<213> Artificial
<220>
<223> VLP299.15 vector
<400> 47
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc 240
attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat 300
tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt 360
tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt gacgcgtgtt ggcattgatt 420
attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga 480
gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg 540
cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg 600
acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca 660
tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc 720
ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc 780
tattaccatg gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc 840
acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt ggcaccaaaa 900
tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag 960
gcgtgtacgg tgggaggtct atataagcag agctcgttta gtgaaccgtc agataactgc 1020
aggtcgacga tatcgcggcc gccaccatgt tcccgttcca gccaatgtat ccgatgcagc 1080
caatgcccta tcgcaacccg ttcgcggccc cgcgcaggcc ctggttcccc agaaccgacc 1140
cttttctggc gatgcaggtg caggaattaa cccgctcgat ggctaacctg acgttcaagc 1200
aacgccggga cgcgccacct gaggggccat ccgctaataa accgaagaag gaggcctcgc 1260
aaaaacagaa agggggaggc caagggaaga agaagaagaa ccaagggaag aagaaggcta 1320
agacagggcc gcctaatccg aaggcacaga atggaaacaa gaagaagacc aacaagaaac 1380
caggcaagag acagcgcatg gtcatgaaat tggaatctga caagacgttc ccaatcatgt 1440
tggaagggaa gataaacggc tacgcttgtg tggtcggagg gaagttattc aggccgatgc 1500
atgtggaagg caagatcgac aacgacgttc tggccgcgct taagacgaag aaagcatcca 1560
aatacgatct tgagtatgca gatgtgccac agaacatgcg ggccgataca ttcaaataca 1620
cccatgagaa accccaaggc tattacagct ggcatcatgg agcagtccaa tatgaaaatg 1680
ggcgtttcac ggtgccgaaa ggagttgggg ccaagggaga cagcggacga cccattctgg 1740
ataaccaggg acgggtggtc gctattgtgc tgggaggtgt gaatgaagga tctaggacag 1800
ccctttcagt cgtcatgtgg aacgagaagg gagttaccgt gaagtatact ccagagaact 1860
gcgagcaatg gtcactagtg accaccatgt gtctgctcgc caatgtgacg ttcccatgtg 1920
ctcaaccacc aatttgctac gacagaaaac cagcagagac tttggccatg ctcagcgtta 1980
acgttgacaa cccgggctac gatgagctgc tggaagcagc tgttaagtgc cccggaagga 2040
aaaggagatc caccgaggag ctgtttaatg agtataagct aacgcgccct tacatggcca 2100
gatgcatcag atgtgcagtt gggagctgcc atagtccaat agcaatcgag gcagtaaaga 2160
gcgacgggca cgacggttat gttagacttc agacttcctc gcagtatggc ctggattcct 2220
ccggcaactt aaagggcagg accatgcggt atgacatgca cgggaccatt aaagagatac 2280
cactacatca agtgtcactc tatacatctc gcccgtgtca cattgtggat gggcacggtt 2340
atttcctgct tgccaggtgc ccggcagggg actccatcac catggaattt aagaaagatt 2400
ccgtcagaca ctcctgctcg gtgccgtatg aagtgaaatt taatcctgta ggcagagaac 2460
tctatactca tcccccagaa cacggagtag agcaagcgtg ccaagtctac gcacatgatg 2520
cacagaacag aggagcttat gtcgagatgc acctcccggg ctcagaagtg gacagcagtt 2580
tggtttcctt gagcggcagt tccggaggct gcatcatcag ctacggcgga gccgactact 2640
gcggcggatc ctcagtcacc gtgacacctc ctgatgggac tagcgccctg gtggaatgcg 2700
agtgtggcgg cacaaagatc tccgagacca tcaacaagac aaaacagttc agccagtgca 2760
caaagaagga gcagtgcaga gcatatcggc tgcagaacga taagtgggtg tataattctg 2820
acaaactgcc caaagcagcg ggagccacct taaaaggaaa actgcatgtc ccattcttgc 2880
tggcagacgg caaatgcacc gtgcctctag caccagaacc tatgataacc ttcggtttca 2940
gatcagtgtc actgaaactg caccctaaga atcccacata tctaatcacc cgccaacttg 3000
ctgatgagcc tcactacacg cacgagctca tatctgaacc agctgttagg aattttaccg 3060
tcaccgaaaa agggtgggag tttgtatggg gaaaccaccc gccgaaaagg ttttgggcac 3120
aggaaacagc acccggaaat ccacatgggc taccgcacga ggtgataact cattattacc 3180
acagataccc tatgtccacc atcctgggtt tgtcaatttg tgccgccatt gcaaccgttt 3240
ccgttgcagc gtctacctgg ctgttttgca gatcaagagt tgcgtgccta actccttacc 3300
ggctaacacc taacgctagg ataccatttt gtctggctgt gctttgctgc gcccgcactg 3360
cccgggccga gaccacctgg gagtccttgg atcacctatg gaacaataac caacagatgt 3420
tctggattca attgctgatc cctctggccg ccttgatcgt agtgactcgc ctgctcaggt 3480
gcgtgtgctg tgtcgtgcct tttttagtca tggccggcgc cgcaggcgcc ggcgcctacg 3540
agcacgcgac cacgatgccg agccaagcgg gaatctcgta taacactata gtcaacagag 3600
caggctacgc accactccct atcagcataa caccaacaaa gatcaagctg atacctacag 3660
tgaacttgga gtacgtcacc tgccactaca aaacaggaat ggattcacca gccatcaaat 3720
gctgcggatc tcaggaatgc actccaactt acaggcctga tgaacagtgc aaagtcttca 3780
caggggttta cccgttcatg tggggtggtg catattgctt ttgcgacact gagaacaccc 3840
aagtcagcaa ggcctacgta atgaaatctg acgactgcct tgcggatcat gctgaagcat 3900
ataaagcgca cacagcctca gtgcaggcgt tcctcaacat cacagtggga gaacactcta 3960
ttgtgactac cgtgtatgtg aatggagaaa ctcctgtgaa tttcaatggg gtcaaaataa 4020
ctgcaggtcc gctttccaca gcttggacac cctttgatcg caaaatcgtg cagtatgccg 4080
gggagatata taattatgat tttcctgagt atggggcagg acaaccagga gcatttggag 4140
atatacaatc cagaacagtc tcaagctctg atctgtatgc caataccaac ctagtgctgc 4200
agagacccaa agcaggagcg atccacgtgc catacactca ggcaccttcg ggttttgagc 4260
aatggaagaa agataaagct ccatcattga aatttaccgc ccctttcgga tgcgaaatat 4320
atacaaaccc cattcgcgcc gaaaactgtg ctgtagggtc aattccatta gcctttgaca 4380
ttcccgacgc cttgttcacc agggtgtcag aaacaccgac actttcagcg gccgaatgca 4440
ctcttaacga gtgcgtgtat tcttccgact ttggtgggat cgccacggtc aagtactcgg 4500
ccagcaagtc aggcaagtgc gcagtccatg tgccatcagg gactgctacc ctaaaagaag 4560
cagcagtcga gctaaccgag caagggtcgg cgactatcca tttctcgacc gcaaatatcc 4620
acccggagtt caggctccaa atatgcacat catatgttac gtgcaaaggt gattgtcacc 4680
ccccgaaaga ccatattgtg acacaccctc agtatcacgc ccaaacattt acagccgcgg 4740
tgtcaaaaac cgcgtggacg tggttaacat ccctgctggg aggatcagcc gtaattatta 4800
taattggctt ggtgctggct actattgtgg ccatgtacgt gctgaccaac cagaaacata 4860
attaaggatc tagatctgct gtgccttcta gttgccagcc atctgttgtt tgcccctccc 4920
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 4980
aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 5040
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 5100
tggctcgagc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc acaattccac 5160
acaacatacg agccggaagc ataaagtgta aagcctgggg tgcctaatga gtgagctaac 5220
tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg tcgtgccagc 5280
tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg 5340
cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc 5400
actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt 5460
gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc 5520
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 5580
acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 5640
ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 5700
cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc 5760
tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc 5820
gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca 5880
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 5940
acggctacac tagaagaaca gtatttggta tctgcgctct gctgaagcca gttaccttcg 6000
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt 6060
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6120
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga 6180
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 6240
tctaaagtat atatgagtaa acttggtctg acagttagaa aaactcatcg agcatcaaat 6300
gaaactgcaa tttattcata tcaggattat caataccata tttttgaaaa agccgtttct 6360
gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc tggtatcggt 6420
ctgcgattcc gactcgtcca acatcaatac aacctattaa tttcccctcg tcaaaaataa 6480
ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat ggcaaaagtt 6540
tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca tcaaaatcac 6600
tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg agcgagacga aatacgcgat 6660
cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg aacactgcca 6720
gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg aatgctgttt 6780
tcccagggat cgcagtggtg agtaaccatg catcatcagg agtacggata aaatgcttga 6840
tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca tctgtaacat 6900
cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg ggcttcccat 6960
acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat ttatacccat 7020
ataaatcagc atccatgttg gaatttaatc gcggcctaga gcaagacgtt tcccgttgaa 7080
tatggctcat actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca 7140
tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat 7200
ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata 7260
aaaataggcg tatcacgagg ccctttcgtc 7290
<210> 48
<211> 8491
<212> DNA
<213> Artificial
<220>
<223> VLP31.21 vector
<400> 48
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgtt cccgttccag ccaatgtatc cgatgcagcc aatgccctat cgcaacccgt 960
tcgcggcccc gcgcaggccc tggttcccca gaaccgaccc ttttctggcg atgcaggtgc 1020
aggaattaac ccgctcgatg gctaacctga cgttcaagca acgccgggac gcgccacctg 1080
aggggccatc cgctaataaa ccgaagaagg aggcctcgca aaaacagaaa gggggaggcc 1140
aagggaagaa gaagaagaac caagggaaga agaaggctaa gacagggccg cctaatccga 1200
aggcacagaa tggaaacaag aagaagacca acaagaaacc aggcaagaga cagcgcatgg 1260
tcatgaaatt ggaatctgac aagacgttcc caatcatgtt ggaagggaag ataaacggct 1320
acgcttgtgt ggtcggaggg aagttattca ggccgatgca tgtggaaggc aagatcgaca 1380
acgacgttct ggccgcgctt aagacgaaga aagcatccaa atacgatctt gagtatgcag 1440
atgtgccaca gaacatgcgg gccgatacat tcaaatacac ccatgagaaa ccccaaggct 1500
attacagctg gcatcatgga gcagtccaat atgaaaatgg gcgtttcacg gtgccgaaag 1560
gagttggggc caagggagac agcggacgac ccattctgga taaccaggga cgggtggtcg 1620
ctattgtgct gggaggtgtg aatgaaggat ctaggacagc cctttcagtc gtcatgtgga 1680
acgagaaggg agttaccgtg aagtatactc cagagaactg cgagcaatgg tcactagtga 1740
ccaccatgtg tctgctcgcc aatgtgacgt tcccatgtgc tcaaccacca atttgctacg 1800
acagaaaacc agcagagact ttggccatgc tcagcgttaa cgttgacaac ccgggctacg 1860
atgagctgct ggaagcagct gttaagtgcc ccggaaggaa aaggagatcc accgaggagc 1920
tgtttaatga gtataagcta acgcgccctt acatggccag atgcatcaga tgtgcagttg 1980
ggagctgcca tagtccaata gcaatcgagg cagtaaagag cgacgggcac gacggttatg 2040
ttagacttca gacttcctcg cagtatggcc tggattcctc cggcaactta aagggcagga 2100
ccatgcggta tgacatgcac gggaccatta aagagatacc actacatcaa gtgtcactct 2160
atacatctcg cccgtgtcac attgtggatg ggcacggtta tttcctgctt gccaggtgcc 2220
cggcagggga ctccatcacc atggaattta agaaagattc cgtcagacac tcctgctcgg 2280
tgccgtatga agtgaaattt aatcctgtag gcagagaact ctatactcat cccccagaac 2340
acggagtaga gcaagcgtgc caagtctacg cacatgatgc acagaacaga ggagcttatg 2400
tcgagatgca cctcccgggc tcagaagtgg acagcagttt ggtttccttg agcggcagtt 2460
ccggaggact aaactggtac cgcatgagcc ccagcaacca gacggacaag ctggccgcct 2520
tcggaggatc ctcagtcacc gtgacacctc ctgatgggac tagcgccctg gtggaatgcg 2580
agtgtggcgg cacaaagatc tccgagacca tcaacaagac aaaacagttc agccagtgca 2640
caaagaagga gcagtgcaga gcatatcggc tgcagaacga taagtgggtg tataattctg 2700
acaaactgcc caaagcagcg ggagccacct taaaaggaaa actgcatgtc ccattcttgc 2760
tggcagacgg caaatgcacc gtgcctctag caccagaacc tatgataacc ttcggtttca 2820
gatcagtgtc actgaaactg caccctaaga atcccacata tctaatcacc cgccaacttg 2880
ctgatgagcc tcactacacg cacgagctca tatctgaacc agctgttagg aattttaccg 2940
tcaccgaaaa agggtgggag tttgtatggg gaaaccaccc gccgaaaagg ttttgggcac 3000
aggaaacagc acccggaaat ccacatgggc taccgcacga ggtgataact cattattacc 3060
acagataccc tatgtccacc atcctgggtt tgtcaatttg tgccgccatt gcaaccgttt 3120
ccgttgcagc gtctacctgg ctgttttgca gatcaagagt tgcgtgccta actccttacc 3180
ggctaacacc taacgctagg ataccatttt gtctggctgt gctttgctgc gcccgcactg 3240
cccgggccga gaccacctgg gagtccttgg atcacctatg gaacaataac caacagatgt 3300
tctggattca attgctgatc cctctggccg ccttgatcgt agtgactcgc ctgctcaggt 3360
gcgtgtgctg tgtcgtgcct tttttagtca tggccggcgc cgcaggcgcc ggcgcctacg 3420
agcacgcgac cacgatgccg agccaagcgg gaatctcgta taacactata gtcaacagag 3480
caggctacgc accactccct atcagcataa caccaacaaa gatcaagctg atacctacag 3540
tgaacttgga gtacgtcacc tgccactaca aaacaggaat ggattcacca gccatcaaat 3600
gctgcggatc tcaggaatgc actccaactt acaggcctga tgaacagtgc aaagtcttca 3660
caggggttta cccgttcatg tggggtggtg catattgctt ttgcgacact gagaacaccc 3720
aagtcagcaa ggcctacgta atgaaatctg acgactgcct tgcggatcat gctgaagcat 3780
ataaagcgca cacagcctca gtgcaggcgt tcctcaacat cacagtggga gaacactcta 3840
ttgtgactac cgtgtatgtg aatggagaaa ctcctgtgaa tttcaatggg gtcaaaataa 3900
ctgcaggtcc gctttccaca gcttggacac cctttgatcg caaaatcgtg cagtatgccg 3960
gggagatcta taattatgat tttcctgagt atggggcagg acaaccagga gcatttggag 4020
atatacaatc cagaacagtc tcaagctctg atctgtatgc caataccaac ctagtgctgc 4080
agagacccaa agcaggagcg atccacgtgc catacactca ggcaccttcg ggttttgagc 4140
aatggaagaa agataaagct ccatcattga aatttaccgc ccctttcgga tgcgaaatat 4200
atacaaaccc cattcgcgcc gaaaactgtg ctgtagggtc aattccatta gcctttgaca 4260
ttcccgacgc cttgttcacc agggtgtcag aaacaccgac actttcagcg gccgaatgca 4320
ctcttaacga gtgcgtgtat tcttccgact ttggtgggat cgccacggtc aagtactcgg 4380
ccagcaagtc aggcaagtgc gcagtccatg tgccatcagg gactgctacc ctaaaagaag 4440
cagcagtcga gctaaccgag caagggtcgg cgactatcca tttctcgacc gcaaatatcc 4500
acccggagtt caggctccaa atatgcacat catatgttac gtgcaaaggt gattgtcacc 4560
ccccgaaaga ccatattgtg acacaccctc agtatcacgc ccaaacattt acagccgcgg 4620
tgtcaaaaac cgcgtggacg tggttaacat ccctgctggg aggatcagcc gtaattatta 4680
taattggctt ggtgctggct actattgtgg ccatgtacgt gctgaccaac cagaaacata 4740
attaaggatc tagatctgct gtgccttcta gttgccagcc atctgttgtt tgcccctccc 4800
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 4860
aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 4920
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 4980
tgggtaccca ggtgctgaag aattgacccg gttcctcctg ggccagaaag aagcaggcac 5040
atccccttct ctgtgacaca ccctgtccac gcccctggtt cttagttcca gccccactca 5100
taggacactc atagctcagg agggctccgc cttcaatccc acccgctaaa gtacttggag 5160
cggtctctcc ctccctcatc agcccaccaa accaaaccta gcctccaaga gtgggaagaa 5220
attaaagcaa gataggctat taagtgcaga gggagagaaa atgcctccaa catgtgagga 5280
agtaatgaga gaaatcatag aattttaagg ccatgattta aggccatcat ggcctaagct 5340
tgaaaggaga taggatcaaa gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa 5400
ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg 5460
gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca 5520
gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg 5580
tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg 5640
gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg 5700
ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa 5760
ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg 5820
acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc 5880
tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc 5940
ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt atctcagttc 6000
ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg 6060
ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc 6120
actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga 6180
gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg gtatctgcgc 6240
tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac 6300
caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg 6360
atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc 6420
acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa 6480
ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta 6540
ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt 6600
tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag 6660
tgctgcaatg ataccgcgag aaccacgctc accggctcca gatttatcag caataaacca 6720
gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc 6780
tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt 6840
tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag 6900
ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt 6960
tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat 7020
ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt 7080
gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc 7140
ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat 7200
cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag 7260
ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt 7320
ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg 7380
gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta 7440
ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc 7500
gcgcacattt ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt 7560
aacctataaa aataggcgta tcacgaggcc ctttcgggtc gcgcgtttcg gtgatgacgg 7620
tgaaaacctc tgacacatgc agctcccgtt gacggtcaca gcttgtctgt aagcggatgc 7680
cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc ggggctggct 7740
taactatgcg gcatcagagc agattgtact gagagtgcac cataaaattg taaacgttaa 7800
tattttgtta aaattcgcgt taaatttttg ttaaatcagc tcatttttta accaataggc 7860
cgaaatcggc aaaatccctt ataaatcaaa agaatagccc gagatagggt tgagtgttgt 7920
tccagtttgg aacaagagtc cactattaaa gaacgtggac tccaacgtca aagggcgaaa 7980
aaccgtctat cagggcgatg gcccactacg tgaaccatca cccaaatcaa gttttttggg 8040
gtcgaggtgc cgtaaagcac taaatcggaa ccctaaaggg agcccccgat ttagagcttg 8100
acggggaaag ccggcgaacg tggcgagaaa ggaagggaag aaagcgaaag gagcgggcgc 8160
tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc accacacccg ccgcgcttaa 8220
tgcgccgcta cagggcgcgt actatggttg ctttgacgta tgcggtgtga aataccgcac 8280
agatgcgtaa ggagaaaata ccgcatcagg cgccattcgc cattcaggct gcgcaactgt 8340
tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc agctggcgaa agggggatgt 8400
gctgcaaggc gattaagttg ggtaacgcca gggttttccc agtcacgacg ttgtaaaacg 8460
acggccagtg aattccatgg tctcaacttt c 8491
<210> 49
<211> 8476
<212> DNA
<213> Artificial
<220>
<223> VLP274.21 vector
<400> 49
gaattcccat tgcatacgtt gtatccatat cataatatgt acatttatat tggctcatgt 60
ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta atcaattacg 120
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 180
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 240
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 300
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 360
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 420
tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac 480
atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac 540
gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg tcgtaacaac 600
tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta tataagcaga 660
gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt tgacctccat 720
agaagacacc gggaccgatc cagcctccgt taacggtgga gggcagtgta gtctgagcag 780
tactcgttgc tgccgcgcgc gccaccagac ataatagctg acagactaac agactgttcc 840
tttccatggg tcttttctgc agtcaccgtc gtcgacacgt gtgatcagat atcgcggccg 900
ccaccatgtt cccgttccag ccaatgtatc cgatgcagcc aatgccctat cgcaacccgt 960
tcgcggcccc gcgcaggccc tggttcccca gaaccgaccc ttttctggcg atgcaggtgc 1020
aggaattaac ccgctcgatg gctaacctga cgttcaagca acgccgggac gcgccacctg 1080
aggggccatc cgctaataaa ccgaagaagg aggcctcgca aaaacagaaa gggggaggcc 1140
aagggaagaa gaagaagaac caagggaaga agaaggctaa gacagggccg cctaatccga 1200
aggcacagaa tggaaacaag aagaagacca acaagaaacc aggcaagaga cagcgcatgg 1260
tcatgaaatt ggaatctgac aagacgttcc caatcatgtt ggaagggaag ataaacggct 1320
acgcttgtgt ggtcggaggg aagttattca ggccgatgca tgtggaaggc aagatcgaca 1380
acgacgttct ggccgcgctt aagacgaaga aagcatccaa atacgatctt gagtatgcag 1440
atgtgccaca gaacatgcgg gccgatacat tcaaatacac ccatgagaaa ccccaaggct 1500
attacagctg gcatcatgga gcagtccaat atgaaaatgg gcgtttcacg gtgccgaaag 1560
gagttggggc caagggagac agcggacgac ccattctgga taaccaggga cgggtggtcg 1620
ctattgtgct gggaggtgtg aatgaaggat ctaggacagc cctttcagtc gtcatgtgga 1680
acgagaaggg agttaccgtg aagtatactc cagagaactg cgagcaatgg tcactagtga 1740
ccaccatgtg tctgctcgcc aatgtgacgt tcccatgtgc tcaaccacca atttgctacg 1800
acagaaaacc agcagagact ttggccatgc tcagcgttaa cgttgacaac ccgggctacg 1860
atgagctgct ggaagcagct gttaagtgcc ccggaaggaa aaggagatcc accgaggagc 1920
tgtttaatga gtataagcta acgcgccctt acatggccag atgcatcaga tgtgcagttg 1980
ggagctgcca tagtccaata gcaatcgagg cagtaaagag cgacgggcac gacggttatg 2040
ttagacttca gacttcctcg cagtatggcc tggattcctc cggcaactta aagggcagga 2100
ccatgcggta tgacatgcac gggaccatta aagagatacc actacatcaa gtgtcactct 2160
atacatctcg cccgtgtcac attgtggatg ggcacggtta tttcctgctt gccaggtgcc 2220
cggcagggga ctccatcacc atggaattta agaaagattc cgtcagacac tcctgctcgg 2280
tgccgtatga agtgaaattt aatcctgtag gcagagaact ctatactcat cccccagaac 2340
acggagtaga gcaagcgtgc caagtctacg cacatgatgc acagaacaga ggagcttatg 2400
tcgagatgca cctcccgggc tcagaagtgg acagcagttt ggtttccttg agcggcagtt 2460
ccggaggcgg cgccatcagc ctgcacccca aggccaagat cgaggaatct ggatcctcag 2520
tcaccgtgac acctcctgat gggactagcg ccctggtgga atgcgagtgt ggcggcacaa 2580
agatctccga gaccatcaac aagacaaaac agttcagcca gtgcacaaag aaggagcagt 2640
gcagagcata tcggctgcag aacgataagt gggtgtataa ttctgacaaa ctgcccaaag 2700
cagcgggagc caccttaaaa ggaaaactgc atgtcccatt cttgctggca gacggcaaat 2760
gcaccgtgcc tctagcacca gaacctatga taaccttcgg tttcagatca gtgtcactga 2820
aactgcaccc taagaatccc acatatctaa tcacccgcca acttgctgat gagcctcact 2880
acacgcacga gctcatatct gaaccagctg ttaggaattt taccgtcacc gaaaaagggt 2940
gggagtttgt atggggaaac cacccgccga aaaggttttg ggcacaggaa acagcacccg 3000
gaaatccaca tgggctaccg cacgaggtga taactcatta ttaccacaga taccctatgt 3060
ccaccatcct gggtttgtca atttgtgccg ccattgcaac cgtttccgtt gcagcgtcta 3120
cctggctgtt ttgcagatca agagttgcgt gcctaactcc ttaccggcta acacctaacg 3180
ctaggatacc attttgtctg gctgtgcttt gctgcgcccg cactgcccgg gccgagacca 3240
cctgggagtc cttggatcac ctatggaaca ataaccaaca gatgttctgg attcaattgc 3300
tgatccctct ggccgccttg atcgtagtga ctcgcctgct caggtgcgtg tgctgtgtcg 3360
tgcctttttt agtcatggcc ggcgccgcag gcgccggcgc ctacgagcac gcgaccacga 3420
tgccgagcca agcgggaatc tcgtataaca ctatagtcaa cagagcaggc tacgcaccac 3480
tccctatcag cataacacca acaaagatca agctgatacc tacagtgaac ttggagtacg 3540
tcacctgcca ctacaaaaca ggaatggatt caccagccat caaatgctgc ggatctcagg 3600
aatgcactcc aacttacagg cctgatgaac agtgcaaagt cttcacaggg gtttacccgt 3660
tcatgtgggg tggtgcatat tgcttttgcg acactgagaa cacccaagtc agcaaggcct 3720
acgtaatgaa atctgacgac tgccttgcgg atcatgctga agcatataaa gcgcacacag 3780
cctcagtgca ggcgttcctc aacatcacag tgggagaaca ctctattgtg actaccgtgt 3840
atgtgaatgg agaaactcct gtgaatttca atggggtcaa aataactgca ggtccgcttt 3900
ccacagcttg gacacccttt gatcgcaaaa tcgtgcagta tgccggggag atctataatt 3960
atgattttcc tgagtatggg gcaggacaac caggagcatt tggagatata caatccagaa 4020
cagtctcaag ctctgatctg tatgccaata ccaacctagt gctgcagaga cccaaagcag 4080
gagcgatcca cgtgccatac actcaggcac cttcgggttt tgagcaatgg aagaaagata 4140
aagctccatc attgaaattt accgcccctt tcggatgcga aatatataca aaccccattc 4200
gcgccgaaaa ctgtgctgta gggtcaattc cattagcctt tgacattccc gacgccttgt 4260
tcaccagggt gtcagaaaca ccgacacttt cagcggccga atgcactctt aacgagtgcg 4320
tgtattcttc cgactttggt gggatcgcca cggtcaagta ctcggccagc aagtcaggca 4380
agtgcgcagt ccatgtgcca tcagggactg ctaccctaaa agaagcagca gtcgagctaa 4440
ccgagcaagg gtcggcgact atccatttct cgaccgcaaa tatccacccg gagttcaggc 4500
tccaaatatg cacatcatat gttacgtgca aaggtgattg tcaccccccg aaagaccata 4560
ttgtgacaca ccctcagtat cacgcccaaa catttacagc cgcggtgtca aaaaccgcgt 4620
ggacgtggtt aacatccctg ctgggaggat cagccgtaat tattataatt ggcttggtgc 4680
tggctactat tgtggccatg tacgtgctga ccaaccagaa acataattaa ggatctagat 4740
ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg ccttccttga 4800
ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 4860
gtctgagtag gtgtcattct attctggggg gtggggtggg gcaggacagc aagggggagg 4920
attgggaaga caatagcagg catgctgggg atgcggtggg ctctatgggt acccaggtgc 4980
tgaagaattg acccggttcc tcctgggcca gaaagaagca ggcacatccc cttctctgtg 5040
acacaccctg tccacgcccc tggttcttag ttccagcccc actcatagga cactcatagc 5100
tcaggagggc tccgccttca atcccacccg ctaaagtact tggagcggtc tctccctccc 5160
tcatcagccc accaaaccaa acctagcctc caagagtggg aagaaattaa agcaagatag 5220
gctattaagt gcagagggag agaaaatgcc tccaacatgt gaggaagtaa tgagagaaat 5280
catagaattt taaggccatg atttaaggcc atcatggcct aagcttgaaa ggagatagga 5340
tcaaagcttg gcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac 5400
aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt 5460
gagctaactc acattaattg cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc 5520
gtgccagctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg 5580
ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt 5640
atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa 5700
gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc 5760
gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag 5820
gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt 5880
gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg 5940
aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg 6000
ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg 6060
taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac 6120
tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg 6180
gcctaactac ggctacacta gaagaacagt atttggtatc tgcgctctgc tgaagccagt 6240
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg 6300
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 6360
tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt 6420
ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 6480
taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 6540
tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt 6600
cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg caatgatacc 6660
gcgagaacca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc 6720
cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg 6780
ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac 6840
aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg 6900
atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc 6960
tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact 7020
gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 7080
aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat 7140
acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 7200
ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac 7260
tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa 7320
aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 7380
catactcttc ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg 7440
atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg 7500
aaaagtgcca cctgacgtct aagaaaccat tattatcatg acattaacct ataaaaatag 7560
gcgtatcacg aggccctttc gggtcgcgcg tttcggtgat gacggtgaaa acctctgaca 7620
catgcagctc ccgttgacgg tcacagcttg tctgtaagcg gatgccggga gcagacaagc 7680
ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact atgcggcatc 7740
agagcagatt gtactgagag tgcaccataa aattgtaaac gttaatattt tgttaaaatt 7800
cgcgttaaat ttttgttaaa tcagctcatt ttttaaccaa taggccgaaa tcggcaaaat 7860
cccttataaa tcaaaagaat agcccgagat agggttgagt gttgttccag tttggaacaa 7920
gagtccacta ttaaagaacg tggactccaa cgtcaaaggg cgaaaaaccg tctatcaggg 7980
cgatggccca ctacgtgaac catcacccaa atcaagtttt ttggggtcga ggtgccgtaa 8040
agcactaaat cggaacccta aagggagccc ccgatttaga gcttgacggg gaaagccggc 8100
gaacgtggcg agaaaggaag ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag 8160
tgtagcggtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc cgctacaggg 8220
cgcgtactat ggttgctttg acgtatgcgg tgtgaaatac cgcacagatg cgtaaggaga 8280
aaataccgca tcaggcgcca ttcgccattc aggctgcgca actgttggga agggcgatcg 8340
gtgcgggcct cttcgctatt acgccagctg gcgaaagggg gatgtgctgc aaggcgatta 8400
agttgggtaa cgccagggtt ttcccagtca cgacgttgta aaacgacggc cagtgaattc 8460
catggtctca actttc 8476
<210> 50
<211> 7290
<212> DNA
<213> Artificial
<220>
<223> VLP299.25 vector
<400> 50
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgcc 240
attcgccatt caggctgcgc aactgttggg aagggcgatc ggtgcgggcc tcttcgctat 300
tacgccagct ggcgaaaggg ggatgtgctg caaggcgatt aagttgggta acgccagggt 360
tttcccagtc acgacgttgt aaaacgacgg ccagtgaatt gacgcgtgtt ggcattgatt 420
attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga 480
gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg 540
cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg 600
acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca 660
tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct ggcattatgc 720
ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc 780
tattaccatg gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc 840
acggggattt ccaagtctcc accccattga cgtcaatggg agtttgtttt ggcaccaaaa 900
tcaacgggac tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag 960
gcgtgtacgg tgggaggtct atataagcag agctcgttta gtgaaccgtc agataactgc 1020
aggtcgacga tatcgcggcc gccaccatgt tcccgttcca gccaatgtat ccgatgcagc 1080
caatgcccta tcgcaacccg ttcgcggccc cgcgcaggcc ctggttcccc agaaccgacc 1140
cttttctggc gatgcaggtg caggaattaa cccgctcgat ggctaacctg acgttcaagc 1200
aacgccggga cgcgccacct gaggggccat ccgctaataa accgaagaag gaggcctcgc 1260
aaaaacagaa agggggaggc caagggaaga agaagaagaa ccaagggaag aagaaggcta 1320
agacagggcc gcctaatccg aaggcacaga atggaaacaa gaagaagacc aacaagaaac 1380
caggcaagag acagcgcatg gtcatgaaat tggaatctga caagacgttc ccaatcatgt 1440
tggaagggaa gataaacggc tacgcttgtg tggtcggagg gaagttattc aggccgatgc 1500
atgtggaagg caagatcgac aacgacgttc tggccgcgct taagacgaag aaagcatcca 1560
aatacgatct tgagtatgca gatgtgccac agaacatgcg ggccgataca ttcaaataca 1620
cccatgagaa accccaaggc tattacagct ggcatcatgg agcagtccaa tatgaaaatg 1680
ggcgtttcac ggtgccgaaa ggagttgggg ccaagggaga cagcggacga cccattctgg 1740
ataaccaggg acgggtggtc gctattgtgc tgggaggtgt gaatgaagga tctaggacag 1800
ccctttcagt cgtcatgtgg aacgagaagg gagttaccgt gaagtatact ccagagaact 1860
gcgagcaatg gtcactagtg accaccatgt gtctgctcgc caatgtgacg ttcccatgtg 1920
ctcaaccacc aatttgctac gacagaaaac cagcagagac tttggccatg ctcagcgtta 1980
acgttgacaa cccgggctac gatgagctgc tggaagcagc tgttaagtgc cccggaagga 2040
aaaggagatc caccgaggag ctgtttaatg agtataagct aacgcgccct tacatggcca 2100
gatgcatcag atgtgcagtt gggagctgcc atagtccaat agcaatcgag gcagtaaaga 2160
gcgacgggca cgacggttat gttagacttc agacttcctc gcagtatggc ctggattcct 2220
ccggcaactt aaagggcagg accatgcggt atgacatgca cgggaccatt aaagagatac 2280
cactacatca agtgtcactc tatacatctc gcccgtgtca cattgtggat gggcacggtt 2340
atttcctgct tgccaggtgc ccggcagggg actccatcac catggaattt aagaaagatt 2400
ccgtcagaca ctcctgctcg gtgccgtatg aagtgaaatt taatcctgta ggcagagaac 2460
tctatactca tcccccagaa cacggagtag agcaagcgtg ccaagtctac gcacatgatg 2520
cacagaacag aggagcttat gtcgagatgc acctcccggg ctcagaagtg gacagcagtt 2580
tggtttcctt gagcggcagt tccggaggct gcatcatcag ctacggcgga gccgactact 2640
gcggcggatc ctcagtcacc gtgacacctc ctgatgggac tagcgccctg gtggaatgcg 2700
agtgtggcgg cacaaagatc tccgagacca tcaacaagac aaaacagttc agccagtgca 2760
caaagaagga gcagtgcaga gcatatcggc tgcagaacga taagtgggtg tataattctg 2820
acaaactgcc caaagcagcg ggagccacct taaaaggaaa actgcatgtc ccattcttgc 2880
tggcagacgg caaatgcacc gtgcctctag caccagaacc tatgataacc ttcggtttca 2940
gatcagtgtc actgaaactg caccctaaga atcccacata tctaatcacc cgccaacttg 3000
ctgatgagcc tcactacacg cacgagctca tatctgaacc agctgttagg aattttaccg 3060
tcaccgaaaa agggtgggag tttgtatggg gaaaccaccc gccgaaaagg ttttgggcac 3120
aggaaacagc acccggaaat ccacatgggc taccgcacga ggtgataact cattattacc 3180
acagataccc tatgtccacc atcctgggtt tgtcaatttg tgccgccatt gcaaccgttt 3240
ccgttgcagc gtctacctgg ctgttttgca gatcaagagt tgcgtgccta actccttacc 3300
ggctaacacc taacgctagg ataccatttt gtctggctgt gctttgctgc gcccgcactg 3360
cccgggccga gaccacctgg gagtccttgg atcacctatg gaacaataac caacagatgt 3420
tctggattca attgctgatc cctctggccg ccttgatcgt agtgactcgc ctgctcaggt 3480
gcgtgtgctg tgtcgtgcct tttttagtca tggccggcgc cgcaggcgcc ggcgcctacg 3540
agcacgcgac cacgatgccg agccaagcgg gaatctcgta taacactata gtcaacagag 3600
caggctacgc accactccct atcagcataa caccaacaaa gatcaagctg atacctacag 3660
tgaacttgga gtacgtcacc tgccactaca aaacaggaat ggattcacca gccatcaaat 3720
gctgcggatc tcaggaatgc actccaactt acaggcctga tgaacagtgc aaagtcttca 3780
caggggttta cccgttcatg tggggtggtg catattgctt ttgcgacact gagaacaccc 3840
aagtcagcaa ggcctacgta atgaaatctg acgactgcct tgcggatcat gctgaagcat 3900
ataaagcgca cacagcctca gtgcaggcgt tcctcaacat cacagtggga gaacactcta 3960
ttgtgactac cgtgtatgtg aatggagaaa ctcctgtgaa tttcaatggg gtcaaaataa 4020
ctgcaggtcc gctttccaca gcttggacac cctttgatcg caaaatcgtg cagtatgccg 4080
gggagatata taattatgat tttcctgagt atggggcagg acaaccagga gcatttggag 4140
atatacaatc cagaacagtc tcaagctctg atctgtatgc caataccaac ctagtgctgc 4200
agagacccaa agcaggagcg atccacgtgc catacactca ggcaccttcg ggttttgagc 4260
aatggaagaa agataaagct ccatcattga aatttaccgc ccctttcgga tgcgaaatat 4320
atacaaaccc cattcgcgcc gaaaactgtg ctgtagggtc aattccatta gcctttgaca 4380
ttcccgacgc cttgttcacc agggtgtcag aaacaccgac actttcagcg gccgaatgca 4440
ctcttaacga gtgcgtgtat tcttccgact ttggtgggat cgccacggtc aagtactcgg 4500
ccagcaagtc aggcaagtgc gcagtccatg tgccatcagg gactgctacc ctaaaagaag 4560
cagcagtcga gctaaccgag caagggtcgg cgactatcca tttctcgacc gcaaatatcc 4620
acccggagtt caggctccaa atatgcacat catatgttac gtgcaaaggt gattgtcacc 4680
ccccgaaaga ccatattgtg acacaccctc agtatcacgc ccaaacattt acagccgcgg 4740
tgtcaaaaac cgcgtggacg tggttaacat ccctgctggg aggatcagcc gtaattatta 4800
taattggctt ggtgctggct actattgtgg ccatgtacgt gctgaccaac cagaaacata 4860
attaaggatc tagatctgct gtgccttcta gttgccagcc atctgttgtt tgcccctccc 4920
ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 4980
aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 5040
acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 5100
tggctcgagc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc acaattccac 5160
acaacatacg agccggaagc ataaagtgta aagcctgggg tgcctaatga gtgagctaac 5220
tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg tcgtgccagc 5280
tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg cgctcttccg 5340
cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc 5400
actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt 5460
gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc 5520
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 5580
acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 5640
ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 5700
cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc 5760
tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc 5820
gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca 5880
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact 5940
acggctacac tagaagaaca gtatttggta tctgcgctct gctgaagcca gttaccttcg 6000
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt 6060
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6120
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga 6180
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 6240
tctaaagtat atatgagtaa acttggtctg acagttagaa aaactcatcg agcatcaaat 6300
gaaactgcaa tttattcata tcaggattat caataccata tttttgaaaa agccgtttct 6360
gtaatgaagg agaaaactca ccgaggcagt tccataggat ggcaagatcc tggtatcggt 6420
ctgcgattcc gactcgtcca acatcaatac aacctattaa tttcccctcg tcaaaaataa 6480
ggttatcaag tgagaaatca ccatgagtga cgactgaatc cggtgagaat ggcaaaagtt 6540
tatgcatttc tttccagact tgttcaacag gccagccatt acgctcgtca tcaaaatcac 6600
tcgcatcaac caaaccgtta ttcattcgtg attgcgcctg agcgagacga aatacgcgat 6660
cgctgttaaa aggacaatta caaacaggaa tcgaatgcaa ccggcgcagg aacactgcca 6720
gcgcatcaac aatattttca cctgaatcag gatattcttc taatacctgg aatgctgttt 6780
tcccagggat cgcagtggtg agtaaccatg catcatcagg agtacggata aaatgcttga 6840
tggtcggaag aggcataaat tccgtcagcc agtttagtct gaccatctca tctgtaacat 6900
cattggcaac gctacctttg ccatgtttca gaaacaactc tggcgcatcg ggcttcccat 6960
acaatcgata gattgtcgca cctgattgcc cgacattatc gcgagcccat ttatacccat 7020
ataaatcagc atccatgttg gaatttaatc gcggcctaga gcaagacgtt tcccgttgaa 7080
tatggctcat actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca 7140
tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat 7200
ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata 7260
aaaataggcg tatcacgagg ccctttcgtc 7290
<210> 51
<211> 72
<212> DNA
<213> Artificial
<220>
<223> VLP31 insert
<400> 51
tccggaggac taaactggta ccgcatgagc cccagcaacc agacggacaa gctggccgcc 60
ttcggaggat cc 72
<210> 52
<211> 24
<212> PRT
<213> Artificial
<220>
<223> VLP31 insert
<400> 52
Ser Gly Gly Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp
1 5 10 15
Lys Leu Ala Ala Phe Gly Gly Ser
20
<210> 53
<211> 78
<212> DNA
<213> Artificial
<220>
<223> VLP32 insert
<400> 53
tccggaggaa tgctaaactg gtaccgcatg agccccagca accagacgga caagctggcc 60
gccttctcag gaggatcc 78
<210> 54
<211> 26
<212> PRT
<213> Artificial
<220>
<223> VLP32 insert
<400> 54
Ser Gly Gly Met Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr
1 5 10 15
Asp Lys Leu Ala Ala Phe Ser Gly Gly Ser
20 25
<210> 55
<211> 78
<212> DNA
<213> Artificial
<220>
<223> VLP33 insert
<400> 55
tccggaggag tgctaaactg gtaccgcatg agccccagca accagacgga caagctggcc 60
gccttccccg gaggatcc 78
<210> 56
<211> 26
<212> PRT
<213> Artificial
<220>
<223> VLP33 insert
<400> 56
Ser Gly Gly Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr
1 5 10 15
Asp Lys Leu Ala Ala Phe Pro Gly Gly Ser
20 25
<210> 57
<211> 48
<212> DNA
<213> Artificial
<220>
<223> VLP299 insert
<400> 57
tccggaggat gcatcatcag ctacggcgga gccgactacg gaggatcc 48
<210> 58
<211> 17
<212> PRT
<213> Artificial
<220>
<223> VLP299 insert
<400> 58
Ser Gly Gly Cys Ile Ile Ser Tyr Gly Gly Ala Asp Tyr Cys Gly Gly
1 5 10 15
Ser
<210> 59
<211> 60
<212> DNA
<213> Artificial
<220>
<223> VLP274 insert
<400> 59
tccggaggag gcgccatcag cctgcacccc aaggccaaga tcgaggaatc tggaggatcc 60
<210> 60
<211> 19
<212> PRT
<213> Artificial
<220>
<223> VLP274 insert
<400> 60
Ser Gly Gly Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu Glu
1 5 10 15
Ser Gly Ser
<210> 61
<211> 60
<212> DNA
<213> Artificial
<220>
<223> VLP275 insert
<400> 61
tccggaggat gtggcgccat cagcctgcac cccaaggcca agatcgagga aggaggatcc 60
<210> 62
<211> 21
<212> PRT
<213> Artificial
<220>
<223> VLP275 insert
<400> 62
Ser Gly Gly Cys Gly Ala Ile Ser Leu His Pro Lys Ala Lys Ile Glu
1 5 10 15
Glu Cys Gly Gly Ser
20
<210> 63
<211> 3747
<212> DNA
<213> Chikungunya virus
<400> 63
atggagttca tcccaaccca aactttttac aataggaggt accagcctcg accctggact 60
ccgcgcccta ctatccaagt catcaggccc agaccgcgcc ctcagaggca agctgggcaa 120
cttgcccagc tgatctcagc agttaataaa ctgacaatgc gcgcggtacc acaacagaag 180
ccacgcagga atcggaagaa taagaagcaa aagcaaaaac aacaggcgcc acaaaacaac 240
acaaatcaaa agaagcagcc acctaaaaag aaaccggctc aaaagaaaaa gaagccgggc 300
cgcagagaga ggatgtgcat gaaaatcgaa aatgattgta ttttcgaagt caagcacgaa 360
ggtaaggtaa caggttacgc gtgcctggtg ggggacaaag taatgaaacc agcacacgta 420
aaggggacca tcgataacgc ggacctggcc aaactggcct ttaagcggtc atctaagtat 480
gaccttgaat gcgcgcagat acccgtgcac atgaagtccg acgcttcgaa gttcacccat 540
gagaaaccgg aggggtacta caactggcac cacggagcag tacagtactc aggaggccgg 600
ttcaccatcc ctacaggtgc tggcaaacca ggggacagcg gcagaccgat cttcgacaac 660
aagggacgcg tggtggccat agtcttagga ggagctaatg aaggagcccg tacagccctc 720
tcggtggtga cctggaataa agacattgtc actaaaatca cccccgaggg ggccgaagag 780
tggagtcttg ccatcccagt tatgtgcctg ttggcaaaca ccacgttccc ctgctcccag 840
cccccttgca cgccctgctg ctacgaaaag gaaccggagg aaaccctacg catgcttgag 900
gacaacgtca tgagacctgg gtactatcag ctgctacaag catccttaac atgttctccc 960
caccgccagc gacgcagcac caaggacaac ttcaatgtct ataaagccac aagaccatac 1020
ttagctcact gtcccgactg tggagaaggg cactcgtgcc atagtcccgt agcactagaa 1080
cgcatcagaa atgaagcgac agacgggacg ctgaaaatcc aggtctcctt gcaaatcgga 1140
ataaagacgg atgacagcca cgattggacc aagctgcgtt atatggacaa ccacatgcca 1200
gcagacgcag agagggcggg gctatttgta agaacatcag caccgtgtac gattactgga 1260
acaatgggac acttcatcct ggcccgatgt ccaaaagggg aaactctgac ggtgggattc 1320
actgacagta ggaagattag tcactcatgt acgcacccat ttcaccacga ccctcctgtg 1380
ataggtcggg aaaaattcca ttcccgaccg cagcacggta aagagctacc ttgcagcacg 1440
tacgtgcaga gcaccgccgc aactaccgag gagatagagg tacacatgcc cccagacacc 1500
cctgatcgca cattaatgtc acaacagtcc ggcaacgtaa agatcacagt caatggccag 1560
acggtgcggt acaagtgtaa ttgcggtggc tcaaatgaag gactaacaac tacagacaaa 1620
gtgattaata actgcaaggt tgatcaatgt catgccgcgg tcaccaatca caaaaagtgg 1680
cagtataact cccctctggt cccgcgtaat gctgaacttg gggaccgaaa aggaaaaatt 1740
cacatcccgt ttccgctggc aaatgtaaca tgcagggtgc ctaaagcaag gaaccccacc 1800
gtgacgtacg ggaaaaacca agtcatcatg ctactgtatc ctgaccaccc aacactcctg 1860
tcctaccgga atatgggaga agaaccaaac tatcaagaag agtgggtgat gcataagaag 1920
gaagtcgtgc taaccgtgcc gactgaaggg ctcgaggtca cgtggggcaa caacgagccg 1980
tataagtatt ggccgcagtt atctacaaac ggtacagccc atggccaccc gcatgagata 2040
attctgtatt attatgagct gtaccccact atgactgtag tagttgtgtc agtggccacg 2100
ttcatactcc tgtcgatggt gggtatggca gcggggatgt gcatgtgtgc acgacgcaga 2160
tgcatcacac cgtatgaact gacaccagga gctaccgtcc ctttcctgct tagcctaata 2220
tgctgcatca gaacagctaa agcggccaca taccaagagg ctgcgatata cctgtggaac 2280
gagcagcaac ctttgttttg gctacaagcc cttattccgc tggcagccct gattgttcta 2340
tgcaactgtc tgagactctt accatgctgc tgtaaaacgt tggctttttt agccgtaatg 2400
agcgtcggtg cccacactgt gagcgcgtac gaacacgtaa cagtgatccc gaacacggtg 2460
ggagtaccgt ataagactct agtcaataga cctggctaca gccccatggt attggagatg 2520
gaactactgt cagtcacttt ggagccaaca ctatcgcttg attacatcac gtgcgagtac 2580
aaaaccgtca tcccgtctcc gtacgtgaag tgctgcggta cagcagagtg caaggacaaa 2640
aacctacctg actacagctg taaggtcttc accggcgtct acccatttat gtggggcggc 2700
gcctactgct tctgcgacgc tgaaaacacg cagttgagcg aagcacacgt ggagaagtcc 2760
gaatcatgca aaacagaatt tgcatcagca tacagggctc ataccgcatc tgcatcagct 2820
aagctccgcg tcctttacca aggaaataac atcactgtaa ctgcctatgc aaacggcgac 2880
catgccgtca cagttaagga cgccaaattc attgtggggc caatgtcttc agcctggaca 2940
cctttcgaca acaaaattgt ggtgtacaaa ggtgacgtct ataacatgga ctacccgccc 3000
tttggcgcag gaagaccagg acaatttggc gatatccaaa gtcgcacacc tgagagtaaa 3060
gacgtctatg ctaatacaca actggtactg cagagaccgg ctgtgggtac ggtacacgtg 3120
ccatactctc aggcaccatc tggctttaag tattggctaa aagaacgcgg ggcgtcgctg 3180
cagcacacag caccatttgg ctgccaaata gcaacaaacc cggtaagagc ggtgaactgc 3240
gccgtaggga acatgcccat ctccatcgac ataccggaag cggccttcac tagggtcgtc 3300
gacgcgccct ctttaacgga catgtcgtgc gaggtaccag cctgcaccca ttcctcagac 3360
tttgggggcg tcgccattat taaatatgca gccagcaaga aaggcaagtg tgcggtgcat 3420
tcgatgacta acgccgtcac tattcgggaa gctgagatag aagttgaagg gaattctcag 3480
ctgcaaatct ctttctcgac ggccttagcc agcgccgaat tccgcgtaca agtctgttct 3540
acacaagtac actgtgcagc cgagtgccac cccccgaagg accacatagt caactacccg 3600
gcgtcacata ccaccctcgg ggtccaggac atctccgcta cggcgatgtc atgggtgcag 3660
aagatcacgg gaggtgtggg actggttgtt gctgttgccg cactgattct aatcgtggtg 3720
ctatgcgtgt cgttcagcag gcactaa 3747
<210> 64
<211> 3765
<212> DNA
<213> Venezuelan equine encephalitis virus
<400> 64
atgttcccgt tccagccaat gtatccgatg cagccaatgc cctatcgcaa cccgttcgcg 60
gccccgcgca ggccctggtt ccccagaacc gacccttttc tggcgatgca ggtgcaggaa 120
ttaacccgct cgatggctaa cctgacgttc aagcaacgcc gggacgcgcc acctgagggg 180
ccatccgcta ataaaccgaa gaaggaggcc tcgcaaaaac agaaaggggg aggccaaggg 240
aagaagaaga agaaccaagg gaagaagaag gctaagacag ggccgcctaa tccgaaggca 300
cagaatggaa acaagaagaa gaccaacaag aaaccaggca agagacagcg catggtcatg 360
aaattggaat ctgacaagac gttcccaatc atgttggaag ggaagataaa cggctacgct 420
tgtgtggtcg gagggaagtt attcaggccg atgcatgtgg aaggcaagat cgacaacgac 480
gttctggccg cgcttaagac gaagaaagca tccaaatacg atcttgagta tgcagatgtg 540
ccacagaaca tgcgggccga tacattcaaa tacacccatg agaaacccca aggctattac 600
agctggcatc atggagcagt ccaatatgaa aatgggcgtt tcacggtgcc gaaaggagtt 660
ggggccaagg gagacagcgg acgacccatt ctggataacc agggacgggt ggtcgctatt 720
gtgctgggag gtgtgaatga aggatctagg acagcccttt cagtcgtcat gtggaacgag 780
aagggagtta ccgtgaagta tactccggag aactgcgagc aatggtcact agtgaccacc 840
atgtgtctgc tcgccaatgt gacgttccca tgtgctcaac caccaatttg ctacgacaga 900
aaaccagcag agactttggc catgctcagc gttaacgttg acaacccggg ctacgatgag 960
ctgctggaag cagctgttaa gtgccccgga aggaaaagga gatccaccga ggagctgttt 1020
aatgagtata agctaacgcg cccttacatg gccagatgca tcagatgtgc agttgggagc 1080
tgccatagtc caatagcaat cgaggcagta aagagcgacg ggcacgacgg ttatgttaga 1140
cttcagactt cctcgcagta tggcctggat tcctccggca acttaaaggg caggaccatg 1200
cggtatgaca tgcacgggac cattaaagag ataccactac atcaagtgtc actctataca 1260
tctcgcccgt gtcacattgt ggatgggcac ggttatttcc tgcttgccag gtgcccggca 1320
ggggactcca tcaccatgga atttaagaaa gattccgtca gacactcctg ctcggtgccg 1380
tatgaagtga aatttaatcc tgtaggcaga gaactctata ctcatccccc agaacacgga 1440
gtagagcaag cgtgccaagt ctacgcacat gatgcacaga acagaggagc ttatgtcgag 1500
atgcacctcc cgggctcaga agtggacagc agtttggttt ccttgagcgg cagttcagtc 1560
accgtgacac ctcctgatgg gactagcgcc ctggtggaat gcgagtgtgg cggcacaaag 1620
atctccgaga ccatcaacaa gacaaaacag ttcagccagt gcacaaagaa ggagcagtgc 1680
agagcatatc ggctgcagaa cgataagtgg gtgtataatt ctgacaaact gcccaaagca 1740
gcgggagcca ccttaaaagg aaaactgcat gtcccattct tgctggcaga cggcaaatgc 1800
accgtgcctc tagcaccaga acctatgata accttcggtt tcagatcagt gtcactgaaa 1860
ctgcacccta agaatcccac atatctaatc acccgccaac ttgctgatga gcctcactac 1920
acgcacgagc tcatatctga accagctgtt aggaatttta ccgtcaccga aaaagggtgg 1980
gagtttgtat ggggaaacca cccgccgaaa aggttttggg cacaggaaac agcacccgga 2040
aatccacatg ggctaccgca cgaggtgata actcattatt accacagata ccctatgtcc 2100
accatcctgg gtttgtcaat ttgtgccgcc attgcaaccg tttccgttgc agcgtctacc 2160
tggctgtttt gcagatctag agttgcgtgc ctaactcctt accggctaac acctaacgct 2220
aggataccat tttgtctggc tgtgctttgc tgcgcccgca ctgcccgggc cgagaccacc 2280
tgggagtcct tggatcacct atggaacaat aaccaacaga tgttctggat tcaattgctg 2340
atccctctgg ccgccttgat cgtagtgact cgcctgctca ggtgcgtgtg ctgtgtcgtg 2400
ccttttttag tcatggccgg cgccgcaggc gccggcgcct acgagcacgc gaccacgatg 2460
ccgagccaag cgggaatctc gtataacact atagtcaaca gagcaggcta cgcaccactc 2520
cctatcagca taacaccaac aaagatcaag ctgataccta cagtgaactt ggagtacgtc 2580
acctgccact acaaaacagg aatggattca ccagccatca aatgctgcgg atctcaggaa 2640
tgcactccaa cttacaggcc tgatgaacag tgcaaagtct tcacaggggt ttacccgttc 2700
atgtggggtg gtgcatattg cttttgcgac actgagaaca cccaagtcag caaggcctac 2760
gtaatgaaat ctgacgactg ccttgcggat catgctgaag catataaagc gcacacagcc 2820
tcagtgcagg cgttcctcaa catcacagtg ggagaacact ctattgtgac taccgtgtat 2880
gtgaatggag aaactcctgt gaatttcaat ggggtcaaaa taactgcagg tccgctttcc 2940
acagcttgga caccctttga tcgcaaaatc gtgcagtatg ccggggagat ctataattat 3000
gattttcctg agtatggggc aggacaacca ggagcatttg gagatataca atccagaaca 3060
gtctcaagct ctgatctgta tgccaatacc aacctagtgc tgcagagacc caaagcagga 3120
gcgatccacg tgccatacac tcaggcacct tcgggttttg agcaatggaa gaaagataaa 3180
gctccatcat tgaaatttac cgcccctttc ggatgcgaaa tatatacaaa ccccattcgc 3240
gccgaaaact gtgctgtagg gtcaattcca ttagcctttg acattcccga cgccttgttc 3300
accagggtgt cagaaacacc gacactttca gcggccgaat gcactcttaa cgagtgcgtg 3360
tattcttccg actttggtgg gatcgccacg gtcaagtact cggccagcaa gtcaggcaag 3420
tgcgcagtcc atgtgccatc agggactgct accctaaaag aagcagcagt cgagctaacc 3480
gagcaagggt cggcgactat ccatttctcg accgcaaata tccacccgga gttcaggctc 3540
caaatatgca catcatatgt tacgtgcaaa ggtgattgtc accccccgaa agaccatatt 3600
gtgacacacc ctcagtatca cgcccaaaca tttacagccg cggtgtcaaa aaccgcgtgg 3660
acgtggttaa catccctgct gggaggatca gccgtaatta ttataattgg cttggtgctg 3720
gctactattg tggccatgta cgtgctgacc aaccagaaac ataat 3765
1/
Claims (16)
- 바이러스 구조 단백질 및 PD-1 에서 유래한 항원 및 PD-1 의 리간드에서 유래한 항원으로 이루어지는 군에서 선택되는 항원을 포함하는 입자.
- 제 1 항에 있어서, 바이러스 구조 단백질이 캡시드 및/또는 외피 단백질 E1 및 E2 를 포함하는 입자.
- 제 2 항에 있어서, PD-1 에서 유래한 하나 이상의 항원 또는 PD-L1 에서 유래한 하나 이상의 항원이 외피 단백질의 E2 에 삽입되는 입자.
- 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 입자가 PD-1에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 치쿤구니야 바이러스 유사 입자이며,
PD-1 에서 유래한 항원이 삽입되는 외피 단백질 E2 가 SEQ ID No.:33-35 로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 이 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어지고; 캡시드가 SEQ ID No.:38 로 나타내는 아미노산 서열로 이루어지는 입자. - 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 입자가 PD-1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 베네수엘라 말 바이러스 유사 입자이며,
PD-1 에서 유래한 항원이 삽입되는 외피 단백질 E2 가 SEQ ID No.:39-41 로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 가 SEQ ID No.:43 로 나타내는 아미노산 서열로 이루어지고; 캡시드가 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어지는 입자. - 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 입자가 PD-L1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 치쿤구니야 바이러스 유사 입자이며,
PD-L1 에서 유래한 항원이 삽입되는 외피 단백질 E2 가 SEQ ID No.:36 으로 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 가 SEQ ID No.:37 로 나타내는 아미노산 서열로 이루어지고; 캡시드가 SEQ ID No.:38 로 나타내는 아미노산 서열로 이루어지는 입자. - 제 1 항 내지 제 3 항 중 어느 한 항에 있어서, 입자가 PD-L1 에서 유래한 항원이 삽입되는 하나 이상의 외피 단백질 E2, 하나 이상의 외피 단백질 E1 및 하나 이상의 캡시드로 이루어지는 베네수엘라 말 바이러스 유사 입자이며, PD-L1 에서 유래한 항원이 삽입되는 외피 단백질 E2 가 SEQ ID No.:42 에 의해 나타내는 아미노산 서열로 이루어지고; 외피 단백질 E1 이 SEQ ID No.:43 으로 나타내는 아미노산 서열로 이루어지고; 캡시드가 SEQ ID No.:44 로 나타내는 아미노산 서열로 이루어지는 입자.
- 제 4 항 내지 제 7 항 중 어느 한 항에 따른 입자의 아미노산 서열과 90% 이상의 서열 동일성을 갖는 아미노산 서열로 이루어지는 입자.
- 제 1 항 내지 제 8 항 중 어느 한 항에 따른 입자를 발현하기 위한 뉴클레오티드 서열을 포함하는 단리된 핵산 분자.
- SEQ ID No.:27-32 으로 나타내는 뉴클레오티드 서열과 90% 이상의 서열 동일성을 갖는 뉴클레오티드 서열로 이루어지는 단리된 핵산 분자.
- 제 9 항 또는 제 10 항에 따른 핵산 분자를 포함하는 벡터로서, 상기 벡터가 핵산 분자에 작동가능하게 연결된 발현 제어 서열을 임의로 포함하는 벡터.
- 하기를 포함하는 약학 조성물:
(a) 제 1 항 내지 제 8 항 중 어느 한 항에 따른 입자, 제 9 항 또는 제 10 항에 따른 핵산 분자 및/또는 제 11 항에 따른 벡터; 및
(b) 약학적으로 허용가능한 담체. - 제 12 항에 있어서, 약학 조성물이 백신인 약학 조성물.
- 암 또는 감염성 질환의 치료 또는 예방; 포유동물에서의 PD-1 또는 PD-1 의 리간드에 대항하는 항체의 생성; 면역 반응의 조절; 면역자극; PD-1 과 PD-1 의 리간드 사이의 상호작용 억제; 또는 PD-1 활성의 억제를 위한 약학 조성물 또는 키트의 제조를 위한, 제 1 항 내지 제 8 항 중 어느 한 항에 따른 입자, 제 9 항 또는 제 10 항에 따른 핵산 분자 및/또는 제 11 항에 따른 벡터의 용도.
- 하기를 포함하는 키트로서:
(a) 제 1 항 내지 제 8 항 중 어느 한 항에 따른 입자를 포함하는 약학 조성물; 및
(b) 제 1 항 내지 제 8 항 중 어느 한 항에 따른 입자를 포함하는 또 다른 약학 조성물,
(a) 에 포함된 입자가 (b) 에 포함된 입자와 상이한 바이러스 유사 입자인 키트. - 제 15 항에 있어서, (a) 에 포함된 입자가 치쿤구니야 바이러스 유사 입자이고 (b) 에 포함된 입자가 베네수엘라 말 뇌염 바이러스 유사 입자이거나, (a) 에 포함된 입자가 베네수엘라 말 뇌염 바이러스 유사 입자이고 (b) 에 포함된 입자가 치쿤구니야 바이러스 유사 입자인 키트.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845712P | 2013-07-12 | 2013-07-12 | |
US61/845,712 | 2013-07-12 | ||
PCT/JP2014/069122 WO2015005500A1 (en) | 2013-07-12 | 2014-07-11 | Virus like particle comprising pd-1 antigen or pd-1 ligand antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20160029124A true KR20160029124A (ko) | 2016-03-14 |
Family
ID=52277262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020167003373A KR20160029124A (ko) | 2013-07-12 | 2014-07-11 | Pd-1 항원 또는 pd-1 리간드 항원을 포함하는 바이러스 유사 입자 |
Country Status (13)
Country | Link |
---|---|
US (2) | US9637532B2 (ko) |
EP (2) | EP3666890A1 (ko) |
JP (1) | JP6557208B2 (ko) |
KR (1) | KR20160029124A (ko) |
CN (1) | CN105358683A (ko) |
AR (1) | AR096885A1 (ko) |
AU (1) | AU2014288147B2 (ko) |
BR (1) | BR112016000303A2 (ko) |
CA (1) | CA2916458A1 (ko) |
IL (1) | IL243304B (ko) |
MX (1) | MX364952B (ko) |
TW (1) | TWI676636B (ko) |
WO (1) | WO2015005500A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2014007864A0 (en) | 2012-02-16 | 2014-08-31 | Vlp Therapeutics Llc | Virus like particle composition |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
BR112016020919A2 (pt) | 2014-03-12 | 2018-01-23 | Yeda Res & Dev | redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
CN106795513B (zh) | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | 包含修饰的包膜蛋白e3的病毒样颗粒 |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
MX2017003117A (es) | 2014-09-11 | 2017-06-14 | Vlp Therapeutics Llc | Particula tipo virus de flavivirus. |
EP3270958A4 (en) * | 2015-03-18 | 2018-11-14 | Omnicyte | Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof |
US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
US11447550B2 (en) | 2016-10-04 | 2022-09-20 | The Curators Of The University Of Missouri | Peptides for molecular detection of PD-L1 |
KR20190125481A (ko) * | 2017-03-17 | 2019-11-06 | 백심 아게 | 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신 |
AU2018243920A1 (en) * | 2017-03-28 | 2019-10-31 | Mayo Foundation For Medical Education And Research | Human PD1 peptide vaccines and uses thereof |
US20210000946A1 (en) * | 2018-03-05 | 2021-01-07 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
JP7304421B2 (ja) * | 2018-10-05 | 2023-07-06 | アールエヌエージーン インコーポレイテッド | 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途 |
US20220064259A1 (en) * | 2019-01-04 | 2022-03-03 | George Mason Research Foundation, Inc. | Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related Thereto |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
CN111116733B (zh) * | 2019-11-28 | 2021-11-05 | 广东药科大学 | 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体 |
WO2021169673A1 (en) * | 2020-02-26 | 2021-09-02 | Versitech Limited | Pd-1-based vaccines against coronavirus infection |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
WO1993010152A1 (en) | 1991-11-16 | 1993-05-27 | Smithkline Beecham Biologicals S.A. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
AU716466B2 (en) | 1995-09-27 | 2000-02-24 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
WO1999041383A1 (en) | 1998-02-11 | 1999-08-19 | Maxygen, Inc. | Antigen library immunization |
JP4896327B2 (ja) * | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
US20110262389A1 (en) | 2001-02-13 | 2011-10-27 | Mosca Joseph D | Tumor-derived Biological Antigen Presenting Particles |
CA2448908C (en) | 2001-05-30 | 2008-03-18 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
AU2002327614B2 (en) | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
AU2003267943C1 (en) | 2002-02-26 | 2009-05-21 | Altravax, Inc. | Novel flavivirus antigens |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
BRPI0317276B8 (pt) | 2002-12-13 | 2021-05-25 | Alphavax Inc | método para a preparação de partículas de replicon de alfavírus (arps) |
PL1608762T3 (pl) | 2003-03-20 | 2014-06-30 | Alphavax Inc | Udoskonalone replikony alfawirusowe i konstrukty plazmidów pomocniczych |
CA2527636A1 (en) | 2003-05-29 | 2005-01-06 | United States Army Medical Research Institute For Infectious Diseases, A Research Laboratory Owned And Operated By The United States Government A | Live attenuated viral vaccines for eastern equine encephalitis virus |
BRPI0417159A (pt) * | 2003-12-01 | 2007-03-06 | Dow Global Technologies Inc | produção de partìcula semelhante a vìrus icosaédrico recombinante em pseudomÈnades |
MXPA06013124A (es) * | 2004-05-18 | 2007-05-23 | Alphavax Inc | Vectores de alfavirus derivados de tc-83, particulas y metodos. |
ATE523205T1 (de) | 2004-10-14 | 2011-09-15 | Crucell Holland Bv | Prime-boost-impfstoffe gegen malaria |
JP4819792B2 (ja) | 2005-02-16 | 2011-11-24 | 国立大学法人東京工業大学 | 改変されたウイルスカプシドタンパク質及びその使用 |
CN104436190A (zh) * | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
WO2007100098A1 (ja) | 2006-03-03 | 2007-09-07 | Kyoto University | 細胞表面機能分子の細胞外領域多量体 |
US7499304B2 (en) | 2006-07-31 | 2009-03-03 | Sandisk 3D Llc | Systems for high bandwidth one time field-programmable memory |
US20100120092A1 (en) | 2006-08-30 | 2010-05-13 | Hepgenics Pty Ltd. | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
GB2453155A (en) | 2007-09-26 | 2009-04-01 | Rolls Royce Plc | Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine |
US20110035004A1 (en) | 2007-11-14 | 2011-02-10 | Maxwell G | Interfaced medical implant |
JP5627464B2 (ja) | 2007-11-26 | 2014-11-19 | ノバルティス アーゲー | アルファウイルス粒子を生成する方法 |
SG171828A1 (en) | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
CA2774640C (en) | 2009-09-18 | 2019-11-26 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
JP5600741B2 (ja) | 2010-07-13 | 2014-10-01 | 帝人株式会社 | 炭素繊維束及びその製造方法、ならびにそれからの成形品 |
WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
JP6147734B2 (ja) | 2011-06-17 | 2017-06-14 | バハラ バイオテック インターナショナル リミテッド | 不活化チクングニアウイルス株を含むワクチン組成物 |
EP2731961A4 (en) | 2011-07-12 | 2015-12-09 | Us Government | IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF |
CN102321639B (zh) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
WO2013063248A1 (en) | 2011-10-25 | 2013-05-02 | Florida Gulf Coast University | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
AP2014007864A0 (en) | 2012-02-16 | 2014-08-31 | Vlp Therapeutics Llc | Virus like particle composition |
BR112014024612A2 (pt) | 2012-04-02 | 2021-06-08 | Univ North Carolina Chapel Hill | ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue |
NZ701881A (en) * | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
CA2913832C (en) | 2013-06-03 | 2023-07-04 | Vlp Therapeutics, Llc | A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
US10060924B2 (en) | 2014-03-18 | 2018-08-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
CN106795513B (zh) | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | 包含修饰的包膜蛋白e3的病毒样颗粒 |
MX2017003117A (es) | 2014-09-11 | 2017-06-14 | Vlp Therapeutics Llc | Particula tipo virus de flavivirus. |
US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
WO2016109792A2 (en) | 2014-12-31 | 2016-07-07 | The Usa, As Represented By The Secretary, Detp. Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
CN107849558A (zh) | 2015-06-12 | 2018-03-27 | 国立大学法人三重大学 | 2型人副流感病毒载体和疫苗 |
US10799575B2 (en) | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
CN108601825B (zh) | 2015-07-16 | 2023-06-20 | 巴拉特生物技术国际有限公司 | 疫苗组合物 |
MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
WO2017150683A1 (en) | 2016-03-04 | 2017-09-08 | Vlp Therapeutics, Llc | Zika virus virus like particle |
CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2014
- 2014-07-10 US US14/328,268 patent/US9637532B2/en active Active
- 2014-07-10 TW TW103123759A patent/TWI676636B/zh not_active IP Right Cessation
- 2014-07-11 CA CA2916458A patent/CA2916458A1/en not_active Abandoned
- 2014-07-11 CN CN201480039571.4A patent/CN105358683A/zh active Pending
- 2014-07-11 EP EP19219213.6A patent/EP3666890A1/en not_active Withdrawn
- 2014-07-11 KR KR1020167003373A patent/KR20160029124A/ko active Search and Examination
- 2014-07-11 MX MX2016000381A patent/MX364952B/es active IP Right Grant
- 2014-07-11 AR ARP140102570A patent/AR096885A1/es unknown
- 2014-07-11 BR BR112016000303A patent/BR112016000303A2/pt not_active Application Discontinuation
- 2014-07-11 AU AU2014288147A patent/AU2014288147B2/en not_active Expired - Fee Related
- 2014-07-11 JP JP2016501252A patent/JP6557208B2/ja active Active
- 2014-07-11 WO PCT/JP2014/069122 patent/WO2015005500A1/en active Application Filing
- 2014-07-11 EP EP14823398.4A patent/EP3019600B1/en active Active
-
2015
- 2015-12-23 IL IL243304A patent/IL243304B/en not_active IP Right Cessation
-
2017
- 2017-04-27 US US15/498,971 patent/US10464986B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014288147B2 (en) | 2020-04-09 |
AR096885A1 (es) | 2016-02-03 |
TW201536812A (zh) | 2015-10-01 |
US10464986B2 (en) | 2019-11-05 |
EP3019600B1 (en) | 2019-12-25 |
CA2916458A1 (en) | 2015-01-15 |
BR112016000303A2 (pt) | 2017-12-12 |
EP3019600A1 (en) | 2016-05-18 |
CN105358683A (zh) | 2016-02-24 |
WO2015005500A1 (en) | 2015-01-15 |
AU2014288147A1 (en) | 2016-01-21 |
EP3666890A1 (en) | 2020-06-17 |
JP2016526374A (ja) | 2016-09-05 |
IL243304B (en) | 2020-02-27 |
TWI676636B (zh) | 2019-11-11 |
IL243304A0 (en) | 2016-03-31 |
US9637532B2 (en) | 2017-05-02 |
EP3019600A4 (en) | 2017-04-12 |
JP6557208B2 (ja) | 2019-08-07 |
MX364952B (es) | 2019-05-14 |
MX2016000381A (es) | 2016-09-07 |
US20170233450A1 (en) | 2017-08-17 |
US20150017194A1 (en) | 2015-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20160029124A (ko) | Pd-1 항원 또는 pd-1 리간드 항원을 포함하는 바이러스 유사 입자 | |
US11965012B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
US7527966B2 (en) | Gene regulation in transgenic animals using a transposon-based vector | |
KR20220141332A (ko) | 홍역-벡터화된 covid-19 면역원성 조성물 및 백신 | |
US20030119104A1 (en) | Chromosome-based platforms | |
IL190324A (en) | Modular cloning vector plasmids | |
CN108348594A (zh) | 犬科动物细小病毒(cpv)病毒样颗粒(vlp)疫苗及其用途 | |
CN109913425B (zh) | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 | |
WO2005081716A2 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
KR101440159B1 (ko) | 이동가능한 혼성 복제개시점 플라스미드 | |
KR101616572B1 (ko) | 홍역-말라리아 조합 백신 | |
CN114026242A (zh) | 具有髓鞘蛋白零启动子的aav载体及其用于治疗雪旺细胞相关疾病如charcot-marie-tooth疾病的用途 | |
CN112877292A (zh) | 产生人抗体的细胞 | |
US20210130818A1 (en) | Compositions and Methods for Enhancement of Homology-Directed Repair Mediated Precise Gene Editing by Programming DNA Repair with a Single RNA-Guided Endonuclease | |
US20040028653A1 (en) | Self-rearranging DNA vectors | |
CN101679976A (zh) | 核酸和文库 | |
KR20230109353A (ko) | 유전자 침묵문제를 극복한 신규 유전자 발현유도 스위치 | |
KR20220150323A (ko) | 코로나바이러스를 방지하는 백신 생산을 위한 완전 합성 장쇄 핵산 | |
KR20230153437A (ko) | 코로나바이러스를 방지하는 백신 생산을 위한 완전 합성 장쇄 핵산 | |
KR20230007808A (ko) | 재배열 레오바이러스과 바이러스를 제조하는 방법 및 이를 위한 벡터 라이브러리 | |
AU2020327783A1 (en) | Oncolytic vaccinia virus | |
CA2522166C (en) | Lambda integrase mutein for use in recombination | |
KR20230117327A (ko) | 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터 | |
CN109777832A (zh) | 碱基编辑模拟、修复与甘露糖苷贮积症相关的man2b1c2248t突变的试剂和方法 | |
CN110819657A (zh) | 一种减毒棒状病毒的制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination |